Document:

EX-10.19

 Exhibit 10.19 
 480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 1 
 LEASE
AGREEMENT 
 THIS LEASE AGREEMENT is made as of this 16th day of November, 2006, between ARE-480 Arsenal Street, LLC, a
Delaware limited liability company (“Landlord”), and Tetraphase Pharmaceuticals, Inc., a Delaware corporation (“Tenant”). 
 BASIC LEASE PROVISIONS 
  

			
	Address:	  	480 Arsenal Street, Watertown, Massachusetts
		
	Premises:	  	That portion of the Project, containing approximately 15,149 rentable square feet, as determined by Landlord, consisting of Area 1-A East, as shown on
Exhibit A.
		
	Project:	  	The real property on which the building (the “Building”) in which the Premises are located, together with all improvements thereon and appurtenances thereto as
described on Exhibit B.
		
	Base Rent:	  	$40,271.09, per month      Rentable Area of Premises: 15,149 sq. ft.
	
	Rentable Area of Project:      140,744 sq. ft.      Tenant’s Share of Operating Expenses:
10.764%
	
	Security Deposit: $120,813.27
	
	Commencement Date: November 15, 2006
	
	Rent Commencement Date: Commencement Date
	
	Rent Adjustment Percentage: 3%
		
	Base Term:	  	A term beginning on the Commencement Date and ending on December 31, 2012
		
	Permitted Use:	  	research and development laboratory (including, without limitation, drug development research and process and medicinal chemistry), related office and other related uses consistent
with the character of the Project and otherwise in compliance with the provisions of Section 8 hereof.

  

			
	Address for Rent Payment:	  	Landlord’s Notice Address:
	385 E. Colorado Boulevard, Suite 299	  	385 E. Colorado Boulevard, Suite 299
	Pasadena, CA 91101	  	Pasadena, CA 91101
	Attention: Accounts Receivable	  	Attention: Accounts Receivable
		
	Tenant’s Notice Address:	  	
	  
	  	
	  
	  	
	  
	  	
	Attention:	  	

 The following Exhibits and Addenda are attached hereto and incorporated herein by this reference: 

 

			
	[ X ] EXHIBIT A – PREMISES DESCRIPTION	  	[ X ] EXHIBIT B – DESCRIPTION OF PROJECT
	[ X ] EXHIBIT C – WORK LETTER	  	[ X ] EXHIBIT D – TENANT’S PERSONAL PROPERTY
	[ X ] EXHIBIT E – RULES AND REGULATIONS	  	[ X ] EXHIBIT F – FORM OF LETTER OF CREDIT

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 2
 
  

 1. Lease of Premises. Upon and subject to all of the terms and conditions hereof,
Landlord hereby leases to Tenant and Tenant hereby leases from Landlord, the Premises. Tenant shall have, as appurtenant to the Premises, the right to use those portions of the Project which are for the non-exclusive use of tenants of the Project
(collectively, the “Common Areas”), including, without limitation, those portions of the elevators and parking areas serving the Project which are included in the Common Areas. Notwithstanding the foregoing, Landlord reserves the
right to modify Common Areas, provided that such modifications do not materially adversely affect Tenant’s use of the Premises for the Permitted Use. Tenant shall have access to the Premises 24 hours per day, 365 days per year, subject to
Landlord’s reasonable requirements with regard to any work to be performed by Landlord on the Project or the Premises. 

2. Delivery; Acceptance of Premises; Commencement Date. Tenant acknowledges and agrees that Landlord will be constructing
Landlord’s Work following the Commencement Date. Accordingly, the entire Premises will not be delivered to Tenant for Tenant’s use on the Commencement Date. Landlord shall use reasonable efforts to deliver the entire Premises to Tenant,
with Landlord’s Work Substantially Completed, as soon as possible following the Commencement Date (“Delivery” or “Deliver”). Landlord shall not be liable to Tenant for any loss or damage resulting from delays
in the Delivery of the Premises (subject to the provisions regarding Landlord’s waiver of Base Rent and Operating Expenses during performance of Landlord’s Work set forth in Section 4 hereof), and this Lease shall not be void
or voidable except as provided herein. Notwithstanding the foregoing, in the event that Landlord has not Substantially Completed Landlord’s Work on or before May 15, 2007 (“Outside Date”), then Tenant shall have the right
to terminate this Lease by written notice to Landlord within 5 days after the Outside Date. As used herein, the terms “Landlord’s Work,” “Tenants’ Work,”, “Force Majeure
Delays,” “Tenant Delays” and “Substantially Completed” shall have the meanings set forth for such terms in the work letter to be entered into by Landlord and Tenant, which work letter shall be in
substantially the form attached hereto as Exhibit C (the “Work Letter”). 
 The “Term”
of this Lease shall be the Base Term, as defined above in the Basic Lease Provisions and any Extension Terms which Tenant may elect pursuant to Section 40 hereof. 
 Except as set forth in the Work Letter, if applicable: (i) Tenant shall accept the Premises in their condition as of the Commencement Date, subject to all applicable Legal Requirements (as defined in
Section 8 hereof); (ii) Landlord shall have no obligation for any defects in the Premises; and (iii) Tenant’s taking possession of the Premises shall be conclusive evidence that Tenant accepts the Premises and that the
Premises were in good condition at the time possession was taken. Any occupancy of the Premises by Tenant before the Commencement Date shall be subject to all of the terms and conditions of this Lease, including the obligation to pay Rent except as
specifically set forth in Section 4 hereof. 
 Tenant agrees and acknowledges that neither Landlord nor any agent of
Landlord has made any representation or warranty with respect to the condition of all or any portion of the Premises or the Project, and/or the suitability of the Premises or the Project for the conduct of Tenant’s business, and Tenant waives
any implied warranty that the Premises or the Project are suitable for the Permitted Use. This Lease constitutes the complete agreement of Landlord and Tenant with respect to the subject matter hereof and supersedes any and all prior
representations, inducements, promises, agreements, understandings and negotiations which are not contained herein. Landlord in executing this Lease does so in reliance upon Tenant’s representations, warranties, acknowledgments and agreements
contained herein. 
 3. Right to Terminate. Tenant may terminate the Term of this Lease for any
reason effective as of the last calendar day of the 42nd
full calendar month of the Term hereof (the “Early Termination Date”), upon 9 months’ prior written notice to Landlord. Such notice to Landlord (a “Termination Notice”) shall be accompanied by Tenant’s
payment to Landlord of a termination payment in an amount equal to 9 months’ Base Rent at the rate which will be in effect as of the Early Termination Date. Any Termination Notice so delivered shall apply to the entire Premises and shall be
final and irrevocable. If Tenant delivers a Termination Notice in accordance with the foregoing requirements, then 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 3
 
  

 
(i) the Early Termination Date shall be deemed to be the date on which the Term expires for all purposes under the Lease, (ii) Tenant shall comply with all of the obligations of Tenant under
this Lease that arise during or are attributable to the period ending on such Early Termination Date, (iii) Tenant shall have no further right to exercise the Extension Option set forth in Section 40 hereof, and (iv) Tenant
shall vacate and surrender the Premises on the Early Termination Date in accordance with Section 29 hereof. Such termination right shall not apply to any assignee of Tenant’s interest in the Lease that requires Landlord’s
consent under Section 23 hereof or, at Landlord’s election, if an Event of Default (as hereinafter defined) has occurred and is continuing at the time of Tenant’s exercise of such option. 

4. Rent. 

(a) Base Rent. The first month’s Base Rent and the Security Deposit shall be due and payable on delivery of an executed copy
of this Lease to Landlord. Tenant shall pay to Landlord in advance, without demand, abatement, deduction or set-off except as expressly set forth herein, monthly installments of Base Rent on or before the first day of each calendar month during the
Term hereof, in lawful money of the United States of America, at the office of Landlord for payment of Rent set forth above, or to such other person or at such other place as Landlord may from time to time designate in writing. Payments of Base Rent
for any fractional calendar month shall be prorated. The obligation of Tenant to pay Base Rent and other sums to Landlord and the obligations of Landlord under this Lease are independent obligations. Tenant shall have no right at any time to abate,
reduce, or set-off any Rent (as defined in Section 6) due hereunder except for any abatement as may be expressly provided in this Lease. Notwithstanding the foregoing, Base Rent due and payable during the first 12 calendar months of the
Term (including any partial month following the Commencement Date), i.e., from the Commencement Date until November 14, 2007, shall be reduced to an amount equal to 50% of the Base Rent set forth above, or $20,135.55 per month. Thereafter, Base
Rent due and payable during the immediately succeeding 6 calendar months of the Term (increased by the Rent Adjustment Percentage as provided in Section 5 hereof), i.e., November 15, 2007 until May 14, 2008, shall be increased
to an amount equal to 72.5% of such increased Base Rent, or $30,072.44. Commencing on May 15, 2008, and continuing thereafter for the remainder of the Term, Base Rent shall be due and payable in the amount set forth above, subject to adjustment
as provided in Section 5 hereof. 
 (b) Rent During Construction of Landlord’s Work. Notwithstanding
anything herein to the contrary, Landlord agrees that, during Landlord’s construction of Landlord’s Work following the Commencement Date, in addition to the reduction in Base Rent set forth in Section 4(a), Landlord shall waive
Tenant’s obligation to pay Base Rent and Operating Expenses hereunder on a day-for-day basis with respect to the portion of the Premises which is rendered unusable to Tenant due to such construction activity. Such waiver with respect to Base
Rent shall only take effect if and to the extent that more than 50% of the Premises is rendered unusable as aforesaid. By way of example, and without intending to limit the generality of the foregoing, if 60% of the Premises is rendered unusable due
to such construction activity, 60% of Operating Expenses shall be waived and 10% of Base Rent shall be waived, in each case for the number of days that such portion of the Premises is rendered unusable. Following Substantial Completion of
Landlord’s Work, Landlord shall prepare and deliver to Tenant an accounting of the reduction in Base Rent and Operating Expenses to which Tenant is entitled pursuant to this section, and such amounts shall be deducted from Tenant’s next
payment of Base Rent and Operating Expenses hereunder. Calculation of any credit against Base Rent hereunder shall be based on the full amount of Base Rent set forth in the Basic Lease Provisions above, not the reduced amount to be paid by Tenant
pursuant to Section 4(a). 
 (c) Additional Rent. In addition to Base Rent, Tenant agrees to pay to Landlord
as additional rent (“Additional Rent”): (i) Tenant’s Share of “Operating Expenses” (as defined in Section 6), and (ii) any and all other amounts Tenant assumes or agrees to pay under the
provisions of this Lease, including, without limitation, any and all other sums that may become due by reason of any default of Tenant or failure to comply with the agreements, terms, covenants and conditions of this Lease to be performed by Tenant,
after any applicable notice and cure period. 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 4
 
  

 5. Base Rent Adjustments. Base Rent shall be increased on each annual anniversary
of the first day of the first full month during the Term of this Lease, i.e., each December 1 (each an “Adjustment Date”) by multiplying the Base Rent payable immediately before such Adjustment Date by the Rent Adjustment
Percentage and adding the resulting amount to the Base Rent payable immediately before such Adjustment Date. Base Rent, as so adjusted, shall thereafter be due as provided herein. Base Rent adjustments for any fractional calendar month shall be
prorated. 
 6. Operating Expense Payments. Landlord shall deliver to Tenant a written estimate of
Operating Expenses for each calendar year during the Term (the “Annual Estimate”), which may be revised by Landlord from time to time during such calendar year. During each month of the Term, on the same date that Base Rent is due,
Tenant shall pay Landlord an amount equal to 1/12th of
Tenant’s Share of the Annual Estimate. Payments for any fractional calendar month shall be prorated. 
 The term
“Operating Expenses” means all Building and Project related operating costs in connection with the shell and core of the Building, site improvements, maintenance, taxes, utilities, transportation services, insurance, the costs of
capital repairs and improvements amortized over the lesser of 7 years and the useful life of such capital items, in the case of repairs or improvements to the HVAC system and equipment serving the Premises, or, in the case of any other work, over
the useful life of such capital items, and the costs of Landlord’s third party property manager, not to exceed 3.0% of Base Rent, or, if there is no third party property manager, administration rent in the amount of 3.0% of Base Rent),
excluding only: 
 (a) the original construction costs of the Project and renovation prior to the date of the Lease and costs of
correcting defects in such original construction or renovation; 
 (b) capital expenditures for expansion of the Project;

 (c) interest, principal payments of Mortgage (as defined in Section 28) debts of Landlord, financing costs and
amortization of funds borrowed by Landlord, whether secured or unsecured and all payments of base rent (but not taxes or operating expenses) under any ground lease or other underlying lease of all or any portion of the Project; 

(d) depreciation of the Project (except for capital improvements, the cost of which are includable in Operating Expenses); 

(e) advertising, legal and space planning expenses and leasing commissions and other costs and expenses incurred in procuring and leasing
space to tenants for the Project, including any leasing office maintained in the Project, free rent and construction allowances for tenants; 
 (f) legal and other expenses incurred in the negotiation or enforcement of leases; 

(g) completing, fixturing, improving, renovating, painting, redecorating or other work, which Landlord pays for or performs for other
tenants within their premises, and costs of correcting defects in such work; 
 (h) costs of utilities outside normal business
hours sold to tenants of the Project; 
 (i) costs to be reimbursed by other tenants of the Project or Taxes to be paid directly
by Tenant or other tenants of the Project, whether or not actually paid; 
 (j) salaries, wages, benefits and other compensation
paid to officers and employees of Landlord who are not assigned in whole or in part to the operation, management, maintenance or repair of the Project; 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 5
 
  

 (k) general organizational, administrative and overhead costs relating to maintaining
Landlord’s existence, either as a corporation, partnership, or other entity, including general corporate, legal and accounting expenses; 
 (l) costs (including attorneys’ fees and costs of settlement, judgments and payments in lieu thereof) incurred in connection with disputes with tenants, other occupants, or prospective tenants, and
costs and expenses, including legal fees, incurred in connection with negotiations or disputes with employees, consultants, management agents, leasing agents, purchasers or mortgagees of the Building; 

(m) costs incurred by Landlord due to the violation by Landlord, its employees, agents or contractors or any tenant of the terms and
conditions of any lease of space in the Project or any Legal Requirement (as defined in Section 8); 
 (n)
penalties, fines or interest incurred as a result of Landlord’s inability or failure to make payment of Taxes and/or to file any tax or informational returns when due, or from Landlord«’s failure to make any payment of Taxes required
to be made by Landlord hereunder before delinquency; 
 (o) overhead and profit increment paid to Landlord or to subsidiaries or
affiliates of Landlord for goods and/or services in or to the Project to the extent the same exceeds the costs of such goods and/or services rendered by unaffiliated third parties on a competitive basis; 

(p) costs of Landlord’s charitable or political contributions, or of fine art maintained at the Project; 

(q) costs in connection with services (including electricity), items or other benefits of a type which are not standard for the Project
and which are not available to Tenant without specific charges therefor, but which are provided to another tenant or occupant of the Project, whether or not such other tenant or occupant is specifically charged therefor by Landlord; 

(r) costs incurred in the sale or refinancing of the Project; 
 (s) net income taxes of Landlord or the owner of any interest in the Project, franchise, capital stock, gift, estate or inheritance taxes or any federal, state or local documentary taxes imposed against
the Project or any portion thereof or interest therein, or any income taxes arising out of or related to ownership and operation of income producing real estate, or any excise taxes imposed upon Landlord based upon gross or net rentals or other
income received by it; 
 (t) costs incurred in connection with upgrading the Building to comply with laws, rules, codes and
other Legal Requirements in effect prior to the Commencement Date; and 
 (u) any expenses otherwise includable within Operating
Expenses to the extent actually reimbursed by persons other than tenants of the Project under leases for space in the Project. 

Within 90 days after the end of each calendar year (or such longer period as may be reasonably required), Landlord shall furnish to
Tenant a statement (an “Annual Statement”) showing in reasonable detail: (a) the total and Tenant’s Share of actual Operating Expenses for the previous calendar year, and (b) the total of Tenant’s payments
in respect of Operating Expenses for such year. If Tenant’s Share of actual Operating Expenses for such year exceeds Tenant’s payments of Operating Expenses for such year, the excess shall be due and payable by Tenant as Rent within 30
days after delivery of such Annual Statement to Tenant. If Tenant’s payments of Operating Expenses for such year exceed Tenant’s Share of actual Operating Expenses for such year Landlord shall pay the excess to Tenant within 30 days after
delivery of such Annual Statement, except that after the expiration, or earlier termination of the Term or if Tenant is delinquent in its obligation to pay Rent, Landlord shall pay the excess to Tenant after deducting all other amounts due Landlord.

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 6
 
  

 The Annual Statement shall be final and binding upon Tenant unless Tenant, within 90
days after Tenant’s receipt thereof, shall contest any item therein by giving written notice to Landlord, specifying each item contested and the reason therefor. If, during such 90 day period, Tenant reasonably and in good faith questions or
contests the accuracy of Landlord’s statement of Tenant’s Share of Operating Expenses, Landlord will provide Tenant with access to Landlord’s books and records relating to the operation of the Project and such information as Landlord
reasonably determines to be responsive to Tenant’s questions (the “Expense Information”). If, after Tenant’s review of such Expense Information, Landlord and Tenant cannot agree upon the amount of Tenant’s Share of
Operating Expenses, then Tenant shall have the right to have an independent public accounting firm selected by Tenant working pursuant to a fee arrangement other than a contingent fee (at Tenant’s sole cost and expense) and approved by Landlord
(which approval shall not be unreasonably withheld or delayed), audit and/or review the Expense Information for the year in question (the “Independent Review”). The results of any such Independent Review shall be binding on Landlord
and Tenant. If the Independent Review shows that the payments actually made by Tenant with respect to Operating Expenses for the calendar year in question exceeded Tenant’s Share of Operating Expenses for such calendar year, Landlord shall at
Landlord’s option either (i) credit the excess amount to the next succeeding installments of estimated Operating Expenses or (ii) pay the excess to Tenant within 30 days after delivery of such statement, except that after the
expiration or earlier termination of this Lease or if Tenant is delinquent in its obligation to pay Rent, Landlord shall pay the excess to Tenant after deducting all other amounts due Landlord. If the Independent Review shows that Tenant’s
payments with respect to Operating Expenses for such calendar year were less than Tenant’s Share of Operating Expenses for the calendar year, Tenant shall pay the deficiency to Landlord within 30 days after delivery of such statement. If the
Independent Review shows that Tenant has overpaid with respect to Operating Expenses by more than 5% then Landlord shall reimburse Tenant for all costs incurred by Tenant for the Independent Review. Operating Expenses for the calendar years in which
Tenant’s obligation to share therein begins and ends shall be prorated. Notwithstanding anything set forth herein to the contrary, if the Project is not at least 95% occupied on average during any year of the Term, Tenant’s Share of
Operating Expenses for such year shall be computed as though the Building had been 95% occupied on average during such year. 

“Tenant’s Share” shall be the percentage set forth in the Basic Lease Provisions as Tenant’s Share as
reasonably adjusted by Landlord for changes in the physical size of the Premises or the Project occurring thereafter. Landlord may equitably increase Tenant’s Share for any item of expense or cost reimbursable by Tenant that relates to a
repair, replacement, or service that benefits only the Premises or only a portion of the Project that includes the Premises or that varies with occupancy or use. Base Rent, Tenant’s Share of Operating Expenses and all other amounts payable by
Tenant to Landlord hereunder are collectively referred to herein as “Rent.” 
 7. Security Deposit.
Tenant shall deposit with Landlord, upon delivery of an executed copy of this Lease to Landlord, a security deposit (the “Security Deposit”) for the performance of all of Tenant’s obligations hereunder in the amount set
forth in the Basic Lease Provisions, which Security Deposit shall be in the form of an unconditional and irrevocable letter of credit (the “Letter of Credit”): (i) substantially in the form attached hereto as Exhibit
F or such other form satisfactory to Landlord, (ii) naming Landlord as beneficiary, (iii) expressly allowing Landlord to draw upon it at any time from time to time by delivering to the issuer notice that Landlord is entitled to draw
thereunder, (iv) issued by an FDIC-insured financial institution satisfactory to Landlord; Landlord approves Silicon Valley Bank as an approved issuer, and (v) redeemable by presentation of a sight draft in the State of California.
If Tenant does not provide Landlord with a substitute Letter of Credit complying with all of the requirements hereof at least 10 days before the stated expiration date of any then current Letter of Credit, Landlord shall have the right to draw the
full amount of the current Letter of Credit and hold the funds drawn in cash without obligation for interest thereon as the Security Deposit. The Security Deposit shall be held by Landlord as security for the performance of Tenant’s obligations
under this Lease. The Security Deposit is not an advance rental deposit or a measure of Landlord’s damages in case of Tenant’s default. Upon each occurrence of a Default (as defined in Section 21), Landlord may use all or any
part of the Security Deposit to pay delinquent payments due under this Lease, and the cost of any damage, injury, expense or liability caused by such Default, without prejudice to any other remedy provided herein or provided by law. Upon any such
use of all or any portion of the Security Deposit, 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 7
 
  

 
Tenant shall pay Landlord on demand the amount that will restore the Security Deposit to the amount set forth in the Basic Lease Provisions. Tenant hereby waives the provisions of any law, now or
hereafter in force, which provide that Landlord may claim from a security deposit only those sums reasonably necessary to remedy defaults in the payment of Rent, to repair damage caused by Tenant or to clean the Premises, it being agreed that
Landlord may, in addition, claim those sums reasonably necessary to compensate Landlord for any other loss or damage, foreseeable or unforeseeable, caused by the act or omission of Tenant or any officer, employee, agent or invitee of Tenant. Upon
bankruptcy or other debtor-creditor proceedings against Tenant, the Security Deposit shall be deemed to be applied first to the payment of Rent and other charges due Landlord for periods prior to the filing of such proceedings. Upon any such use of
all or any portion of the Security Deposit, Tenant shall, within 5 days after demand from Landlord, restore the Security Deposit to its original amount. If Tenant shall fully perform every provision of this Lease to be performed by Tenant, the
Security Deposit, or any balance thereof (i.e., after deducting therefrom all amounts to which Landlord is entitled under the provisions of this Lease), shall be returned to Tenant (or, at Landlord’s option, to the last assignee of
Tenant’s interest hereunder) within 30 days after the expiration or earlier termination of this Lease. 
 If Landlord
transfers its interest in the Project or this Lease, Landlord shall either (a) transfer any Security Deposit then held by Landlord to a person or entity assuming Landlord’s obligations under this Section 7, or (b) return
to Tenant any Security Deposit then held by Landlord and remaining after the deductions permitted herein. Upon such transfer to such transferee or the return of the Security Deposit to Tenant, Landlord shall have no further obligation with respect
to the Security Deposit, and Tenant’s right to the return of the Security Deposit shall apply solely against Landlord’s transferee. The Security Deposit is not an advance rental deposit or a measure of Landlord’s damages in case of
Tenant’s default. Landlord’s obligation respecting the Security Deposit is that of a debtor, not a trustee, and no interest shall accrue thereon. 
 8. Use. The Premises shall be used solely for the Permitted Use set forth in the Basic Lease Provisions, and in compliance with all laws, orders, judgments, ordinances, regulations, codes,
directives, permits, licenses, covenants and restrictions now or hereafter applicable to the Premises, and to the use and occupancy thereof, including, without limitation, the Americans With Disabilities Act, 42 U.S.C. § 12101, et seq.
(together with the regulations promulgated pursuant thereto, “ADA”) (collectively, “Legal Requirements” and each, a “Legal Requirement”). Tenant shall, upon 5 days’ written
notice from Landlord (a “Discontinuance Notice”), discontinue any use of the Premises which is declared by any Governmental Authority (as defined in Section 10) having jurisdiction to be a violation of a Legal
Requirement. Upon receipt of any Discontinuance Notice, Tenant shall have the right to terminate this Lease by written notice to Landlord given not more than 90 days thereafter. Tenant will not use or permit the Premises to be used for any purpose
or in any manner that would void Tenant’s or Landlord’s insurance, increase the insurance risk, or cause the disallowance of any sprinkler or other credits. Tenant shall not permit any part of the Premises to be used as a “place of
public accommodation”, as defined in the ADA or any similar legal requirement. Tenant shall reimburse Landlord promptly upon demand for any additional premium charged for any such insurance policy by reason of Tenant’s failure to comply
with the provisions of this Section or otherwise caused by Tenant’s use and/or occupancy of the Premises. Tenant will use the Premises in a careful, safe and proper manner and will not commit or permit waste, overload the floor or structure of
the Premises, subject the Premises to use that would damage the Premises or obstruct or interfere with the rights of Landlord or other tenants or occupants of the Project, including conducting or giving notice of any auction, liquidation, or going
out of business sale on the Premises, or using or allowing the Premises to be used for any unlawful purpose. Tenant shall cause any equipment or machinery to be installed in the Premises so as to reasonably prevent sounds or vibrations from the
Premises from extending into Common Areas, or other space in the Project. Tenant shall not place any machinery or equipment weighing 500 pounds or more in or upon the Premises or transport or move such items through the Common Areas of the Project
or in the Project elevators without the prior written consent of Landlord. Landlord consents to the installation of NMR machinery in the Premises. Except as may be provided under the Work Letter, Tenant shall not, without the prior written consent
of Landlord, use the Premises in any manner which will require ventilation, air exchange, heating, gas, steam, electricity or water beyond the existing capacity of the Project as proportionately allocated to the Premises based upon Tenant’s
Share as usually furnished for the Permitted Use. 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 8
 
  

 Landlord shall, as an Operating Expense (to the extent such Legal Requirement is
generally applicable to similar buildings in the area in which the Project is located) or at Tenant’s expense (to the extent such Legal Requirement is applicable solely by reason of Tenant’s, as compared to other tenants of the Project,
particular use of the Premises) make any alterations or modifications to the Common Areas or the exterior of the Building that are required by Legal Requirements, including the Americans With Disabilities Act, 42 U.S.C. § 12101, et seq.
(together with regulations promulgated pursuant thereto, “ADA”). Tenant, at its sole expense, shall make any alterations or modifications to the interior of the Premises that are required by Legal Requirements (including,
without limitation, compliance of the Premises with the ADA. Notwithstanding any other provision herein to the contrary, Tenant shall be responsible for any and all demands, claims, liabilities, losses, costs, expenses, actions, causes of action,
damages or judgments, and all reasonable expenses incurred in investigating or resisting the same (including, without limitation, reasonable attorneys’ fees, charges and disbursements and costs of suit) (collectively,
“Claims”) arising out of or in connection with any Legal Requirements which apply to Tenant’s particular use of the Premises, as opposed to general use categories such as research and development or office use, and
Tenant shall indemnify, defend, hold and save Landlord harmless from and against any and all Claims arising out of or in connection with any failure of the Premises to comply with any Legal Requirement. Notwithstanding the foregoing or any other
provision of this Lease, however, Tenant shall not be responsible for compliance with any such Legal Requirements requiring (a) any structural repairs or modifications; (b) any repairs or modification of any condition existing in the
Premises or the Building prior to the Lease Commencement Date; (c) repairs or modifications to any utility or any building service equipment; or (c) installation of new building service equipment, such as fire detection or suppression
equipment, unless such repairs, modifications, or installations shall (i) be due to Tenant’s particular manner of use of the Premises (as opposed to research and development or office use generally), or (ii) be due to the negligence
or willful misconduct of Tenant or any agent, employee, or contractor of Tenant. 
 9. Holding Over. If, with
Landlord’s express written consent, Tenant retains possession of the Premises after the termination of the Term, (i) unless otherwise agreed in such written consent, such possession shall be subject to immediate termination by Landlord at
any time, (ii) all of the other terms and provisions of this Lease (including, without limitation, the adjustment of Base Rent pursuant to Section 5 hereof) shall remain in full force and effect (excluding any expansion or renewal
option or other similar right or option) during such holdover period, (iii) Tenant shall continue to pay Base Rent in the amount payable upon the date of the expiration or earlier termination of this Lease or such other amount as Landlord may
indicate, in Landlord’s sole and absolute discretion, in such written consent, and (iv) all other payments shall continue under the terms of this Lease. If Tenant remains in possession of the Premises after the expiration or earlier
termination of the Term without the express written consent of Landlord, (A) Tenant shall become a tenant at sufferance upon the terms of this Lease except that the monthly rental shall be equal to 150% of Rent in effect during the last 30 days
of the Term, and (B) if Tenant holds over for more than 30 days and Landlord gives Tenant written notice that Landlord requires possession of the Premises for delivery to a subsequent tenant, Tenant shall be responsible for all damages suffered
by Landlord resulting from or occasioned by Tenant’s holding over, including consequential damages of which Tenant has received prior notice. No holding over by Tenant, whether with or without consent of Landlord, shall operate to extend this
Lease except as otherwise expressly provided, and this Section 9 shall not be construed as consent for Tenant to retain possession of the Premises. Acceptance by Landlord of Rent after the expiration of the Term or earlier termination of
this Lease shall not result in a renewal or reinstatement of this Lease. 
 10. Taxes. Landlord shall pay, as part of
Operating Expenses, all taxes, levies, assessments and governmental charges of any kind (collectively referred to as “Taxes”) imposed by any federal, state, regional, municipal, local or other governmental authority or
agency, including, without limitation, quasi-public agencies (collectively, “Governmental Authority”) during the Term, including, without limitation, all Taxes: (i) imposed on or measured by or based, in whole or in
part, on rent payable to Landlord under this Lease and/or from the rental by Landlord of the Project or any portion thereof, or (ii) based on the square footage, assessed value or other measure or evaluation of any kind of the Premises or the
Project, or (iii) assessed or imposed by or on the operation or maintenance of any portion of the Premises or the Project, including parking, or (iv) assessed or imposed by, or at the direction of, or resulting from

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 9
 
  

 
statutes or regulations, or interpretations thereof, promulgated by, any Governmental Authority, or (v) imposed as a license or other fee on Landlord’s business of leasing space in the
Project. Landlord may contest by appropriate legal proceedings the amount, validity, or application of any Taxes or liens securing Taxes. Taxes shall not include any net income taxes imposed on Landlord. If any such Tax is levied or assessed
directly against Tenant, then Tenant shall be responsible for and shall pay the same at such times and in such manner as the taxing authority shall require. Tenant shall pay, prior to delinquency, any and all Taxes levied or assessed against any
personal property or trade fixtures placed by Tenant in the Premises, whether levied or assessed against Landlord or Tenant. If any Taxes on Tenant’s personal property or trade fixtures are levied against Landlord or Landlord’s property,
or if the assessed valuation of the Project is increased by a value attributable to improvements in or alterations to the Premises, whether owned by Landlord or Tenant and whether or not affixed to the real property so as to become a part thereof,
higher than the base valuation on which Landlord from time-to-time allocates Taxes to all tenants in the Project, Landlord shall have the right, but not the obligation, to pay such Taxes. Landlord’s determination of any excess assessed
valuation shall be binding and conclusive, absent manifest error. The amount of any such payment by Landlord shall constitute Additional Rent due from Tenant to Landlord immediately upon demand. The Landlord’s taxes shall mean such amounts as
shall be finally determined after deducting abatements, rebates or refunds, if any, less the costs and expenses of obtaining the same. For the purposes of determining payments due from Tenant to Landlord, the Landlord’s taxes shall be deemed to
be the taxes assessed for each calendar year until such time as an abatement, rebate or refund shall be made for such tax year, and if any such abatement, rebate or refund shall be made for any tax year, an appropriate adjustment or refund shall be
made within thirty (30) days of receipt of the same by Landlord in the amount due from or paid by Tenant to Landlord on account of such Taxes dependent upon the amount of such abatement, rebate or refund less the cost and expense of obtaining
the same. Landlord’s obligations pursuant to this Section 10 to rebate, refund or otherwise adjust any payment by Tenant of Additional Rent shall survive the expiration or earlier termination of this Lease. 

11. Parking. Subject to all matters of record, Force Majeure, a Taking (as defined in Section 19 below) and the
exercise by Landlord of its rights hereunder, Tenant shall have the right, at no additional cost to Tenant, in common with other tenants of the Project pro rata in accordance with the rentable area of the Premises and the rentable areas of the
Project occupied by such other tenants, to park in those areas designated for non-reserved parking, subject in each case to Landlord’s rules and regulations. Landlord may allocate parking spaces among Tenant and other tenants in the Project pro
rata as described above if Landlord determines that such parking facilities are becoming crowded, provided that, subject to all matters of record, Force Majeure, a Taking and the exercise by Landlord of its rights hereunder as aforesaid, Tenant
shall at all times be entitled to use 22 parking spaces. Landlord shall not be responsible for enforcing Tenant’s parking rights against any third parties, including other tenants of the Project. Notwithstanding anything herein to the contrary,
Tenant shall at all times be entitled to 22 parking spaces. 
 12. Utilities, Services. 

Landlord shall provide, subject to the terms of this Section 12, water, electricity, heat, light, power, telephone, sewer,
and other utilities (including gas and fire sprinklers to the extent the Project is plumbed for such services), refuse and trash collection and janitorial services (collectively, “Utilities”). Landlord shall pay, as Operating
Expenses or subject to Tenant’s reimbursement obligation, for all Utilities used on the Premises, all maintenance charges for Utilities, and any storm sewer charges or other similar charges for Utilities imposed by any Governmental Authority or
Utility provider, and any taxes, penalties, surcharges or similar charges thereon. Landlord may cause, at Tenant’s expense, any Utilities to be separated metered or charged directly to Tenant by the provider. Landlord represents that the
Premises are currently submetered with respect to electrical service and that Landlord shall pass through to Tenant the actual amount charged by the electrical provider, as measured by such submeter, without any mark-up by Landlord. Tenant shall pay
directly to the Utility provider, prior to delinquency, any separately metered Utilities and services which may be furnished to Tenant or the Premises during the Term. Tenant shall pay, as part of Operating Expenses, its share of all charges for
jointly metered Utilities based upon consumption, as reasonably determined by Landlord. No 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 10
 
  

 
interruption or failure of Utilities, from any cause whatsoever other than Landlord’s willful misconduct, shall result in eviction or constructive eviction of Tenant, termination of this
Lease or the abatement of Rent. Tenant agrees to limit use of water and sewer with respect to Common Areas to normal restroom use. 
 13. Alterations and Tenant’s Property. Any alterations, additions, or improvements made to the Premises by or on behalf of Tenant, including additional locks or bolts of any kind or nature
upon any doors or windows in the Premises, but excluding installation, removal or realignment of furniture systems (other than removal of furniture systems owned or paid for by Landlord) not involving any modifications to the structure or
connections (other then by ordinary plugs or jacks) to Building Systems (as defined in Section 14) (“Alterations”) shall be subject to Landlord’s prior written consent, which may be given or withheld in
Landlord’s sole discretion if any such Alteration affects the structure or Building Systems, but which shall otherwise not be unreasonably withheld or delayed. Notwithstanding the foregoing, Tenant may make alterations to the Premises which do
not affect the Building structure without Landlord’s consent and without the need for construction documents, provided that such alterations involve only non-structural work to the Premises (such as replacement of floor coverings, window
coverings, fixtures, equipment and signage), and do not exceed $50,000 in cost for any one project. If Landlord approves any Alterations, Landlord may impose such conditions on Tenant in connection with the commencement, performance and completion
of such Alterations as Landlord may deem appropriate in Landlord’s reasonable discretion. Any request for approval shall be in writing, delivered not less than 15 business days in advance of any proposed construction, and accompanied by plans,
specifications, bid proposals, work contracts and such other information concerning the nature and cost of the alterations as may be reasonably requested by Landlord, including the identities and mailing addresses of all persons performing work or
supplying materials. Landlord’s right to review plans and specifications and to monitor construction shall be solely for its own benefit, and Landlord shall have no duty to ensure that such plans and specifications or construction comply with
applicable Legal Requirements. Tenant shall cause, at its sole cost and expense, all Alterations to comply with insurance requirements and with Legal Requirements and shall implement at its sole cost and expense any alteration or modification
required by Legal Requirements as a result of any Alterations. Tenant shall reimburse Landlord, as Additional Rent, for the actual out-of pocket expense incurred by Landlord (in an amount not to exceed $2,000 for any one project) for review and
approval of Tenant’s plans and specifications and monitoring of construction (i.e., engineering plan review, on-site inspections of work and similar work by or on behalf of Landlord). Before Tenant begins any Alteration, Landlord may post on
and about the Premises notices of non-responsibility pursuant to applicable law. Tenant shall reimburse Landlord for, and indemnify and hold Landlord harmless from, any expense incurred by Landlord by reason of faulty work done by Tenant or its
contractors, delays caused by such work, or inadequate cleanup. 
 Tenant shall furnish security or make other arrangements
satisfactory to Landlord to assure payment for the completion of all Alterations work free and clear of liens, and shall provide (and cause each contractor or subcontractor to provide) certificates of insurance for workers’ compensation and
other coverage in amounts and from an insurance company satisfactory to Landlord protecting Landlord against liability for personal injury or property damage during construction. Upon completion of any Alterations, Tenant shall deliver to Landlord:
(i) sworn statements setting forth the names of all contractors and subcontractors who did the work and final lien waivers from all such contractors and subcontractors; and (ii) “as built” plans for any such Alteration.

 Other than (i) the items, if any, listed on Exhibit E attached hereto, (ii) any items agreed by
Landlord in writing to be included on Exhibit E in the future, and (iii) any trade fixtures, machinery, equipment and other personal property not paid for out of the TI Fund (as defined in the Work Letter) which may be removed without
material damage to the Premises, which damage shall be repaired (including capping or terminating utility hook-ups behind walls) by Tenant during the Term (collectively, “Tenant’s Property”), all property of any kind
paid for with the TI Fund, all Alterations, real property fixtures, built-in machinery and equipment, built-in casework and cabinets and other similar additions and improvements built into the Premises so as to become an integral part of the
Premises such as fume hoods which penetrate the roof or plenum area, built-in cold rooms, built-in warm rooms, walk-in cold rooms, walk-in warm rooms, deionized water systems, glass 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 11
 
  

 
washing equipment, autoclaves, chillers, built-in plumbing, electrical and mechanical equipment and systems, and any power generator and transfer switch (collectively,
“Installations”) shall be and shall remain the property of Landlord during the Term and following the expiration or earlier termination of the Term, shall not be removed by Tenant at any time during the Term and shall remain
upon and be surrendered with the Premises as a part thereof in accordance with Section 29 following the expiration or earlier termination of this Lease; provided, however, that Landlord shall, at the time its approval of
such Installation is requested, notify Tenant if it has elected to cause Tenant to remove such Installation upon the expiration or earlier termination of this Lease. Landlord agrees that Tenant shall have no obligation to remove any Installation
included within the initial Landlord’s Work. If Landlord so elects, Tenant shall remove such Installation upon the expiration or earlier termination of this Lease and restore any damage caused by or occasioned as a result of such removal,
including, when removing any of Tenant’s Property which was plumbed, wired or otherwise connected to any of the Building Systems, capping off all such connections behind the walls of the Premises and repairing any holes. During any such
restoration period, Tenant shall pay Rent to Landlord as provided herein as if said space were otherwise occupied by Tenant. 

14. Landlord’s Repairs. Landlord, as an Operating Expense, shall maintain all of the structural, exterior, parking and other
Common Areas of the Project, including foundation, roof, exterior walls, structural floors, HVAC, plumbing, fire sprinklers, elevators and all other building systems serving the Premises and other portions of the Project (“Building
Systems”), in good repair, reasonable wear and tear and uninsured losses and damages caused by Tenant, or by any of Tenant’s agents, servants, employees, invitees and contractors (collectively, “Tenant Parties”)
excluded. Losses and damages caused by Tenant or any Tenant Party shall be repaired by Landlord, to the extent not covered by insurance, at Tenant’s sole cost and expense. Landlord reserves the right to stop Building Systems services when
necessary (i) by reason of accident or emergency, or (ii) for planned repairs, alterations or improvements, which are, in the judgment of Landlord, desirable or necessary to be made, until said repairs, alterations or improvements shall
have been completed. Landlord shall have no responsibility or liability for failure to supply Building Systems services during any such period of interruption; provided, however, that Landlord shall, except in case of emergency, make a
commercially reasonable effort to give Tenant 24 hours advance notice of any planned stoppage of Building Systems services for routine maintenance, repairs, alterations or improvements. Tenant shall promptly give Landlord written notice of any
repair required by Landlord pursuant to this Section, after which Landlord shall have a reasonable opportunity to effect such repair. Landlord shall not be liable for any failure to make any repairs or to perform any maintenance unless such failure
shall persist for an unreasonable time after Tenant’s written notice of the need for such repairs or maintenance. Tenant waives its rights under any state or local law to terminate this Lease or to make such repairs at Landlord’s expense
and agrees that the parties’ respective rights with respect to such matters shall be solely as set forth herein. Repairs required as the result of fire, earthquake, flood, vandalism, war, or similar cause of damage or destruction shall be
controlled by Section 19. 
 15. Tenant’s Repairs. Subject to Section 14 hereof, Tenant, at
its expense, shall repair, replace and maintain in good condition all portions of the Premises, including, without limitation, entries, doors, ceilings, interior windows, interior walls, and the interior side of demising walls. Should Tenant fail to
make any such repair or replacement or fail to maintain the Premises, Landlord shall give Tenant notice of such failure. If Tenant fails to commence cure of such failure within 10 days of Landlord’s notice, and thereafter diligently prosecute
such cure to completion, Landlord may perform such work and shall be reimbursed by Tenant within 10 days after demand therefor; provided, however, that if such failure by Tenant creates or could create an emergency, Landlord may immediately commence
cure of such failure and shall thereafter be entitled to recover the costs of such cure from Tenant. Subject to Sections 18 and 19, Tenant shall bear the full uninsured cost of any repair or replacement to any part of the Project that results
from damage caused by Tenant or any Tenant Party and any repair that benefits only the Premises. 
 16. Mechanic’s
Liens. Tenant shall discharge, by bond or otherwise, any mechanic’s lien filed against the Premises or against the Project for work claimed to have been done for, or materials 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 12
 
  

 
claimed to have been furnished to, Tenant within 10 days after the filing thereof, at Tenant’s sole cost and shall otherwise keep the Premises and the Project free from any liens arising out
of work performed, materials furnished or obligations incurred by Tenant. Should Tenant fail to discharge any lien described herein, Landlord shall have the right, but not the obligation, to pay such claim or post a bond or otherwise provide
security to eliminate the lien as a claim against title to the Project and the cost thereof shall be immediately due from Tenant as Additional Rent. If Tenant shall lease or finance the acquisition of office equipment, furnishings, or other personal
property of a removable nature utilized by Tenant in the operation of Tenant’s business, Tenant warrants that any Uniform Commercial Code Financing Statement filed as a matter of public record by any lessor or creditor of Tenant will upon its
face or by exhibit thereto indicate that such Financing Statement is applicable only to removable personal property of Tenant located within the Premises. In no event shall the address of the Project be furnished on the statement without qualifying
language as to applicability of the lien only to removable personal property, located in an identified suite held by Tenant. 

17. Indemnification. Tenant hereby indemnifies and agrees to defend, save and hold Landlord harmless from and against any and all
Claims for injury or death to persons or damage to property occurring within or about the Premises, arising directly or indirectly out use or occupancy of the Premises or a breach or default by Tenant in the performance of any of its obligations
hereunder, unless caused solely by the willful misconduct or negligence of Landlord or any of Landlord’s agents, employees or contractors. Landlord shall not be liable to Tenant for, and Tenant assumes all risk of damage to, personal property
(including, without limitation, loss of records kept within the Premises). Tenant further hereby irrevocably waives any and all Claims for injury to Tenant’s business or loss of income relating to any such damage or destruction of personal
property (including, without limitation, any loss of records), unless caused by the willful misconduct or negligence of Landlord. Landlord shall not be liable for any damages arising from any act, omission or neglect of any tenant in the Project or
of any other third party. 
 Landlord shall indemnify and save harmless Tenant, and the directors, officers, agents, and
employees of Tenant, against and from all claims, expenses, or liabilities of whatever nature (a) arising directly or indirectly from any default or breach by Landlord or Landlord’s contractors, licensees, agents, servants, or employees
under any of the terms or covenants of this Lease or failure of Landlord or such persons to comply with any rule, order, regulation, or lawful direction now or hereafter in force of any public authority, in each case to the extent the same related,
directly or indirectly to the management operation or repair of the Building and/or the use of the common areas; or (b) arising directly or indirectly from any accident, injury, or damage, however caused, to any person or property, on the
common area; or (c) arising directly or indirectly from any accident, injury, or damage to any person or property occurring outside the Premises but within the Building or on the land, to the extent such accident, injury, or damage results, or
is claimed to have resulted, from any negligent act or omission, or negligence on the part of Landlord, or Landlord’s contractors, licensees, agents, servants, employees, or customers, or anyone claiming by or through Landlord; provided,
however, that in no event shall Landlord be obligated under this Section 17 to indemnify or save harmless Tenant, or the directors, officers, agents, employees of Tenant, to the extent such claim, expense, or liability results from any
omission, fault, negligence, or other misconduct of Tenant or the officers, agents, or employees of Tenant. 
 This indemnity
and hold harmless agreement shall include, without limitation, indemnity against all expenses, attorneys’ fees and liabilities incurred in connection with any such claim or proceeding brought thereon and the defense thereof with counsel
reasonably acceptable to Tenant. At the request of Tenant, Landlord shall defend any such claim or proceeding directly on behalf and for the benefit of Tenant. The provisions of this Section shall survive the Term of this Lease. 

18. Insurance. Landlord shall maintain all risk property and, if applicable, sprinkler damage insurance covering the full
replacement cost of the Project. Landlord shall further procure and maintain commercial general liability insurance with a single loss limit of not less than $2,000,000 for bodily injury and property damage with respect to the Project. Landlord may,
but is not obligated to, maintain such other insurance and additional coverages as it may deem necessary, including, but not limited to, flood, environmental hazard and earthquake, loss or failure of building equipment, errors and omissions, rental
loss during the period of repair or rebuilding, workers’ compensation insurance and fidelity bonds for 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 13
 
  

 
employees employed to perform services and insurance for any improvements installed by Tenant or which are in addition to the standard improvements customarily furnished by Landlord without
regard to whether or not such are made a part of the Project. All such insurance shall be included as part of the Operating Expenses. The Project may be included in a blanket policy (in which case the cost of such insurance allocable to the Project
will be determined by Landlord based upon the insurer’s cost calculations). 
 Tenant, at its sole cost and expense, shall
maintain during the Term: all risk property insurance with business interruption and extra expense coverage, covering the full replacement cost of all property and improvements installed or placed in the Premises by Tenant at Tenant’s expense;
workers’ compensation insurance with no less than the minimum limits required by law; employer’s liability insurance with such limits as required by law; and commercial general liability insurance, with a minimum limit of not less than
$2,000,000 per occurrence for bodily injury and property damage with respect to the Premises. The commercial general liability insurance policy shall name Landlord and Alexandria Real Estate Equities, Inc. and their respective officers, directors,
employees, managers, agents, invitees and contractors (collectively, “Landlord Parties”), as additional insureds. In addition, the commercial general liability insurance policy shall insure on an occurrence and not a claims-made
basis; shall be issued by insurance companies which have a rating of not less than policyholder rating of A and financial category rating of at least Class X in “Best’s Insurance Guide”; shall not be cancelable for nonpayment of
premium unless 30 days prior written notice shall have been given to Landlord from the insurer; shall contain a hostile fire endorsement and a contractual liability endorsement; and shall provide primary coverage to Landlord (any policy issued to
Landlord providing duplicate or similar coverage shall be deemed excess over Tenant’s policies). Copies of such policies (if requested by Landlord), or certificates of insurance showing the limits of coverage required hereunder and showing
Landlord and Alexandria Real Estate Equities, Inc. as additional insureds, along with reasonable evidence of the payment of premiums for the applicable period, shall be delivered to Landlord by Tenant upon commencement of the Term and upon each
renewal of said insurance. Tenant’s policy may be a “blanket policy” with an aggregate per location endorsement which specifically provides that the amount of insurance shall not be prejudiced by other losses covered by the policy.
Tenant shall, at least 5 days prior to the expiration of such policies, furnish Landlord with renewal certificates. 
 In each
instance where insurance is to name Landlord as an additional insured, Tenant shall upon written request of Landlord also designate and furnish certificates so evidencing Landlord as additional insured to: (i) any lender of Landlord holding a
security interest in the Project or any portion thereof, (ii) the landlord under any lease wherein Landlord is tenant of the real property on which the Project is located, if the interest of Landlord is or shall become that of a tenant under a
ground or other underlying lease rather than that of a fee owner, and/or (iii) any management company retained by Landlord to manage the Project. 
 The property insurance obtained by Landlord and Tenant shall include a waiver of subrogation by the insurers and all rights based upon an assignment from its insured, against Landlord or Tenant, and their
respective officers, directors, employees, managers, agents, invitees and contractors (“Related Parties”), in connection with any loss or damage thereby insured against. Neither party nor its respective Related Parties shall be
liable to the other for loss or damage caused by any risk insured against under property insurance required to be maintained hereunder, and each party waives any claims against the other party, and its respective Related Parties, for such loss or
damage. The failure of a party to insure its property shall not void this waiver. Landlord and its respective Related Parties shall not be liable for, and Tenant hereby waives all claims against such parties for, business interruption and losses
occasioned thereby sustained by Tenant or any person claiming through Tenant resulting from any accident or occurrence in or upon the Premises or the Project from any cause whatsoever. If the foregoing waivers shall contravene any law with respect
to exculpatory agreements, the liability of Landlord or Tenant shall be deemed not released but shall be secondary to the other’s insurer. 
 Landlord may require insurance policy limits to be raised to conform with requirements of Landlord’s lender and/or to bring coverage limits to levels then being generally required of new tenants
within the Project. 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 14
 
  

 19. Restoration. If, at any time during the Term, the Project or the Premises are
damaged or destroyed by a fire or other insured casualty, Landlord shall notify Tenant within 60 days after discovery of such damage as to the amount of time Landlord reasonably estimates it will take to restore the Project or the Premises, as
applicable (the “Restoration Period”). If the Restoration Period is estimated to exceed 12 months (the “Maximum Restoration Period”), either Landlord or Tenant may, by written notice to the other within 30 days
after Tenant’s receipt of such estimate, elect to terminate this Lease as of the date that is 75 days after the date of discovery of such damage or destruction. Unless either party so elects to terminate this Lease, Landlord shall, subject to
receipt of sufficient insurance proceeds (with any deductible to be treated as a current Operating Expense), promptly restore the Premises, including the initial Landlord’s Work (excluding any improvements installed thereafter by Tenant or by
Landlord and paid for by Tenant), subject to delays arising from the collection of insurance proceeds, from Force Majeure events or as needed to obtain any license, clearance or other authorization of any kind required to enter into and restore the
Premises issued by any Governmental Authority having jurisdiction over the use, storage, handling, treatment, generation, release, disposal, removal or remediation of Hazardous Materials (as defined in Section 31) in, on or about the
Premises (collectively referred to herein as “Hazardous Materials Clearances”); provided, however, that if repair or restoration of the Premises is not substantially complete as of the end of the Maximum Restoration
Period or, if longer, the Restoration Period, (a) Landlord may, in its sole and absolute discretion, elect not to proceed with such repair and restoration, in which event Landlord shall be relieved of its obligation to make such repairs or
restoration, or (b) Tenant may elect to terminate this Lease by notice thereof to Landlord, and, in either case, this Lease shall terminate as of the date that is 75 days after the later of: (i) discovery of such damage or destruction, or
(ii) the date all required Hazardous Materials Clearances are obtained, but Landlord shall retain any Rent paid and the right to any Rent payable by Tenant prior to such election by Landlord or Tenant. 

Tenant, at its expense, shall promptly perform, subject to delays arising from the collection of insurance proceeds, from Force Majeure
(as defined in Section 35) events or to obtain Hazardous Material Clearances, all repairs or restoration not required to be done by Landlord and shall promptly re-enter the Premises and commence doing business in accordance with this
Lease. Notwithstanding the foregoing, either Landlord or Tenant may terminate this Lease if the Premises are damaged during the last 1 year of the Term and Landlord reasonably estimates that it will take more than 2 months to repair such damage, or
if insurance proceeds are not available for such restoration. Rent shall be abated from the date all required Hazardous Material Clearances are obtained until the Premises are repaired and restored, in the proportion which the area of the Premises,
if any, which is not usable by Tenant bears to the total area of the Premises. Such abatement shall be the sole remedy of Tenant, and except as provided in this Section 19, Tenant waives any right to terminate the Lease by reason of
damage or casualty loss. 
 The provisions of this Lease, including this Section 19, constitute an express agreement
between Landlord and Tenant with respect to any and all damage to, or destruction of, all or any part of the Premises, or any other portion of the Project, and any statute or regulation which is now or may hereafter be in effect shall have no
application to this Lease or any damage or destruction to all or any part of the Premises or any other portion of the Project, the parties hereto expressly agreeing that this Section 19 sets forth their entire understanding and agreement
with respect to such matters. 
 20. Condemnation. If the whole or any material part of the Premises or the Project is
taken for any public or quasi-public use under governmental law, ordinance, or regulation, or by right of eminent domain, or by private purchase in lieu thereof (a “Taking” or “Taken”), and the Taking would in
Landlord’s reasonable judgment either prevent or materially interfere with Tenant’s use of the Premises for the conduct of Tenant’s business, including parking and access, or materially interfere with or impair Landlord’s
ownership or operation of the Project, then upon written notice by Landlord or Tenant this Lease shall terminate and Rent shall be apportioned as of said date. If part of the Premises shall be Taken, and this Lease is not terminated as provided
above, Landlord shall promptly restore the Premises and the Project as nearly as is commercially reasonable under the circumstances to their condition prior to such partial Taking and the rentable square footage of the Building, the rentable square
footage of the Premises, Tenant’s Share of Operating Expenses and the Rent payable hereunder during the unexpired 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 15
 
  

 
Term shall be reduced to such extent as may be fair and reasonable under the circumstances. During the performance of such restoration by Landlord, Rent shall be abated in the proportion which
the area of the Premises, if any, which is not usable by Tenant bears to the total area of the Premises. Upon any such Taking, Landlord shall be entitled to receive the entire price or award from any such Taking without any payment to Tenant, and
Tenant hereby assigns to Landlord Tenant’s interest, if any, in such award. Tenant shall have the right, to the extent that same shall not diminish Landlord’s award, to make a separate claim against the condemning authority (but not
Landlord) for such compensation as may be separately awarded or recoverable by Tenant for moving expenses and damage to Tenant’s Property, if a separate award for such items is made to Tenant. Tenant hereby waives any and all rights it might
otherwise have pursuant to any provision of state law to terminate this Lease upon a partial Taking of the Premises or the Project. 
 21. Events of Default. Each of the following events shall be a default (“Default”) by Tenant under this Lease: 

(a) Payment Defaults. Tenant shall fail to pay any installment of Rent or any other payment hereunder within 5 days after written
notice from Landlord that the same is due, provided that Landlord shall not be obligated to give such a notice more than one time in any 12 month period. 
 (b) Insurance. Any insurance required to be maintained by Tenant pursuant to this Lease shall be canceled or terminated or shall expire or shall be reduced or materially changed, and Tenant shall
fail to obtain replacement insurance within 30 days after receipt of notice thereof from Landlord or Tenant’s insurer, as applicable, or Landlord shall receive a notice of nonrenewal of any such insurance and Tenant shall fail to obtain
replacement insurance at least 20 days before the expiration of the current coverage. 
 (c) Abandonment. Tenant shall
abandon the Premises. Landlord agrees that Tenant shall not be deemed to have abandoned the Premises if (i) Tenant provides Landlord with reasonable advance notice prior to vacating and, at the time of vacating the Premises, (ii) Tenant
completes Tenant’s obligations with respect to the Surrender Plan in compliance with Section 29, (iii) Tenant has made reasonable arrangements with Landlord for the security of the Premises for the balance of the Term, and
(iv) Tenant continues during the balance of the Term to satisfy all of its obligations under the Lease as they come due. 

(d) Improper Transfer. Tenant shall assign, sublease or otherwise transfer or attempt to transfer all or any portion of
Tenant’s interest in this Lease or the Premises except as expressly permitted herein, or Tenant’s interest in this Lease shall be attached, executed upon, or otherwise judicially seized and such action is not released within 90 days of the
action. 
 (e) Liens. Tenant shall fail to discharge, bond over or otherwise obtain the release of any lien placed upon
the Premises in violation of this Lease within 10 days after any notice to Tenant that such lien is filed against the Premises. 

(f) Insolvency Events. Tenant or any guarantor or surety of Tenant’s obligations hereunder shall: (A) make a general
assignment for the benefit of creditors; (B) commence any case, proceeding or other action seeking to have an order for relief entered on its behalf as a debtor or to adjudicate it a bankrupt or insolvent, or seeking reorganization,
arrangement, adjustment, liquidation, dissolution or composition of it or its debts or seeking appointment of a receiver, trustee, custodian or other similar official for it or for all or of any substantial part of its property (collectively a
“Proceeding for Relief”); (C) become the subject of any Proceeding for Relief which is not dismissed within 90 days of its filing or entry; or (D) die or suffer a legal disability (if Tenant, guarantor, or surety is an
individual) or be dissolved or otherwise fail to maintain its legal existence (if Tenant, guarantor or surety is a corporation, partnership or other entity). 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 16
 
  

 (g) Estoppel Certificate or Subordination Agreement. Tenant fails to execute any
document required from Tenant under Sections 24 or 28 within 5 business days after a second notice requesting such document. 
 (h) Other Defaults. Tenant shall fail to comply with any provision of this Lease other than those specifically referred to in this Section 21, and, except as otherwise expressly
provided herein, such failure shall continue for a period of 21 days after written notice thereof from Landlord to Tenant. 
 Any notice given
under Section 21(h) hereof shall: (i) specify the alleged default, (ii) demand that Tenant cure such default, (iii) be in lieu of, and not in addition to, or shall be deemed to be, any notice required under any provision
of applicable law, and (iv) not be deemed a forfeiture or a termination of this Lease unless Landlord elects otherwise in such notice; provided that if the nature of Tenant’s default pursuant to Section 21(h) is such
that it cannot be cured by the payment of money and reasonably requires more than 21 days to cure, then Tenant shall not be deemed to be in default if Tenant commences such cure within said 21 day period and thereafter diligently prosecutes the same
to completion; provided, however, that such cure shall be completed no later than 45 days from the date of Landlord’s notice. 
 22. Landlord’s Remedies. 
 (a) Payment By Landlord; Interest.
Upon a Default by Tenant hereunder, Landlord may, without waiving or releasing any obligation of Tenant hereunder, make such payment or perform such act. All sums so paid or incurred by Landlord, together with interest thereon, from the date such
sums were paid or incurred, at the annual rate equal to 12% per annum or the highest rate permitted by law (the “Default Rate”), whichever is less, shall be payable to Landlord on demand as Additional Rent. Nothing herein shall
be construed to create or impose a duty on Landlord to mitigate any damages resulting from Tenant’s Default hereunder. 

(b) Late Payment Rent. Late payment by Tenant to Landlord of Rent and other sums due will cause Landlord to incur costs not
contemplated by this Lease, the exact amount of which will be extremely difficult and impracticable to ascertain. Such costs include, but are not limited to, processing and accounting charges and late charges which may be imposed on Landlord under
any Mortgage covering the Premises. Therefore, if any installment of Rent due from Tenant is not received by Landlord within 5 days after the date such payment is due, Tenant shall pay to Landlord an additional sum equal to 3% of the overdue Rent as
a late charge. The parties agree that this late charge represents a fair and reasonable estimate of the costs Landlord will incur by reason of late payment by Tenant. In addition to the late charge, Rent not paid when due shall bear interest at the
Default Rate from the 5th day after the date due until paid. 
 (c) Remedies. Upon the occurrence of a Default, Landlord,
at its option, without further notice or demand to Tenant, shall have in addition to all other rights and remedies provided in this Lease, at law or in equity, the option to pursue any one or more of the following remedies, each and all of which
shall be cumulative and nonexclusive, without any notice or demand whatsoever. 
 (i) Terminate this Lease, or at
Landlord’s option, Tenant’s right to possession only, in which event Tenant shall immediately surrender the Premises to Landlord, and if Tenant fails to do so, Landlord may, without prejudice to any other remedy which it may have for
possession or arrearages in rent, enter upon and take possession of the Premises and expel or remove Tenant and any other person who may be occupying the Premises or any part thereof, without being liable for prosecution or any claim or damages
therefor; 
 (ii) Upon any termination of this Lease, whether pursuant to the foregoing Section 22(c)(i) or
otherwise, Landlord may recover from Tenant the following: 
 (1) The worth at the time of award of any unpaid rent which has
been earned at the time of such termination; plus 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 17
 
  

 (2) The worth at the time of award of the amount by which the unpaid rent which would
have been earned after termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus 
 (3) The worth at the time of award of the amount by which the unpaid rent for the balance of the Term after the time of award exceeds the amount of such rental loss that Tenant proves could have been
reasonably avoided; plus 
 (4) Any other amount necessary to compensate Landlord for costs incurred by Landlord as a result of
Tenant’s default hereunder, specifically including, but not limited to, brokerage commissions and advertising expenses incurred, expenses of remodeling the Premises or any portion thereof for a new tenant, whether for the same or a different
use, and any special concessions made to obtain a new tenant; and 
 (5) At Landlord’s election, such other amounts in
addition to or in lieu of the foregoing as may be permitted from time to time by applicable law. 
 The term “rent” as used in
this Section 22 shall be deemed to be and to mean all sums of every nature required to be paid by Tenant pursuant to the terms of this Lease, whether to Landlord or to others. As used in Sections 22(c)(ii) (A) and (B),
above, the “worth at the time of award” shall be computed by allowing interest at the Default Rate. As used in Section 22(c)(ii)(C) above, the “worth at the time of award” shall be computed by
discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus 1%. 

(iii) Landlord may continue this Lease in effect after Tenant’s Default and recover rent as it becomes due (Landlord and Tenant
hereby agreeing that Tenant has the right to sublet or assign hereunder, subject only to reasonable limitations). Accordingly, if Landlord does not elect to terminate this Lease following a Default by Tenant, Landlord may, from time to time, without
terminating this Lease, enforce all of its rights and remedies hereunder, including the right to recover all Rent as it becomes due. 
 (iv) Whether or not Landlord elects to terminate this Lease following a Default by Tenant, Landlord shall have the right to terminate any and all subleases, licenses, concessions or other consensual
arrangements for possession entered into by Tenant and affecting the Premises or may, in Landlord’s sole discretion, succeed to Tenant’s interest in such subleases, licenses, concessions or arrangements. Upon Landlord’s election to
succeed to Tenant’s interest in any such subleases, licenses, concessions or arrangements, Tenant shall, as of the date of notice by Landlord of such election, have no further right to or interest in the rent or other consideration receivable
thereunder. 
 (v) Independent of the exercise of any other remedy of Landlord hereunder or under applicable law, Landlord may
conduct an environmental test of the Premises as generally described in Section 31(d) hereof, at Tenant’s expense. 
 (d) Effect of Exercise. Exercise by Landlord of any remedies hereunder or otherwise available shall not be deemed to be an acceptance of surrender of the Premises and/or a termination of this Lease
by Landlord, it being understood that such surrender and/or termination can be effected only by the express written agreement of Landlord and Tenant. Any law, usage, or custom to the contrary notwithstanding, Landlord shall have the right at all
times to enforce the provisions of this Lease in strict accordance with the terms hereof; and the failure of Landlord at any time to enforce its rights under this Lease strictly in accordance with same shall not be construed as having created a
custom in any way or manner contrary to the specific terms, provisions, and covenants of this Lease or as having modified the same and shall not be deemed a waiver of Landlord’s right to enforce one or more of its

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 18
 
  

 
rights in connection with any subsequent default. A receipt by Landlord of Rent or other payment with knowledge of the breach of any covenant hereof shall not be deemed a waiver of such breach,
and no waiver by Landlord of any provision of this Lease shall be deemed to have been made unless expressed in writing and signed by Landlord. To the greatest extent permitted by law, Tenant waives the service of notice of Landlord’s intention
to re-enter, re-take or otherwise obtain possession of the Premises as provided in any statute, or to institute legal proceedings to that end, and also waives all right of redemption in case Tenant shall be dispossessed by a judgment or by warrant
of any court or judge. Any reletting of the Premises or any portion thereof shall be on such terms and conditions as Landlord in its sole discretion may determine. Upon termination of this Lease by Landlord, Landlord shall use commercially
reasonable efforts to relet the Premises. Landlord shall not be liable for, nor shall Tenant’s obligations hereunder be diminished because of, Landlord’s failure to relet the Premises or collect rent due in respect of such reletting or
otherwise to mitigate any damages arising by reason of Tenant’s Default. 
 23. Assignment and Subletting.

 (a) General Prohibition. Without Landlord’s prior written consent, subject to and on the conditions described in
this Section 23, except for any Permitted Assignment, Tenant shall not, directly or indirectly, voluntarily or by operation of law, assign this Lease or sublease the Premises or any part thereof or mortgage, pledge, or hypothecate its
leasehold interest or grant any concession or license within the Premises, and any attempt to do any of the foregoing shall be void and of no effect. Except for any Permitted Assignment, if Tenant is a corporation, partnership or limited liability
company, the shares or other ownership interests thereof which are not actively traded upon a stock exchange or in the over-the-counter market, a transfer or series of transfers whereby 50% or more of the issued and outstanding shares or other
ownership interests of such corporation are, or voting control is, transferred (but excepting transfers upon deaths of individual owners) from a person or persons or entity or entities which were owners thereof at time of execution of this Lease to
persons or entities who were not owners of shares or other ownership interests of the corporation, partnership or limited liability company at time of execution of this Lease, shall be deemed an assignment of this Lease requiring the consent of
Landlord as provided in this Section 23. Notwithstanding the foregoing, neither an initial public offering of shares by Tenant, nor any private financing by institutional investors who regularly invest in private life science companies
shall be deemed an assignment of this Lease requiring the consent of Landlord as provided in this Section 23. 
 (b)
Permitted Transfers. If Tenant desires to assign, sublease, hypothecate or otherwise transfer this Lease or sublet the Premises other than pursuant to a Permitted Assignment (as defined below), then at least 10 business days, but not more
than 45 days, before the date Tenant desires the assignment or sublease to be effective (the “Assignment Date”), Tenant shall give Landlord a notice (the “Assignment Notice”) containing such information about the
proposed assignee or sublessee, including the proposed use of the Premises and any Hazardous Materials proposed to be used, stored handled, treated, generated in or released or disposed of from the Premises, the Assignment Date, any relationship
between Tenant and the proposed assignee or sublessee, and all material terms and conditions of the proposed assignment or sublease, including a copy of any proposed assignment or sublease in its final form, and such other information as Landlord
may deem reasonably necessary or appropriate to its consideration whether to grant its consent. Landlord may, by giving written notice to Tenant within 10 business days after receipt of the Assignment Notice: (i) grant such consent,
(ii) refuse such consent, in its sole and absolute discretion, if the proposed assignment, hypothecation or other transfer or subletting concerns more than (together with all other then effective subleases) 50% of the Premises,
(iii) refuse such consent, in its reasonable discretion, if the proposed subletting concerns (together with all other then effective subleases) 50% or less of the Premises (provided that Landlord shall further have the right to review and
approve or disapprove the proposed form of sublease prior to the effective date of any such subletting), or (iv) if the proposed assignment or sublease is for greater than 50% of the Premises or for the remainder of the Base Term or the
Extension Term (as hereinafter defined), as applicable, terminate this Lease with respect to the space described in the Assignment Notice as of the Assignment Date (an “Assignment Termination”). If Landlord delivers notice of its
election to exercise an Assignment Termination, Tenant shall have the right to withdraw such 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 19
 
  

 
Assignment Notice by written notice to Landlord of such election within 5 business days after Landlord’s notice electing to exercise the Assignment Termination. If Tenant withdraws such
Assignment Notice, this Lease shall continue in full force and effect. If Tenant does not withdraw such Assignment Notice, this Lease, and the term and estate herein granted, shall terminate as of the Assignment Date with respect to the space
described in such Assignment Notice. No failure of Landlord to exercise any such option to terminate this Lease, or to deliver a timely notice in response to the Assignment Notice, shall be deemed to be Landlord’s consent to the proposed
assignment, sublease or other transfer. Tenant shall reimburse Landlord for all of Landlord’s reasonable out-of-pocket expenses in connection with its consideration of any Assignment Notice. 

Notwithstanding the foregoing, Landlord’s consent to an assignment of this Lease or a subletting of any portion of the Premises to
any entity controlling, controlled by or under common control with Tenant shall not be required. In addition, Tenant shall have the right to assign this Lease, upon 30 days prior written notice to Landlord but without obtaining Landlord’s prior
written consent, to a corporation or other entity which is a successor-in-interest to Tenant, by way of merger, consolidation or corporate reorganization, or by the purchase of all or substantially all of the assets or the ownership interests of
Tenant provided that (i) such merger or consolidation, or such acquisition or assumption, as the case may be, is for a good business purpose and not principally for the purpose of transferring the Lease, and (ii) the net worth (as
determined in accordance with generally accepted accounting principles (“GAAP”)) of the assignee is not less than the net worth (as determined in accordance with GAAP) of Tenant as of the date of Tenant’s most current quarterly
or annual financial statements, and (iii) such assignee shall agree in writing to assume all of the terms, covenants and conditions of this Lease arising after the effective date of the assignment (all of the transfers described in this
paragraph are sometimes hereinafter referred to as a “Permitted Assignment”). 
 (c) Additional
Conditions. As a condition to any such assignment or subletting, whether or not Landlord’s consent is required, Landlord may require: 
 (i) that any assignee or subtenant agree, in writing at the time of such assignment or subletting, that if Landlord gives such party notice that Tenant is in default under this Lease, such party shall
thereafter make all payments otherwise due Tenant directly to Landlord, which payments will be received by Landlord without any liability except to credit such payment against those due under the Lease, and any such third party shall agree to attorn
to Landlord or its successors and assigns should this Lease be terminated for any reason; provided, however, in no event shall Landlord or its successors or assigns be obligated to accept such attornment; and 

(ii) A list of Hazardous Materials, certified by the proposed assignee or sublessee to be true and correct, which the proposed assignee
or sublessee intends to use, store, handle, treat, generate in or release or dispose of from the Premises, together with copies of all documents relating to such use, storage, handling, treatment, generation, release or disposal of Hazardous
Materials by the proposed assignee or subtenant in the Premises or on the Project, prior to the proposed assignment or subletting, including, without limitation: permits; approvals; reports and correspondence; storage and management plans; plans
relating to the installation of any storage tanks to be installed in or under the Project (provided, said installation of tanks shall only be permitted after Landlord has given its written consent to do so, which consent may be withheld in
Landlord’s sole and absolute discretion); and all closure plans or any other documents required by any and all federal, state and local Governmental Authorities for any storage tanks installed in, on or under the Project for the closure of any
such tanks. Neither Tenant nor any such proposed assignee or subtenant is required, however, to provide Landlord with any portion(s) of the such documents containing information of a proprietary nature which, in and of themselves, do not contain a
reference to any Hazardous Materials or hazardous activities. 
 (d) No Release of Tenant, Sharing of Excess Rents.
Notwithstanding any assignment or subletting, Tenant and any guarantor or surety of Tenant’s obligations under this Lease shall at all times remain fully and primarily responsible and liable for the payment of Rent and for

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 20
 
  

 
compliance with all of Tenant’s other obligations under this Lease. If the Rent due and payable by a sublessee or assignee (or a combination of the rental payable under such sublease or
assignment plus any bonus or other consideration therefor or incident thereto in any form) exceeds the sum of the rental payable under this Lease (excluding however, any Rent payable under this Section) and actual and reasonable brokerage fees,
legal costs and any design fees or construction costs directly related to and required pursuant to the terms of any such sublease and any tenant concessions granted to obtain such sublease or assignment (“Excess Rent”), then Tenant
shall be bound and obligated to pay Landlord as Additional Rent hereunder 50% of such Excess Rent within 10 days following receipt thereof by Tenant. If Tenant shall sublet the Premises or any part thereof, Tenant hereby immediately and irrevocably
assigns to Landlord, as security for Tenant’s obligations under this Lease, all rent from any such subletting, and Landlord as assignee and as attorney-in-fact for Tenant, or a receiver for Tenant appointed on Landlord’s application, may
collect such rent and apply it toward Tenant’s obligations under this Lease; except that, until the occurrence of a Default, Tenant shall have the right to collect such rent. 

(e) No Waiver. The consent by Landlord to an assignment or subletting shall not relieve Tenant or any assignees of this Lease or
any sublessees of the Premises from obtaining the consent of Landlord to any further assignment or subletting nor shall it release Tenant or any assignee or sublessee of Tenant from full and primary liability under the Lease. The acceptance of Rent
hereunder, or the acceptance of performance of any other term, covenant, or condition thereof, from any other person or entity shall not be deemed to be a waiver of any of the provisions of this Lease or a consent to any subletting, assignment or
other transfer of the Premises. 
 (f) Prior Conduct and Nature of Proposed Transferee. Notwithstanding any other
provision of this Section 23, except for any Permitted Assignment (as to which the terms of this Section 23(f) shall not apply, if (i) the proposed assignee or sublessee of Tenant has been required by any prior landlord,
lender or Governmental Authority to take remedial action in connection with Hazardous Materials contaminating a property, where the contamination resulted from such party’s action or use of the property in question, (ii) the proposed
assignee or sublessee is subject to an enforcement order issued by any Governmental Authority in connection with the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials (including, without limitation, any order
related to the failure to make a required reporting to any Governmental Authority), or (iii) because of the existence of a pre-existing environmental condition in the vicinity of or underlying the Project, the risk that Landlord would be
targeted as a responsible party in connection with the remediation of such pre-existing environmental condition would be materially increased or exacerbated by the proposed use of Hazardous Materials by such proposed assignee or sublessee, Landlord
shall have the absolute right to refuse to consent to any assignment or subletting to any such party. In addition, it shall be reasonable for Landlord to withhold its consent to any assignment or sublease to a proposed assignee or sublessee who, in
Landlord’s reasonable judgment, has an objectionable business reputation or intends to use the Premises or the Project for any purpose which may be controversial. Finally, it shall be reasonable for Landlord to withhold its consent to any
assignment or sublease to a proposed assignee or sublessee who has been offered and is considering a lease of comparable space in any of Landlord’s properties located in Watertown or Waltham, Massachusetts. 

24. Estoppel Certificate. Tenant shall, within 10 business days of written notice from Landlord, execute, acknowledge and deliver
a statement in writing in any form reasonably requested by a proposed lender or purchaser, (i) certifying that this Lease is unmodified and in full force and effect (or, if modified, stating the nature of such modification and certifying that
this Lease as so modified is in full force and effect) and the dates to which the rental and other charges are paid in advance, if any, (ii) acknowledging that there are not any uncured defaults on the part of Landlord hereunder, or specifying
such defaults if any are claimed, and (iii) setting forth such further information with respect to the status of this Lease or the Premises as may be requested thereon. Any such statement may be relied upon by any prospective purchaser or
encumbrancer of all or any portion of the real property of which the Premises are a part. Tenant’s failure to deliver such statement within such time shall, at the option of Landlord, be conclusive upon Tenant that the Lease is in full force
and effect and without modification except as may be represented by Landlord in any certificate prepared by Landlord and delivered to Tenant for execution. 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 21
 
  

 25. Quiet Enjoyment. So long as Tenant shall perform all of the covenants and
agreements herein required to be performed by Tenant, Tenant shall, subject to the terms of this Lease, at all times during the Term, have peaceful and quiet enjoyment of the Premises against any person claiming by, through or under Landlord.

 26. Prorations. All prorations required or permitted to be made hereunder shall be made on the basis of a 360 day year
and 30 day months. 
 27. Rules and Regulations. Tenant shall, at all times during the Term and any extension thereof,
comply with all reasonable rules and regulations at any time or from time to time established by Landlord covering use of the Premises and the Project. The current rules and regulations are attached hereto as Exhibit D. If there is any
conflict between said rules and regulations and other provisions of this Lease, the terms and provisions of this Lease shall control. Landlord shall not have any liability or obligation for the breach of any rules or regulations by other tenants in
the Project and shall not enforce such rules and regulations in a discriminatory manner. 
 28. Subordination. This Lease
and Tenant’s interest and rights hereunder are hereby made and shall be subject and subordinate at all times to the lien of any Mortgage now existing or hereafter created on or against the Project or the Premises, and all amendments,
restatements, renewals, modifications, consolidations, refinancing, assignments and extensions thereof, without the necessity of any further instrument or act on the part of Tenant; provided, however that so long as there is no Default
hereunder, Tenant’s right to possession of the Premises shall not be disturbed by the Holder of any such Mortgage. Tenant agrees, at the election of the Holder of any such Mortgage, to attorn to any such Holder. Tenant agrees upon demand to
execute, acknowledge and deliver such instruments, confirming such subordination, and such instruments of attornment as shall be requested by any such Holder, provided any such instruments contain appropriate non-disturbance provisions assuring
Tenant’s quiet enjoyment of the Premises as set forth in Section 25 hereof. Notwithstanding the foregoing, any such Holder may at any time subordinate its Mortgage to this Lease, without Tenant’s consent, by notice in writing
to Tenant, and thereupon this Lease shall be deemed prior to such Mortgage without regard to their respective dates of execution, delivery or recording and in that event such Holder shall have the same rights with respect to this Lease as though
this Lease had been executed prior to the execution, delivery and recording of such Mortgage and had been assigned to such Holder. The term “Mortgage” whenever used in this Lease shall be deemed to include deeds of trust, security
assignments and any other encumbrances, and any reference to the “Holder” of a Mortgage shall be deemed to include the beneficiary under a deed of trust. 
 29. Surrender. Prior to the Commencement Date, Landlord shall use reasonable efforts to deliver a copy of the Surrender Plan of the prior tenant in the Premises with evidence that such Surrender
Plan is complete. Notwithstanding the foregoing, Landlord’s inability to deliver such Surrender Plan, despite reasonable efforts to do so, shall not be deemed a default hereunder or otherwise excuse Tenant from any of Tenant’s obligations
under this Section 29 or any other provision of this Lease. Upon the expiration of the Term or earlier termination of Tenant’s right of possession, Tenant shall surrender the Premises to Landlord in the same condition as received,
subject to any Alterations or Installations permitted by Landlord to remain in the Premises, free of Hazardous Materials brought upon, kept, used, stored, handled, treated, generated in, or released or disposed of from, the Premises by Tenant or any
Tenant Party (collectively, “Tenant HazMat Operations”) and released of all Hazardous Materials Clearances, broom clean, ordinary wear and tear and casualty loss and condemnation covered by Sections 19 and 20 excepted. At
least 3 months prior to the surrender of the Premises, Tenant shall deliver to Landlord a narrative description of the actions proposed (or required by any Governmental Authority) to be taken by Tenant in order to surrender the Premises (including
any Installations permitted by Landlord to remain in the Premises) at the expiration or earlier termination of the Term, free from any residual impact from the Tenant HazMat Operations and otherwise released for unrestricted use and occupancy (the
“Surrender Plan”). Such Surrender Plan shall be accompanied by a current listing of (i) all Hazardous Materials licenses and permits held by or on behalf of any Tenant Party with respect to the Premises, and (ii) all
Hazardous Materials used, stored, handled, treated, generated, released or disposed of from the Premises by Tenant or any Tenant Party, and shall be subject to the review and 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 22
 
  

 
approval of Landlord’s environmental consultant. In connection with the review and approval of the Surrender Plan, upon the request of Landlord, Tenant shall deliver to Landlord or its
consultant such additional non-proprietary information concerning Tenant HazMat Operations as Landlord shall request. On or before such surrender, Tenant shall deliver to Landlord evidence that the approved Surrender Plan shall have been
satisfactorily completed and Landlord shall have the right, subject to reimbursement at Tenant’s expense as set forth below, to cause Landlord’s environmental consultant to inspect the Premises and perform such additional procedures as may
be deemed reasonably necessary to confirm that the Premises are, as of the effective date of such surrender or early termination of the Lease, free from any residual impact from Tenant HazMat Operations. Tenant shall reimburse Landlord, as
Additional Rent, for the actual out-of pocket expense incurred by Landlord for Landlord’s environmental consultant to review and approve the Surrender Plan and to visit the Premises and verify satisfactory completion of the same, which cost
shall not exceed $5,000. Landlord shall have the unrestricted right to deliver such Surrender Plan and any report by Landlord’s environmental consultant with respect to the surrender of the Premises to third parties. 

If Tenant shall fail to prepare or submit a Surrender Plan approved by Landlord, or if Tenant shall fail to complete the approved
Surrender Plan, or if such Surrender Plan, whether or not approved by Landlord, shall fail to adequately address any residual effect of Tenant HazMat Operations in, on or about the Premises, Landlord shall have the right to take such actions as
Landlord may deem reasonable or appropriate to assure that the Premises and the Project are surrendered free from any residual impact from Tenant HazMat Operations, the cost of which actions shall be reimbursed by Tenant as Additional Rent, without
regard to the limitation set forth in the first paragraph of this Section 29. 
 Tenant shall immediately return to
Landlord all keys and/or access cards to parking, the Project, restrooms or all or any portion of the Premises furnished to or otherwise procured by Tenant. If any such access card or key is lost, Tenant shall pay to Landlord, at Landlord’s
election, either the cost of replacing such lost access card or key or the cost of reprogramming the access security system in which such access card was used or changing the lock or locks opened by such lost key. Any Tenant’s Property,
Alterations and property not so removed by Tenant as permitted or required herein shall be deemed abandoned and may be stored, removed, and disposed of by Landlord at Tenant’s expense, and Tenant waives all claims against Landlord for any
damages resulting from Landlord’s retention and/or disposition of such property. All obligations of Tenant hereunder not fully performed as of the termination of the Term, including the obligations of Tenant under Section 31 hereof,
shall survive the expiration or earlier termination of the Term, including, without limitation, indemnity obligations, payment obligations with respect to Rent and obligations concerning the condition and repair of the Premises. 

30. Waiver of Jury Trial. TENANT AND LANDLORD WAIVE ANY RIGHT TO TRIAL BY JURY OR TO HAVE A JURY PARTICIPATE IN RESOLVING ANY
DISPUTE, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE, BETWEEN LANDLORD AND TENANT ARISING OUT OF THIS LEASE OR ANY OTHER INSTRUMENT, DOCUMENT, OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS RELATED HERETO.

 31. Environmental Requirements. 
 (a) Prohibition/Compliance/Indemnity. Tenant shall not cause or permit any Hazardous Materials (as hereinafter defined) to be brought upon, kept, used, stored, handled, treated, generated in or
about, or released or disposed of from, the Premises or the Project in violation of applicable Environmental Requirements (as hereinafter defined) by Tenant or any Tenant Party. If Tenant breaches the obligation stated in the preceding sentence, or
if the presence of Hazardous Materials used by Tenant or any Tenant Party in the Premises during the Term or any holding over results in contamination of the Premises, the Project or any adjacent property or if contamination of the Premises, the
Project or any adjacent property by Hazardous Materials brought into, kept, used, stored, handled, treated, generated in or about, or released or disposed of from, the Premises by Tenant or any Tenant Party otherwise occurs during the Term or any
holding over, Tenant hereby indemnifies and shall defend and hold Landlord, its officers, directors, employees, agents and contractors harmless from any 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 23
 
  

 
and all actions (including, without limitation, remedial or enforcement actions of any kind, administrative or judicial proceedings, and orders or judgments arising out of or resulting
therefrom), costs, claims, damages (including, without limitation, punitive damages and damages based upon diminution in value of the Premises or the Project, or the loss of, or restriction on, use of the Premises or any portion of the Project),
expenses (including, without limitation, attorneys’, consultants’ and experts’ fees, court costs and amounts paid in settlement of any claims or actions), fines, forfeitures or other civil, administrative or criminal penalties,
injunctive or other relief (whether or not based upon personal injury, property damage, or contamination of, or adverse effects upon, the environment, water tables or natural resources), liabilities or losses (collectively, “Environmental
Claims”) which arise during or after the Term as a result of such contamination. Notwithstanding the foregoing, Tenant shall in no event be liable to Landlord or any Landlord Party hereunder as a result of, and this indemnification of
Landlord and the Landlord Parties by Tenant shall not include Environmental Claims arising from known conditions existing in, on, under or about the Premises on or before the date hereof, as disclosed by those certain environmental reports more
particularly described on Exhibit G hereto (each, a “Pre-existing Condition”), to the extent that the Tenant can reasonably prove that any such Environmental Claim does not arise or result, in whole or part, from any exacerbation of or
contribution to, such a Pre-existing Condition, by (x) the actions of Tenant or any Tenant Party, or (y) any contamination emanating from in, on or under the Premises during the Term. This indemnification of Landlord by Tenant includes, without
limitation, costs incurred in connection with any investigation of site conditions or any cleanup, treatment, remedial, removal, or restoration work required by any federal, state or local Governmental Authority because of Hazardous Materials
present in the air, soil or ground water above, on, or under the Premises. Without limiting the foregoing, if the presence of any Hazardous Materials on the Premises, the Project or any adjacent property caused or permitted by Tenant or any Tenant
Party results in any contamination of the Premises, the Project or any adjacent property, Tenant shall promptly take all actions at its sole expense and in accordance with applicable Environmental Requirements as are necessary to return the
Premises, the Project or any adjacent property to the condition existing prior to the time of such contamination, provided that Landlord’s approval of such action shall first be obtained, which approval shall not unreasonably be withheld so
long as such actions would not potentially have any material adverse long-term or short-term effect on the Premises or the Project.  
 (b) Business. Landlord acknowledges that it is not the intent of this Section 31 to prohibit Tenant from using the Premises for the Permitted Use. Tenant may operate its business
according to prudent industry practices so long as the use or presence of Hazardous Materials is strictly and properly monitored according to all then applicable Environmental Requirements. As a material inducement to Landlord to allow Tenant to use
Hazardous Materials in connection with its business, Tenant agrees to deliver to Landlord prior to the Commencement Date a list identifying each type of Hazardous Materials to be brought upon, kept, used, stored, handled, treated, generated on, or
released or disposed of from, the Premises and setting forth any and all governmental approvals or permits required in connection with the presence, use, storage, handling, treatment, generation, release or disposal of such Hazardous Materials on or
from the Premises (“Hazardous Materials List”). Tenant shall deliver to Landlord an updated Hazardous Materials List at least once a year and shall also deliver an updated list before any new Hazardous Material is brought onto,
kept, used, stored, handled, treated, generated on, or released or disposed of from, the Premises. Tenant shall deliver to Landlord true and correct copies of the following documents (the “Haz Mat Documents”) relating to the use,
storage, handling, treatment, generation, release or disposal of Hazardous Materials prior to the Commencement Date, or if unavailable at that time, concurrent with the receipt from or submission to a Governmental Authority: permits; approvals;
reports and correspondence; storage and management plans, notice of violations of any Legal Requirements; plans relating to the installation of any storage tanks to be installed in or under the Project (provided, said installation of tanks shall
only be permitted after Landlord has given Tenant its written consent to do so, which consent may be withheld in Landlord’s sole and absolute discretion); all closure plans or any other documents required by any and all federal, state and local
Governmental Authorities for any storage tanks installed in, on or under the Project for the closure of any such tanks; and a Surrender Plan (to the extent surrender in accordance with Section 29 cannot be accomplished in 3 months).
Tenant is not required, however, to provide Landlord with any portion(s) of the Haz Mat Documents containing information of a proprietary nature which, in and of themselves, do not contain a reference to any Hazardous Materials or hazardous
activities. It is not the intent of this Section to provide Landlord with information which could be detrimental to Tenant’s business should such information become possessed by Tenant’s competitors. 

(c) Tenant Representation and Warranty. Tenant hereby represents and warrants to Landlord that (i) neither Tenant nor any of
its legal predecessors has been required by any prior landlord, lender or Governmental Authority at any time to take remedial action in connection with 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 24
 
  

 
Hazardous Materials contaminating a property which contamination was permitted by Tenant of such predecessor or resulted from Tenant’s or such predecessor’s action or use of the
property in question, and (ii) Tenant is not subject to any enforcement order issued by any Governmental Authority in connection with the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials (including,
without limitation, any order related to the failure to make a required reporting to any Governmental Authority). If Landlord determines that this representation and warranty was not true as of the date of this lease, Landlord shall have the right
to terminate this Lease in Landlord’s sole and absolute discretion. 
 (d) Testing. Landlord shall have the right to
conduct annual tests of the Premises to determine whether any contamination of the Premises or the Project has occurred as a result of Tenant’s use. Tenant shall be required to pay the cost of such annual test of the Premises; provided,
however, that if Tenant conducts its own tests of the Premises using third party contractors and test procedures acceptable to Landlord which tests are certified to Landlord, Landlord shall accept such tests in lieu of the annual tests to be paid
for by Tenant. In addition, at any time, and from time to time, but not more frequently than once per year unless (i) Landlord has reasonable grounds to believe or release of Hazardous Materials has occurred, or (ii) more frequent testing
is required by the Holder of any Mortgage affecting the Project, prior to the expiration or earlier termination of the Term, Landlord shall have the right to conduct appropriate tests of the Premises and the Project to determine if contamination has
occurred as a result of Tenant’s use of the Premises. In connection with such testing, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such non-proprietary information concerning the use of Hazardous Materials
in or about the Premises by Tenant or any Tenant Party. If contamination has occurred for which Tenant is liable under this Section 31, Tenant shall pay all costs to conduct such tests. If no such contamination is found, Landlord shall
pay the costs of such tests (which shall not constitute an Operating Expense). Landlord shall provide Tenant with a copy of all third party, non-confidential reports and tests of the Premises made by or on behalf of Landlord during the Term without
representation or warranty and subject to a confidentiality agreement. Tenant shall, at its sole cost and expense, promptly and satisfactorily remediate any environmental conditions identified by such testing in accordance with all Environmental
Requirements. Landlord’s receipt of or satisfaction with any environmental assessment in no way waives any rights which Landlord may have against Tenant. 
 (e) Underground Tanks. If underground or other storage tanks storing Hazardous Materials located on the Premises or the Project are used by Tenant or are hereafter placed on the Premises or the
Project by Tenant, Tenant shall install, use, monitor, operate, maintain, upgrade and manage such storage tanks, maintain appropriate records, obtain and maintain appropriate insurance, implement reporting procedures, properly close any underground
storage tanks, and take or cause to be taken all other actions necessary or required under applicable state and federal Legal Requirements, as such now exists or may hereafter be adopted or amended in connection with the installation, use,
maintenance, management, operation, upgrading and closure of such storage tanks. 
 (f) Tenant’s Obligations.
Tenant’s obligations under this Section 31 shall survive the expiration or earlier termination of the Lease. During any period of time after the expiration or earlier termination of this Lease required by Tenant or Landlord to
complete the removal from the Premises of any Hazardous Materials (including, without limitation, the release and termination of any licenses or permits restricting the use of the Premises and the completion of the approved Surrender Plan), Tenant
shall continue to pay the full Rent in accordance with this Lease for any portion of the Premises not relet by Landlord in Landlord’s sole discretion, which Rent shall be prorated daily. 

(g) Definitions. As used herein, the term “Environmental Requirements” means all applicable present and future
statutes, regulations, ordinances, rules, codes, judgments, orders or other similar enactments of any Governmental Authority regulating or relating to health, safety, or environmental conditions on, under, or about the Premises or the Project, or
the environment, including without limitation, the following: the Comprehensive Environmental Response, Compensation and Liability Act; the Resource Conservation and Recovery Act; and all state and local counterparts thereto, and any regulations or
policies promulgated or issued thereunder. As used herein, the term “Hazardous Materials” means and includes any substance, material, waste, pollutant, or contaminant listed or defined

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 25
 
  

 
as hazardous or toxic, or regulated by reason of its impact or potential impact on humans, animals and/or the environment under any Environmental Requirements, asbestos and petroleum, including
crude oil or any fraction thereof, natural gas liquids, liquefied natural gas, or synthetic gas usable for fuel (or mixtures of natural gas and such synthetic gas). As defined in Environmental Requirements, Tenant is and shall be deemed to be the
“operator” of Tenant’s “facility” and the “owner” of all Hazardous Materials brought on the Premises by Tenant or any Tenant Party, and the wastes, by-products, or residues generated,
resulting, or produced therefrom. 
 32. Tenant’s Remedies/Limitation of Liability. Landlord shall not be in default
hereunder unless Landlord fails to perform any of its obligations hereunder within 30 days after written notice from Tenant specifying such failure (unless such performance will, due to the nature of the obligation, require a period of time in
excess of 30 days, then after such period of time as is reasonably necessary). Upon any default by Landlord, Tenant shall give notice by registered or certified mail to any Holder of a Mortgage covering the Premises and to any landlord of any lease
of property in or on which the Premises are located and Tenant shall offer such Holder and/or landlord a reasonable opportunity to cure the default, including time to obtain possession of the Project by power of sale or a judicial action if such
should prove necessary to effect a cure; provided Landlord shall have furnished to Tenant in writing the names and addresses of all such persons who are to receive such notices. All obligations of Landlord hereunder shall be construed as
covenants, not conditions; and, except as may be otherwise expressly provided in this Lease, Tenant may not terminate this Lease for breach of Landlord’s obligations hereunder. 

All obligations of Landlord under this Lease will be binding upon Landlord only during the period of its ownership of the Premises and
not thereafter. The term “Landlord” in this Lease shall mean only the owner for the time being of the Premises. Upon the transfer by such owner of its interest in the Premises, such owner shall thereupon be released and discharged
from all obligations of Landlord thereafter accruing, but such obligations shall be binding during the Term upon each new owner for the duration of such owner’s ownership. 

33. Inspection and Access. Landlord and its agents, representatives, and contractors may enter the Premises at any reasonable time
to inspect the Premises and to make such repairs as may be required or permitted pursuant to this Lease and for any other business purpose. Landlord and Landlord’s representatives may enter the Premises during business hours on not less than 48
hours advance written notice (except in the case of emergencies in which case no such notice shall be required and such entry may be at any time) for the purpose of effecting any such repairs, inspecting the Premises, showing the Premises to
prospective purchasers and, during the last year of the Term, to prospective tenants or for any other business purpose. Landlord may erect a suitable sign on the Premises stating the Premises are available to let or that the Project is available for
sale. Landlord may grant easements, make public dedications, designate Common Areas and create restrictions on or about the Premises, provided that no such easement, dedication, designation or restriction materially, adversely affects
Tenant’s use or occupancy of the Premises for the Permitted Use. At Landlord’s request, Tenant shall execute such instruments as may be necessary for such easements, dedications or restrictions. Tenant shall at all times, except in the
case of emergencies, have the right to escort Landlord or its agents, representatives, contractors or guests while the same are in the Premises, provided such escort does not materially and adversely affect Landlord’s access rights hereunder.

 34. Security. Tenant acknowledges and agrees that security devices and services, if any, while intended to deter crime
may not in given instances prevent theft or other criminal acts and that Landlord is not providing any security services with respect to the Premises. Tenant agrees that Landlord shall not be liable to Tenant for, and Tenant waives any claim against
Landlord with respect to, any loss by theft or any other damage suffered or incurred by Tenant in connection with any unauthorized entry into the Premises or any other breach of security with respect to the Premises. Tenant shall be solely
responsible for the personal safety of Tenant’s officers, employees, agents, contractors, guests and invitees while any such person is in, on or about the Premises and/or the Project. Tenant shall at Tenant’s cost obtain insurance coverage
to the extent Tenant desires protection against such criminal acts. 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 26
 
  

 35. Force Majeure. Other than for the obligations of either party under this
Lease that can be performed by the payment of money, neither Landlord nor Tenant shall be responsible or liable for delays in the performance of its obligations hereunder when caused by, related to, or arising out of acts of God, strikes, lockouts,
or other labor disputes, embargoes, quarantines, weather, national, regional, or local disasters, calamities, or catastrophes, inability to obtain labor or materials (or reasonable substitutes therefor) at reasonable costs or failure of, or
inability to obtain, utilities necessary for performance, governmental restrictions, orders, limitations, regulations, or controls, national emergencies, delay in issuance or revocation of permits, enemy or hostile governmental action, terrorism,
insurrection, riots, civil disturbance or commotion, fire or other casualty, and other causes or events beyond the reasonable control of Landlord or Tenant, as applicable (“Force Majeure”). 

36. Brokers, Entire Agreement, Amendment. Landlord and Tenant each represents and warrants that it has not dealt with any broker,
agent or other person (collectively, “Broker) in connection with this transaction and that no Broker brought about this transaction other than Meredith & Grew, Inc. and CB Richard Ellis/Whittier Partners (whose commission shall
in each case be payable by Landlord under a separate agreement). Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than the broker, if any named in this
Section 36, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this leasing transaction. 

37. Limitation on Landlord’s Liability. NOTWITHSTANDING ANYTHING SET FORTH HEREIN OR IN ANY OTHER AGREEMENT BETWEEN LANDLORD
AND TENANT TO THE CONTRARY: (A) LANDLORD SHALL NOT BE LIABLE TO TENANT OR ANY OTHER PERSON FOR (AND TENANT AND EACH SUCH OTHER PERSON ASSUME ALL RISK OF) LOSS, DAMAGE OR INJURY, WHETHER ACTUAL OR CONSEQUENTIAL TO: TENANT’S PERSONAL
PROPERTY OF EVERY KIND AND DESCRIPTION, INCLUDING, WITHOUT LIMITATION TRADE FIXTURES, EQUIPMENT, INVENTORY, SCIENTIFIC RESEARCH, SCIENTIFIC EXPERIMENTS, LABORATORY ANIMALS, PRODUCT, SPECIMENS, SAMPLES, AND/OR SCIENTIFIC, BUSINESS, ACCOUNTING AND
OTHER RECORDS OF EVERY KIND AND DESCRIPTION KEPT AT THE PREMISES AND ANY AND ALL INCOME DERIVED OR DERIVABLE THEREFROM; (B) THERE SHALL BE NO PERSONAL RECOURSE TO LANDLORD FOR ANY ACT OR OCCURRENCE IN, ON OR ABOUT THE PREMISES OR ARISING IN ANY
WAY UNDER THIS LEASE OR ANY OTHER AGREEMENT BETWEEN LANDLORD AND TENANT WITH RESPECT TO THE SUBJECT MATTER HEREOF AND ANY LIABILITY OF LANDLORD HEREUNDER SHALL BE STRICTLY LIMITED SOLELY TO LANDLORD’S INTEREST IN THE PROJECT OR ANY PROCEEDS
FROM SALE OR CONDEMNATION THEREOF AND ANY INSURANCE PROCEEDS PAYABLE IN RESPECT OF LANDLORD’S INTEREST IN THE PROJECT OR IN CONNECTION WITH ANY SUCH LOSS; AND (C) IN NO EVENT SHALL ANY PERSONAL LIABILITY BE ASSERTED AGAINST ANY OF
LANDLORD’S OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR CONTRACTORS. UNDER NO CIRCUMSTANCES SHALL LANDLORD OR ANY OF LANDLORD’S OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR CONTRACTORS BE LIABLE FOR INJURY TO TENANT’S BUSINESS OR FOR ANY
LOSS OF INCOME OR PROFIT THEREFROM. 
 38. Severability. If any clause or provision of this Lease is illegal, invalid or
unenforceable under present or future laws, then and in that event, it is the intention of the parties hereto that the remainder of this Lease shall not be affected thereby. It is also the intention of the parties to this Lease that in lieu of each
clause or provision of this Lease that is illegal, invalid or unenforceable, there be added, as a part of this Lease, a clause or provision as similar in effect to such illegal, invalid or unenforceable clause or provision as shall be legal, valid
and enforceable. 
 39. Signs; Exterior Appearance. Tenant shall not, without the prior written consent of Landlord,
which may be granted or withheld in Landlord’s sole discretion: (i) attach any awnings, exterior lights, decorations, balloons, flags, pennants, banners, painting or other projection to any outside wall of the Project, (ii) use any
curtains, blinds, shades or screens other than Landlord’s standard window coverings, (iii) coat or otherwise sunscreen the interior or exterior of any windows, (iv) place any bottles, parcels, or other articles on the window sills,
(v) place any equipment, furniture or other items of personal 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 27
 
  

 
property on any exterior balcony, or (vi) paint, affix or exhibit on any part of the Premises or the Project any signs, notices, window or door lettering, placards, decorations, or
advertising media of any type which can be viewed from the exterior of the Premises other than signage in Tenant reception area. Interior signs on doors shall be inscribed, painted or affixed for Tenant by Landlord at the sole cost and expense of
Tenant, and shall be of a size, color and type acceptable to Landlord. Interior signs on the directory tablet within the Building shall be affixed for Tenant by Landlord at Landlord’s expense, and shall be of a size, color and type acceptable
to Landlord. Nothing may be placed on the exterior of corridor walls or corridor doors other than Landlord’s standard lettering. The directory tablet shall be provided exclusively for the display of the name and location of tenants. 

40. Right to Extend Term. Tenant shall have the right to extend the Term of the Lease upon the following terms and conditions:

 (a) Extension Rights. Tenant shall have one right (the “Extension Right”) to extend the term of this
Lease for 5 years (the “Extension Term”) on the same terms and conditions as this Lease (other than Base Rent) by giving Landlord written notice of its election to exercise each Extension Right at least 12 months prior, and no
earlier than 9 months prior, to the expiration of the Base Term of the Lease or the expiration of any prior Extension Term. 

Upon the commencement of any Extension Term, Base Rent shall be payable at the Market Rate (as defined below). Base Rent shall thereafter
be adjusted on each annual anniversary of the commencement of such Extension Term by multiplying the Base Rent payable immediately before such adjustment by the Rent Adjustment Percentage and adding the resulting amount to the Base Rent payable
immediately before such adjustment. The term “Market Rate” for purposes of this Lease shall mean the annual amount per rentable square foot that a willing, comparable, new non-renewal tenant of credit quality similar to Tenant would pay,
and a willing, comparable landlord of the Building or a comparable office building in the immediate vicinity of the Building would accept, at arms length, giving appropriate consideration to annual rental rates per rentable square foot, and
abatement provisions reflecting free rent, length of lease term, size and location of premises being leased, improvement allowances (if any), brokerage commissions (if any) and any other concessions which would be granted by Landlord or a comparable
landlord and other generally applicable terms and conditions. As used herein, “Market Rate” shall be determined by Landlord in accordance with the provisions hereof and agreed to by Tenant, but shall in no event be less than the Base Rent
payable as of the date immediately preceding the commencement of such Extension Term increased by the Rent Adjustment Percentage multiplied by such Base Rent. In addition, Landlord may impose a market rent for the parking rights provided hereunder.

 If, on or before the date which is 120 days prior to the expiration of the Base Term of this Lease, or the expiration of any prior Extension
Term, Tenant has not agreed with Landlord’s determination of the Market Rate and the rent escalations during such subsequent Extension Term after negotiating in good faith, Tenant may by written notice to Landlord not later than 120 days prior
to the expiration of the Base Term of this Lease, or the expiration of any then effective Extension Term, elect arbitration as described in Section 40(b) below. If Tenant does not elect such arbitration, Tenant shall be deemed to have
waived any right to extend, or further extend, the Term of the Lease and all of the remaining Extension Rights shall terminate. 

(b) Arbitration. 
 (i) Within 10 days of Tenant’s notice to Landlord of its election to arbitrate Market Rate and escalations, each party shall deliver to the other a proposal containing the Market Rate and escalations
that the submitting party believes to be correct (“Extension Proposal”). If either party fails to timely submit an Extension Proposal, the other party’s submitted proposal shall determine the Base Rent and escalations for the
Extension Term. If both parties submit Extension Proposals, then Landlord and Tenant shall meet within 7 days after delivery of the last Extension Proposal and make a good faith attempt to mutually appoint a single Arbitrator (and defined below) to
determine the Market 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 28
 
  

 
Rate and escalations. If Landlord and Tenant are unable to agree upon a single Arbitrator, then each shall, by written notice delivered to the other within 10 days after the meeting, select an
Arbitrator. If either party fails to timely give notice of its selection for an Arbitrator, the other party’s submitted proposal shall determine the Base Rent for the Extension Term. The 2 Arbitrators so appointed shall, within 5 business days
after their appointment, appoint a third Arbitrator. If the 2 Arbitrators so selected cannot agree on the selection of the third Arbitrator within the time above specified, then either party, on behalf of both parties, may request such appointment
of such third Arbitrator by application to any state court of general jurisdiction in the jurisdiction in which the Premises are located, upon 10 days prior written notice to the other party of such intent. 

(ii) The decision of the Arbitrator(s) shall be made within 30 days after the appointment of a single Arbitrator or the third
Arbitrator, as applicable. The decision of the single Arbitrator shall be final and binding upon the parties. The average of the two closest Arbitrators in a three Arbitrator panel shall be final and binding upon the parties. Each party shall pay
the fees and expenses of the Arbitrator appointed by or on behalf of such party and the fees and expenses of the third Arbitrator shall be borne equally by both parties. If the Market Rate and escalations are not determined by the first day of the
Extension Term, then Tenant shall pay Landlord Base Rent in an amount equal to the Base Rent in effect immediately prior to the Extension Term and increased by the Rent Adjustment Percentage until such determination is made. After the determination
of the Market Rate and escalations, the parties shall make any necessary adjustments to such payments made by Tenant. Landlord and Tenant shall then execute an amendment recognizing the Market Rate and escalations for the Extension Term. 

(iii) An “Arbitrator” shall be any person appointed by or on behalf of either party or appointed pursuant to the
provisions hereof and: (i) shall be (A) a member of the American Institute of Real Estate Appraisers with not less than 10 years of experience in the appraisal of improved office and high tech industrial real estate in the Watertown,
Massachusetts metropolitan area, or (B) a licensed commercial real estate broker with not less than 15 years experience representing landlords and/or tenants in the leasing of high tech or life sciences space in the Watertown, Massachusetts
metropolitan area, (ii) devoting substantially all of their time to professional appraisal or brokerage work, as applicable, at the time of appointment and (iii) be in all respects impartial and disinterested. 

(c) Rights Personal. Extension Rights are personal to Tenant and any Permitted Assignees and are not otherwise assignable without
Landlord’s consent, which may be granted or withheld in Landlord’s sole discretion separate and apart from any consent by Landlord to an assignment of Tenant’s interest in the Lease. 

(d) Exceptions. Notwithstanding anything set forth above to the contrary, Extension Rights shall not be in effect and Tenant may
not exercise any of the Extension Rights during any period of time that Tenant is in Default under any provision of this Lease. 

(e) No Extensions. The period of time within which any Extension Rights may be exercised shall not be extended or enlarged by
reason of Tenant’s inability to exercise the Extension Rights. 
 (f) Termination. The Extension Rights shall
terminate and be of no further force or effect even after Tenant’s due and timely exercise of an Extension Right, if, after such exercise, but prior to the commencement date of an Extension Term, (i) Tenant fails to timely cure any default
by Tenant under this Lease; or (ii) Tenant has Defaulted 3 or more times during the period from the date of the exercise of an Extension Right to the date of the commencement of the Extension Term, whether or not such Defaults are cured.

 41. Representations. Landlord represents and warrants to Tenant that, as of the date of this Lease, Landlord has full
power and authority to enter into this Lease and has obtained all consents and taken all actions necessary in connection therewith. Tenant represents and warrants to Landlord that, as of the date of this Lease, Tenant has full power and authority to
enter into this Lease and has obtained all consents and take all actions necessary in connection therewith. 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 29
 
  

 42. Miscellaneous. 

(a) Notices. All notices or other communications between the parties shall be in writing and shall be deemed duly given upon
delivery or refusal to accept delivery by the addressee thereof if delivered in person, or upon actual receipt if delivered by reputable overnight guaranty courier, addressed and sent to the parties at their addresses set forth above. Landlord and
Tenant may from time to time by written notice to the other designate another address for receipt of future notices. 
 (b)
Joint and Several Liability. If and when included within the term “Tenant,” as used in this instrument, there is more than one person or entity, each shall be jointly and severally liable for the obligations of Tenant.

 (c) Financial Information. Tenant shall furnish Landlord with true and complete copies of (i) Tenant’s most
recent audited annual financial statements within 45 days of the end of each of Tenant’s fiscal years during the Term, (ii) Tenant’s most recent unaudited quarterly financial statements within 45 days of the end of each of
Tenant’s first three fiscal quarters of each of Tenant’s fiscal years during the Term, (iii) at Landlord’s request from time to time, updated business plans, including cash flow projections and/or pro forma balance sheets and
income statements, all of which shall be treated by Landlord as confidential information belonging to Tenant, (iv) corporate brochures and/or profiles prepared by Tenant for prospective investors, and (v) any other financial information or
summaries that Tenant typically provides to its lenders or shareholders. 
 (d) Recordation. This Lease shall not be
filed by or on behalf of Tenant in any public record. At the request of either party hereto, the other party shall execute and deliver a memorandum of lease in statutory form which may be recorded at the expense of the requesting party. Tenant shall
execute and deliver a termination of such memorandum of lease, in recordable form, to Landlord upon the expiration or earlier termination of this Lease. 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 30
 
  

 (e) Interpretation. The normal rule of construction to the effect that any
ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Lease or any exhibits or amendments hereto. Words of any gender used in this Lease shall be held and construed to include any other gender,
and words in the singular number shall be held to include the plural, unless the context otherwise requires. The captions inserted in this Lease are for convenience only and in no way define, limit or otherwise describe the scope or intent of this
Lease, or any provision hereof, or in any way affect the interpretation of this Lease. 
 (f) Not Binding Until Executed.
The submission by Landlord to Tenant of this Lease shall have no binding force or effect, shall not constitute an option for the leasing of the Premises, nor confer any right or impose any obligations upon either party until execution of this Lease
by both parties. 
 (g) Limitations on Interest. It is expressly the intent of Landlord and Tenant at all times to comply
with applicable law governing the maximum rate or amount of any interest payable on or in connection with this Lease. If applicable law is ever judicially interpreted so as to render usurious any interest called for under this Lease, or contracted
for, charged, taken, reserved, or received with respect to this Lease, then it is Landlord’s and Tenant’s express intent that all excess amounts theretofore collected by Landlord be credited on the applicable obligation (or, if the
obligation has been or would thereby be paid in full, refunded to Tenant), and the provisions of this Lease immediately shall be deemed reformed and the amounts thereafter collectible hereunder reduced, without the necessity of the execution of any
new document, so as to comply with the applicable law, but so as to permit the recovery of the fullest amount otherwise called for hereunder. 
 (h) Choice of Law. Construction and interpretation of this Lease shall be governed by the internal laws of the state in which the Premises are located, excluding any principles of conflicts of
laws. 
 (i) Time. Time is of the essence as to the performance of Tenant’s obligations under this Lease.

 (j) Incorporation by Reference. All exhibits and addenda attached hereto are hereby incorporated into this Lease and
made a part hereof. If there is any conflict between such exhibits or addenda and the terms of this Lease, such exhibits or addenda shall control. 
 (k) Hazardous Activities. Notwithstanding any other provision of this Lease, Landlord, for itself and its employees, agents and contractors, reserves the right to refuse to perform any repairs or
services in any portion of the Premises which, pursuant to Tenant’s routine safety guidelines, practices or custom or prudent industry practices, require any form of protective clothing or equipment other than safety glasses. In any such case,
Tenant shall contract with parties who are acceptable to Landlord, in Landlord’s reasonable discretion, for all such repairs and services, and Landlord shall, to the extent required, equitably adjust Tenant’s Share of Operating Expenses in
respect of such repairs or services to reflect that Landlord is not providing such repairs or services to Tenant. 

[Signatures appear on following page] 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

  480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page
 31
 
  

 IN WITNESS WHEREOF, Landlord and Tenant have executed this Lease as of the day and year
first above written. 
  

							
	TENANT:
	
	Tetraphase Pharmaceuticals, Inc., a Delaware corporation
		
	By:	 	 /s/ David Lubner

	Its:	 	 Sr. VP, COO

	
	LANDLORD:
	
	ARE-480 Arsenal Street, LLC, a Delaware limited liability company
		
	By:	 	Alexandria Real Estate Equities, L.P.,
		 	a Delaware limited partnership,
		 	managing member
			
		 	By:	 	ARE-QRS Corp., a Maryland
		 		 	corporation, general partner
				
		 		 	By:	 	 (illegible)

		 		 	Its:	 	 VP

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 1 

 

 EXHIBIT A TO LEASE 

DESCRIPTION OF PREMISES 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 2 

 

 

 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 3 

 

 

 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 1 

 

 EXHIBIT B TO LEASE 

DESCRIPTION OF PROJECT 
 (see attached) 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 2 

 

 

 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 3 

 

 TetraPhase 
 480 Arsenal Street 
 MEP Scope of Work 
 November 22, 2006 
 Based on Architectural Drawing A-2.1 dated 16 November 2006

  

							
	1.	  	    FIRE PROTECTION
			
		  		  	1.1. Modify existing fire protection system to accommodate new architectural layout.
			
	2.	  	    PLUMBING	  	
			
		  	2.1.	  	Connect and trim four {4) new lab sinks.
			
		  	2.2.	  	Vacuum service to one {1) BSC. No C02 (assumed local)
			
		  	2.3.	  	Nitrogen, compressed air, vacuum and NPCW to two walk-in hoods.
			
		  	2.4.	  	Chilled water piping to one (1) Huber Chiller (approximately 25 feet)
			
		  		  	2.5. Connect to existing nitrogen and compressed air piping and extend nitrogen and compressed air to benchtop hoods and NMR drops (wall turrets).
			
		  	2.6.	  	New compressed air, and NPCW to hoods.
			
		  	2.7.	  	Four (4) RODIpoints of use piped from existing RODIsystem.
			
		  	2.8.	  	Four (4) new deck mounted emergency eyewash units.
			
		  	2.9.	  	Helium and C02 to be local, by tenant.
			
	3.	  	    HVAC	  	
			
		  	3.1.	  	Hoods to be exhausted based on ASHRAE/ANSIstandards.
			
		  	3.2.	  	One (1) new lab exhaust fan (15 hp)
			
		  	3.3.	  	One (1) new air handling unit (5 hp)
			
		  	3.4.	  	Hot water reheat piping
			
		  	3.5.	  	Ductwork demolition, modifications, and installation.
			
		  	3.6.	  	Control modifications to accommodate modified layout.
			
		  	3.7.	  	Tek-air hood management system

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

							
			
	4.	  	    ELECTRICAL	  	
			
		  		  	4.1. Remove wiremold, circuits to wiremold, cord drops, and outlets in affected area.
			
		  	4.2.	  	Remove lighting.
			
		  	4.3.	  	Provide new wiremold on benches with circuits, and new hood wiring.
			
		  		  	4.4. Reinstall existing fixtures and provide new fixtures for coordinated layout.
			
		  	4.5.	  	New localcontrolswitching.
			
		  	4.6.	  	Rework exit/emergency lighting.
			
		  	4.7.	  	Relocate fire alarm devices.
			
		  	4.8.	  	Remove and reinstall tel/data for new floor plan.
			
		  	4.9.	  	Furnish and install transformation and panels as required.
			
		  	4.10.	  	Power to new HVAC equipment.

									
	 TETRAPHASE
	  	 	Date	  	  	 	11/29/2006	  

	
	   

	   

	   

480 ARSENAL STREET 
 WATERTOWN, MASSACHUSETTS 
 PRELIMINARY BUDGET ESTIMATE 

 

																	
	DIVISION/DESCRIPTION	  	QTY	 	  	UNIT$	 	  	LINE SUM	 	  	DIV.SUM	 
	 DEMOLITION
	  				  				  				  			
	 MAKESAFE ELECTRIC
	  	 	1 LS	  	  	 	800	  	  	 	800	  	  			
	 REMOVE WALLS
	  	 	730 SF	  	  	 	2.50	  	  	 	1,825	  	  			
	 REMOVE FLOORING
	  	 	3098 SF	  	  	 	0.85	  	  	 	2,633	  	  			
	 REMOVE CEILINGS
	  	 	3098 SF	  	  	 	0.80	  	  	 	2,478	  	  			
	 DEMOUTIONDUMPSTERS (SUB)
	  	 	2 EA	  	  	 	675	  	  	 	1,350	  	  			
	 DISMANTLE CASEWORK AND BENCHES
	  	 	6 MD	  	  	 	540	  	  	 	3,240	  	  			
	 REMOVE EXISTING HOOD
	  	 	1 EA	  	  	 	400	  	  	 	400	  	  			
	 HOOD DECONTAMINATION BY OTHERS
	  				  				  	 	NIC	  	  			
	 REMOVE GLAZE WALL AT LAB ENTRANCE
	  	 	1 lS	  	  	 	600	  	  	 	600	  	  			
	 REMOVE EXISTING SUPPLY DUCTWORK & REGISTEF
	  	 	1 lS	  	  	 	900	  	  	 	900	  	  			
	 GENERAL lABOR (2 DAYS PER WEEK)
	  	 	9 WKS	  	  	 	600	  	  	 	5,400	  	  			
		  				  				  	$	19,627	  	  			
					
	 CARPENTRY I MILLWORK
	  				  				  				  			
	 INSTALL DOUBLE DOORS
	  	 	1 PR	  	  	 	300	  	  	 	300	  	  			
	 INSTALL SINGLE DOOR
	  	 	3 EA	  	  	 	225	  	  	 	675	  	  			
	 EXHAUST FAN PLATFORM
	  	 	1 EA	  	  	 	600	  	  	 	600	  	  			
	 CARPENTRY & MATERIALS
	  	 	10 DVS	  	  	 	600	  	  	 	6,000	  	  			
		  				  				  				  	$	7,575	  
					
	 ROOF WORK AND CAULKING
	  				  				  				  			
	 FLASHING FOR NEW EXHAUST FAN
	  	 	EA	  	  	 	950	  	  	 	950	  	  			
	 FlASHING INTAKE AIR HOOD
	  	 	EA	  	  	 	950	  	  	 	950	  	  			
	 INTERIOR CAULKING
	  	 	LS	  	  	 	600	  	  	 	600	  	  			
		  				  				  				  	$	2,500	  
					
	 DOORS
	  				  				  				  			
	 DOUBLE SOLID CORE WOOD DRS & HDWRE
	  	 	1 PR	  	  	 	1,775	  	  	 	1,775	  	  			
	 SINGLE SOLID CORE WOOD DR & HDWRE
	  	 	1 EA	  	  	 	930	  	  	 	930	  	  			
	 SINGLE RATED H.M.OR & HDWRE
	  	 	2 EA	  	  	 	985	  	  	 	1,970	  	  			
	 HM.DOUBLE DOOR FRAME
	  	 	1 EA	  	  	 	275	  	  	 	275	  	  			
	 HM SINGLE DOOR FRAME
	  	 	3 EA	  	  	 	200	  	  	 	600	  	  			
	 BORROWED LITES
	  	 	2 EA	  	  	 	125	  	  	 	250	  	  			
	 DOOR CLOSERS
	  	 	3 EA	  	  	 	135	  	  	 	405	  	  			
	 EXISTING DOUBLE LAB ENTRANCE DOOR
	  				  				  	 	TO REMAIN	 	  			
	 ACCESS COORS
	  	 	EA	  	  	 	225	  	  	 	225	  	  			
		  				  				  	 	6,430	  	  			
	 GLASS
	  				  				  				  			
					
	 GLAZING PANELS AT DOORS
	  	 	2 EA	  	  	 	175	  	  	 	350	  	  			
		  				  				  				  	$	350	  

  
 1 

 Tetraphase Pharmaceuticals, Inc. Confidential 

 

									
	 TETRAPHASE
	  	 	Date	  	  	 	11/29/2006	  
	 480 ARSENAL STREET
	  				  			
	
    

    
	  	 	 	 	  	 	 	 

 WATERTOWN, MASSACHUSETTS 
 PRELIMINARY BUDGET ESTIMATE 
  

																	
	DIVISION/DESCRIPTION	  	QTY	 	  	UNIT$	 	  	LINE SUM	 	  	DIV.SUM	 
	 DRYWALL
	  				  				  				  			
					
	 WALL BLOCKING
	  	 	1 LS	  	  	 	2,000	  	  	 	2,000	  	  			
	 INSTALL DOOR FRAMES
	  	 	4 EA	  	  	 	80	  	  	 	320	  	  			
	 INSTALLATION OF ACCESS PANELS
	  	 	1 EA	  	  	 	75	  	  	 	75	  	  			
	 INFILL WALL OPENINGS
	  	 	2 EA	  	  	 	450	  	  	 	900	  	  			
	 FULL HEIGHT PARTITIONS
	  	 	910 SF	  	  	 	9.50	  	  	 	8,645	  	  			
	 CUT IN DOOR OPENINGS
	  	 	2 EA	  	  	 	450	  	  	 	900	  	  			
	 PATCH EXISTING WALLS
	  	 	1 lS	  	  	 	1,800	  	  	 	1,800	  	  			
	 GYPSUM BOARD CEILINGS
	  	 	160 SF	  	  	 	10.00	  	  	 	1,600	  	  			
	 INFILL DOOR OPENINGS
	  	 	4 EA	  	  	 	500	  	  	 	2,000	  	  			
		  				  				  				  	$	18,240	  
					
	 CEILINGS
	  				  				  				  			
					
	 2’×4’ VINYL FACED GYP BD W/ STAND SUSPENSION
	  	 	2,756 SF	  	  	 	2.95	  	  	 	8,130	  	  			
	 2’×4’ FISSURED CEILING W/ STANDARD GRID
	  	 	828 SF	  	  	 	2.55	  	  	 	2,111	  	  			
		  				  				  				  	$	10,242	  
					
	 FLOORING
	  				  				  				  			
					
	 VCT FLOORING
	  	 	4,122 SF	  	  	 	2.60	  	  	 	10,717	  	  			
	 EPOXY FLOORING
	  	 	120 SF	  	  	 	12.50	  	  	 	1,500	  	  			
	 EPOXY BERMS AT DOORS
	  	 	2 EA	  	  	 	150	  	  	 	300	  	  			
	 BASE
	  	 	799 LF	  	  	 	2.65	  	  	 	2,117	  	  			
		  				  				  				  	$	14,636	  
					
	 PAINTING
	  				  				  				  			
					
	 PAINT WALLS
	  	 	6,390 SF	  	  	 	0.90	  	  	 	5,751	  	  			
	 EPOXY WALL PAINT
	  	 	650 SF	  	  	 	1.25	  	  	 	813	  	  			
	 PAINT DOORS
	  	 	4 EA	  	  	 	100	  	  	 	400	  	  			
	 TOUCH UP
	  	 	1 LS	  	  	 	900	  	  	 	900	  	  			
	 ELECTROSTATICALLY PAINT REUSED CASEWORK
	  	 	1 LS	  	  	 	1,200	  	  	 	1,200	  	  			
	 PAINT EXISTING WALLS
	  				  				  	 	NJC	  	  	$	9,064	  
					
	 SPECIALTIES
	  				  				  				  			
				
	 SIGNAGE
	  				  	  
	 BY TETRAPHASE
	   
	  			
	 FIRE EXTINGUISHERS
	  				  	  
	 EXISTING TO REMAIN
	   
	  			
		  				  				  				  	$	0	  
					
	 LAB EQUIPMENT
	  				  				  				  			
				
	 LAB EQUIPMENT
	  				  	  
	 BY TETRAPHASE
	   
	  	$	0	  

  
 2 

 Tetraphase Pharmaceuticals, Inc. Confidential 

 

									
	 TETRAPHASE
	  	 	Date	  	  	 	11/29/2006	  
	     

    
	  	 	 	 	  	 	 	 

 480 ARSENAL STREET 
 WATERTOWN, MASSACHUSETTS 
 PRELIMINARY BUDGET ESTIMATE 

 

																	
	DIVISION/ DESCRlPTION	  	QTY	 	  	UNIT$	 	  	LINESUM	 	  	DIV.SUM	 
	 LAB CASEWORK & CHEMICAL FUME HOODS
	  				  				  				  			
					
	 RELOCATE 8’ CHEMICAL FUME HOOD
	  	 	EA	  	  	 	950	  	  	 	950	  	  			
	 6’·0” CHEMICAL FUME HOODS
	  	 	4 EA	  	  	 	7,200	  	  	 	28,800	  	  			
	 INSTALL 6’-0” CHEMICAL FUME HOODS
	  	 	4 EA	  	  				  	 	INCLUDED	  	  			
	 6’·0” CHEMICAL FUME HOODS
	  	 	5 EA	  	  	 	9,600	  	  	 	48,000	  	  			
	 INSTALL 8’-0” CHEMICAL FUME HOODS
	  	 	5 EA	  	  				  	 	INCLUDED	  	  			
	 RELOCATE PENINSULA BENCHES
	  	 	1 LS	  	  	 	2,800	  	  	 	2,800	  	  			
	 RECONFIGURE EXISTING BASE CABINETS
	  	 	2 EA	  	  	 	1,250	  	  	 	2,500	  	  			
	 6’-0” EPOXY BENCHTOPS
	  	 	26 LF	  	  	 	150	  	  	 	3,900	  	  			
	 3’·0” EPOXY BENCHTOPS
	  	 	44 LF	  	  	 	95	  	  	 	4,180	  	  			
	 REAGENT SHELVING 2 HIGH
	  	 	20 LF	  	  	 	150	  	  	 	3,000	  	  			
	 50% BASE CABINETS
	  	 	48 LF	  	  	 	200	  	  	 	9,600	  	  			
	 25% BASEDRAWER UNITS
	  	 	24 LF	  	  	 	260	  	  	 	6,240	  	  			
	 25% KNEE SPACES
	  	 	24 LF	  	  	 	50	  	  	 	1,200	  	  			
	 NEW EPOXY SINKS
	  	 	3 EA	  	  	 	450	  	  	 	1,350	  	  			
	 UTILITY RISERS
	  	 	2EA	  	  	 	450	  	  	 	900	  	  			
	 REUSE 2 EXISTING PENINSULA ISLANDS & BENCHTOPS
	  				  				  	 	INCLUDED	  	  			
	 INSTALL NEW CASEWORK
	  	 	LS	  	  	 	9,500	  	  	 	9,500	  	  			
	 BUILD IWO (2)EA VENTED ALCOVES
	  	 	ALW	  	  	 	0	  	  	 	0	  	  			
	 8’; WALK IN HOODS
	  	 	2 EA	  	  	 	15,000	  	  	 	30,000	  	  			
	 ENCLOSE VENTED ALCOVES WI GLASS DOORS
	  	 	0 SF	  	  	 	90	  	  	 	0	  	  			
	 LABORATORY TABLES
	  				  				  	 	BY TETRAPHASE	  	  			
		  				  				  				  	$	152,920	  
					
	 SPRINKLER
	  				  				  				  			
				
	 SUPPLEMENTW/ NEW SPRINKLER HEADS AS REQ’D
	  				  				  	 	INCL TRADES PERMITS	  
	 INCL RELOCATIONS
	  				  				  	 	INCL SPRINKLER	  
	 BUDGET
	  	 	1 LS	  	  	 	9,500	  	  	 	9,500	  	  			
					
		  				  				  				  	$	9,600	  
					
	 PLUMBlNG
	  				  				  				  			
					
	 CUT & CAP SERVICES AS REQ’D
	  				  				  	 	INCL	  	  			
	 LAB SINK TRIM
	  	 	4 EA	  	  				  	 	INCL	  	  			
	 RODIFAUCETS
	  	 	4 EA	  	  				  	 	INCL	  	  			
	 6’ 0” FUME HOOD CONNECTS
	  	 	4 EA	  	  				  	 	INCL	  	  			
	 8’·0” FUME HOOD CONNECTS
	  	 	5 EA	  	  				  	 	INCL	  	  			
	 NITROGEN 180 DEG TURRETS
	  	 	3 EA	  	  				  	 	INCL	  	  			
	 COMPRESSED AIR 180 DEG TURRETS
	  	 	3 EA	  	  				  	 	INCL	  	  			
	 HOOKUP RELOCATED 8’-0” CFH
	  	 	1 EA	  	  				  	 	INCL	  	  			
	 EMERGENCY EYEWASH DECK MOUNTED
	  	 	4EA	  	  				  	 	INCL	  	  			
	 PLUMBING PERMIT
	  				  				  	 	INCL	  	  			
	 ALCOVE GASSES
	  	 	2 EA	  	  				  	 	INCL	  	  			
	 PROC CHILLED WATER PIPING TO 1 CHILLER
	  	 	1 EA	  	  				  	 	INCL	  	  			
	 PLUMBING BUDGET
	  	 	1 IS	  	  	 	105,132	  	  	 	105,132	  	  			
		  				  				  				  	$	106,132	  

  
 3 

 Tetraphase Pharmaceuticals, Inc. Confidential 

 

									
	 TETRAPHASE
	  	 	Date	  	  	 	11/29/2006	  
	 480 ARSENAL STREET
	  				  			
	 	 	 
	 	  	 	 	 	  	 	 	 

 WATERTOWN, MASSACHUSETTS 
 PRELIMINARY BUDGET ESTIMATE 
  

															
	DIVISION/DESCRIPTION	  	QTY	  	UNIT$	 	  	LINE SUM	 	  	DIV.SUM	 
	 HVAC
	  		  				  				  			
					
	 CUT AND DROP EXISTING UNUSABLE DUCTWORK
	  		  				  	 	INCLUDED	  	  			
	 REUSE EXISTING MAINAIR HANDLER AND REBALANCE
	  		  				  	 	INCLUDED	  	  			
	 MODIFY EXHAUST SYSTEM TO HANDLE ADDED HOODS & ROTO VAPS
	  				  	 	INCLUDED	  	  			
	 NEW 6,000 CFM (5 HP) TRANSFER FAN W/COOLING (
	  		  				  	 	INCLUDED	  	  			
	 REMOVE EXISTING SECONDARY AIR HANDLER
	  		  				  	 	INCLUDED	  	  			
	 NEW 15 HP LAB EXHAUST FAN
	  		  				  	 	INCLUDED	  	  			
	 ROTC VAP EXHAUST DROPS {150 CFM EA)
	  	10 EA	  				  	 	INCLUDED	  	  			
	 REGISTER.DIFFUSERS, GRILLES
	  		  				  	 	INCLUDED	  	  			
	 SUPPLY & EXHAUST BOXES FOR CHEM LAB & EQUIP RM
	  		  				  	 	INCLUDED	  	  			
	 MODIFY SUPPLY DUCTWORK
	  		  				  	 	INCLUDED	  	  			
	 BALANCING
	  		  				  	 	INCLUDED	  	  			
	 STARTUP
	  		  				  	 	INCLUDED	  	  			
	 HOOD MANAGEMENT
	  	1 LS	  	 	109,000	  	  	 	109,000	  	  			
	 Delete Humidification in NMR Room
	  	1 LS	  	 	-6,500	  	  	 	-6,500	  	  			
	 HVACBUDGET
	  	1 LS	  	 	158,000	  	  	 	158,000	  	  			
		  		  				  				  	$	260,600	  
					
	 ELECTRICAL
	  		  				  				  			
					
	 SWITCHGEAR J DISTRIBUTION
	  	1 LS	  	 	5,780	  	  	 	10,680	  	  			
	 .HVAC POWER WIRING
	  	1 LS	  	 	2,875	  	  	 	3,975	  	  			
	 LIGHTING
	  	1 LS	  	 	4,950	  	  	 	6,450	  	  			
	 EXIT/EMERGENCY LIGHTING
	  	1 LS	  	 	475	  	  	 	755	  	  			
	 “FIRE ALARM
	  	1 LS	  	 	1,130	  	  	 	1,980	  	  			
	 n OUTLETS, WIREMOLD AND HOODS
	  	1 LS	  	 	17,940	  	  	 	29,580	  	  			
	 TEL/DATA
	  	1 LS	  	 	8,760	  	  	 	11,240	  	  			
	 JOB DIRECT EXPENSES & OTHER MATERIALS
	  	1 LS	  	 	3,950	  	  	 	5,350	  	  			
	UGHT & PWR TO SOLVENT, WASTE, NMR & MAT’LS	  		  				  	 	INCLUDED	  	  			
	 ELECTRICAL PERMIT
	  		  				  	 	INCLUDED	  	  			
	 TEMPORARY SERVICES
	  		  				  	 	INCLUDED	  	  			
	 ENGINEERING AND DOCS
	  		  				  	 	INCLUDED	  	  			
		  		  				  				  	$	69,910	  
					
	 SUPERVISION
	  		  				  				  			
					
	 PROJECT SUPERINTENDENT
	  	9 WKS	  	 	2,975	  	  	 	26,775	  	  			
	 PROJECT MANAGER ( 2 DAYS / WK)
	  	8 WKS	  	 	1,190	  	  	 	9,520	  	  			
	 ESTIMATOR/PLANNER
	  	1.5 WK	  	 	3,400	  	  	 	5,100	  	  			
	 ADMINISTRATIVE ASSISTANT
	  	8 DAY	  	 	275	  	  	 	2,200	  	  			
	 ACCOUNTANT
	  	8 DAY	  	 	350	  	  	 	2,800	  	  			
		  		  				  				  	$	46,395	  

  
 4 

 Tetraphase Pharmaceuticals, Inc. Confidential 

 

					
	TETRAPHASE	  	Date	  	11/29/2006
	480 ARSENAL STREET	  		  	
	 	 	 
	 	  		  	 
	 		 
	 	  	 	  	 

																	
	 WATERTOWN,MASSACHUSETTS
	  				 				  				  			
	 PRELIMINARY BUDGET ESTIMATE
	  				 				  				  			
					
	DIVISION/DESCRIPTION	  	QTY	 	 	UNIT$	 	  	UNESUM	 	  	OIV.SUM	 
	 GENERAL CONDITIONS
	  				 				  				  			
	 JOBSJTE TELEPHONE/FAX
	  	 	2 MO	  	 	 	900	  	  	 	1,800	  	  			
	 CONSTRUCTION OFFICES
	  				 				  				  			
	 USEEXISTING COURIER/OVERNITE/POSTAGE
	  	 	2 MO	  	 	 	450	  	  	 	900	  	  			
	 FIELD OFFICE SUPPLIES & COPIER RENTAL
	  	 	2 MO	  	 	 	475	  	  	 	950	  	  			
	 MISC.TOOLS & SUPPLIES
	  	 	2MO	  	 	 	600	  	  	 	1,200	  	  			
	 TEMP. TOILETS
	  				 				  	 	USEEXISTING	  	  			
	 REPRODUCTION OF CONTRACT DOCUMENTS
	  	 	1 LS	  	 	 	950	  	  	 	950	  	  			
	 WEEKLY CLEANING
	  	 	9 DAYS	  	 	 	360	  	  	 	3,240	  	  			
	 DUMPSTER
	  	 	5EA	  	 	 	675	  	  	 	3,375	  	  			
	 SAFETY & PROTECTION
	  	 	1LS	  	 	 	1,500	  	  	 	1,500	  	  			
	 FINALCLEANING
	  	 	1 LS	  	 	 	3,250	  	  	 	3,250	  	  			
		  				 				  				  	$	17,165	  
					
	ENGINEERING	  				 				  				  			
					
	 ARCHITECTURAL DESIGN & DRAWINGS
	  	 	L.S	  	 	 	22,000	  	  	 	22,000	  	  			
	 MECHANICAUELECTRICAL ENGINEERING
	  				 				  	 	W/SUBS	  	  			
	 STRUCTURAL
	  	 	1 LS	  	 	 	2,500	  	  	 	W/SUBS	  	  			
		  				 				  				  	$	22,000	  
					
	INSURANCE & PERMITS	  				 				  				  			
	GENERAL LIABILITY INSURANCE	  	 	1LS	  	 	$	5,194	  	  	 	5,194	  	  			
					
	BUILDING PERMITS	  	 	1LS	  	 	$	7,752	  	  	 	7,752	  	  			
		  				 				  				  	$	12,946	  
					
	 CONTINGENCY
	  	 	1 LS	  	 	 	35,000	  	  	 	35,000	  	  			
		  				 				  				  	$	35,000	  
					
	 OVERHEAD & PROFIT
	  	 	6.5	% 	 	$	53,305	  	  	 	53,305	  	  			
		  				 				  				  	$	53,305	  
					
	 TOTAL BUDGET COST
	  				 				  				  	$	873,435	  

 CLARIFICATIONS AND ALTERNATIVES 
  

	1	Pricing assumes that electric usage and Power Company Backcharges a1e paid for by the Landlord 

	2	Pricing assumes Haz Materials Handlirlg and DisposalIs by Landlord 

	3	Pricing assumes house HVAC system Is adequate to handle new loads. 

	4	Pricing assumes that existing electric service Is adequate to handle new work. 

  
 5 

 480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 1 

 

 EXHIBIT C TO LEASE 

WORK LETTER 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 1 

 

 EXHIBIT D TO LEASE 

Rules and Regulations 
 1. The sidewalk, entries, and driveways of the Project shall not be obstructed by Tenant, or any Tenant Party, or used by them for any purpose other than ingress and egress to and from the Premises.

 2. Tenant shall not place any objects, including antennas, outdoor furniture, etc., in the parking areas, landscaped areas or
other areas outside of its Premises, or on the roof of the Project. 
 3. Except for animals assisting the disabled, no animals
shall be allowed in the offices, halls, or corridors in the Project. 
 4. Tenant shall not disturb the occupants of the Project
or adjoining buildings by the use of any radio or musical instrument or by the making of loud or improper noises. 
 5. If
Tenant desires telegraphic, telephonic or other electric connections in the Premises, Landlord or its agent will direct the electrician as to where and how the wires may be introduced; and, without such direction, no boring or cutting of wires will
be permitted. Any such installation or connection shall be made at Tenant’s expense. 
 6. Tenant shall not install or
operate any steam or gas engine or boiler, or other mechanical apparatus in the Premises, except as specifically approved in the Lease. The use of oil, gas or inflammable liquids for heating, lighting or any other purpose is expressly prohibited.
Explosives or other articles deemed extra hazardous shall not be brought into the Project. 
 7. Parking any type of
recreational vehicles is specifically prohibited on or about the Project. Except for the overnight parking of operative vehicles, no vehicle of any type shall be stored in the parking areas at any time. In the event that a vehicle is disabled, it
shall be removed within 48 hours. There shall be no “For Sale” or other advertising signs on or about any parked vehicle. All vehicles shall be parked in the designated parking areas in conformity with all signs and other markings. All
parking will be open parking, and no reserved parking, numbering or lettering of individual spaces will be permitted except as specified by Landlord. 
 8. Tenant shall maintain the Premises free from rodents, insects and other pests. 

9. Landlord reserves the right to exclude or expel from the Project any person who, in the judgment of Landlord, is intoxicated or under
the influence of liquor or drugs or who shall in any manner do any act in violation of the Rules and Regulations of the Project. 
 10. Tenant shall not cause any unnecessary labor by reason of Tenant’s carelessness or indifference in the preservation of good order and cleanliness. Landlord shall not be responsible to Tenant for
any loss of property on the Premises, however occurring, or for any damage done to the effects of Tenant by the janitors or any other employee or person. 
 11. Tenant shall give Landlord prompt notice of any defects in the water, lawn sprinkler, sewage, gas pipes, electrical lights and fixtures, heating apparatus, or any other service equipment affecting the
Premises. 
 12. Tenant shall not permit storage outside the Premises, including without limitation, outside storage of trucks
and other vehicles, or dumping of waste or refuse or permit any harmful materials to be placed in any drainage system or sanitary system in or about the Premises. 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 2 

 

 13. All moveable trash receptacles provided by the trash disposal firm for the Premises
must be kept in the trash enclosure areas, if any, provided for that purpose. 
 14. No auction, public or private, will be
permitted on the Premises or the Project. 
 15. No awnings shall be placed over the windows in the Premises except with the
prior written consent of Landlord. 
 16. The Premises shall not be used for lodging, sleeping or cooking or for any immoral or
illegal purposes or for any purpose other than that specified in the Lease. No gaming devices shall be operated in the Premises. 
 17. Tenant shall ascertain from Landlord the maximum amount of electrical current which can safely be used in the Premises, taking into account the capacity of the electrical wiring in the Project and the
Premises and the needs of other tenants, and shall not use more than such safe capacity. Landlord’s consent to the installation of electric equipment shall not relieve Tenant from the obligation not to use more electricity than such safe
capacity. 
 18. Tenant assumes full responsibility for protecting the Premises from theft, robbery and pilferage. 

19. Tenant shall not install or operate on the Premises any machinery or mechanical devices of a nature not directly related to
Tenant’s ordinary use of the Premises and shall keep all such machinery free of vibration, noise and air waves which may be transmitted beyond the Premises. 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 1

  

 EXHIBIT E TO LEASE 

TENANT’S PERSONAL PROPERTY 
 I. Existing (purchased from former tenant Protein Forest Inc. “PFI”): 

Lab Equipment: 
 G7883 CD Glasswasher

 GR Ext Ice Flaker MKS 400 Stor 
 Drum
Cabinet w/Rollers for 2-55 Gal. Drums 
 Furniture: 
 Reception Area 
 2 Lounge Chairs w/Wood Arm Cap 

Mojo Side Table 22” × 16” 

Receptionist station 
 Conference Room:

 Epson EMP720c LCD Projector 
 Virtu
Board w/incl Doors, Glass Sh 
 16 Webb Chairs (Conf Room) 
 1 Rectangular Table 48” × 96” (Lg Conf Tbl) 
 Rectangular Table 48” ×
72” (Sm Conf Table) 
 Virtu Server Cart 24” × 36” (Corner Table) 
 Executive Offices and Office Area: 
 All Workstations in 6 offices and all cubicle workstations in
office Area, “area formerly marked on PFI floor plan as “Software Development RoomH and “Tech Station”, OH Bins, Panels, etc. 
 27 lzzy Zachary Chairs (green office chairs) 
 12 Cache in Chairs (Side Chairs in Offices)

 Cafeteria: 
 28 Zag Chairs (Cafe
Chairs) 
 7 Square Table Tops & Bases (Cafe Tables) 
 II. To be purchased in the future (List is meant to be illustrative and not limited to these specific items): 
 Medicinal Chemistry: 
 400 MHzNMR 
 Agilent 1200 LC/MS 
 Agilent 1200 HPLCs 
 Lyophilizer 
 -20° Freezers 
 Fridges 
 Process Chemistry: 
 Large chiller/heater 
 Small chiller/heater 

Large rotovap 
 Large vac.oven 

SOL glass reactors 
 -20° Freezers

 Fridges 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 Tetraphase Pharmaceuticals, Inc. Confidential 

480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 2 

 

 Biology: 
 Microbiology: 
 -80° Freezers 
 Balances, analytical 
 Incubator, water jacketed, stacked 

Water shaker 
 Microplate reader (plus microplate
handling system) 
 Table top centrifuges 
 -20° Freezers 
 Fridges 
 Various rotors 
 Microscope 
 Balances 
 Magnetic stirrer 
 Orbital shaker 
 Electronic pipettor 
 Microcentrifuge 
 Vortex mixers 
 Cell Biology: 
 Cryogenic storage, liquid N2-based 

Incubators (C02) 
 Microplate reader 

Microscope fluorescence 
 Digital camera for
microscope 
 Centrifuges 
 General
Biology: 
 Autoclave 
 Sonicators
(plus Sonicator tip) 
 Thermocyclers 

Hybridization ovens 
 Shaking Incubators

 Electroporation 
 Gyratory shakers

 Western Blot 
 General[R&D
equip. and Computers etc.]: 
 Rotovaps (for hoods) 
 Glasswasher 
 Ice machine 
 Chemical Storage cabinets 
 Computers - New hires -laptops 

Computers - New Hires- desktops 
 IT - general
network etc. 
 Telephone system and phones 
 Fax machines 
 Printers 
 Copier 

 480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 2 

 

 EXHIBIT F TO LEASE 

FORM OF LETTER OF CREDIT 
 IRREVOCABLE STANDBY LETTER OF CREDIT NO.SVBSF         
 DATE:NOVEMBER     , 2006 
 BENEFICIARY: 

ARE-480 ARSENAL STREET, LLC. 
 C/0 ALEXANDRIA
REAL ESTATE EQUITIES, INC. 
 385 EAST COLORADO BLVD, SUITE 299 
 PASADENA, CA 91101 
 APPLICANT: 
 TETRAPHASE PHARMACEUTICALS INC 
 480 ARSENAL STREET, SUITE 110 

WATERTOWN,MA 02472 
 AMOUNT:US$
        ,                     AND 00/100 U.S. DOLLARS) 

EXPIRATION DATE:            , 2007 (ONE YEAR FROM LC ISSUE DATE) 

LOCATION: AT OUR COUNTERS IN SANTA CLARA, CALIFORNIA 
 DEAR SIR/MADAM: 
 WE HEREBY ESTABLISH OUR IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF
        IN YOUR FAVOR AVAILABLE BY YOUR DRAFT DRAWN ON US AT SIGHT IN THE FORM OF EXHIBIT “A” ATTACHED AND ACCOMPANIED BY THE FOLLOWING DOCUMENTS: 

1. THE ORIGINAL OF THIS LETTER OF CREDIT AND ALL AMENDMENT(S),IF ANY. 
 2. A DATED CERTIFICATION FROM THE BENEFICIARY, PURPORTEDLY SIGNED BY AN AUTHORIZED OFFICER, FOLLOWED BY HIS/HER DESIGNATED TITLE, STATING THE FOLLOWING: 

(A) “THE BENEFICIARY HEREBY CERTIFIES THAT TETRAPHASE PHARMACEUTICALS INC OR ITS SUCCESSORS OR ASSIGNS UNDER THE LEASE HAS DEFAULTED IN ITS
OBLIGATIONS UNDER THE LEASE AGREEMENT,DATED            , 2006 [INSERT LEASE DATE] BY AND BETWEEN TETRAPHASE PHARMACEUTICALS INC AND ARE-480 ARSENAL STREET, LLC.(AS THE SAME MAY BE AMENDED
AND ASSIGNED FROM TIME TO TIME, THE “LEASE”) AND THAT BENEFICIARY IS DUE THE AMOUNT REQUESTED IN THIS DRAW REQUEST.” 
 OR 
 (B) “THE BENEFICIARY HEREBY CERTIFIES THAT TETRAPHASE PHARMACEUTICALS INC OR ITS
SUCCESSORS OR ASSIGNS UNDER THE LEASE HAS DEFAULTED IN ITS OBLIGATIONS UNDER THE LEASE, THAT BENEFICIARY IS BARRED BY APPLICABLE LAW FROM SENDING A NOTICE OF DEFAULT AND THAT BENEFICIARY IS DUE THE AMOUNT REQUESTED IN THIS DRAW REQUEST”.

 OR 
 (C) “THE
BENEFICIARY IS IN RECEIPT OF SILICON VALLEY BANK NOTICE OF NON-EXTENSION OF LETTER OF CREDIT NO.SVBSF         (THE “LETTER OF CREDIT) AND CERTIFIES THAT IT IS ENTITLED TO DRAW THE ENTIRE AMOUNT OF THE
LETTER OF CREDIT.” 
 OR 

  
 © All
rights reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 Tetraphase Pharmaceuticals, Inc. Confidential 

480 Arsenal Street Tetraphase Pharmaceuticals, Inc. - Page 3 

 

 (D) “THE BENEFICIARY HEREBY CERTIFIES THAT BENEFICIARY IS DUE THE AMOUNT REQUESTED IN THIS DRAW
REQUEST PURSUANT TO THE TERMS AND CONDITIONS OF THE LEASE.” 
 THE LEASE AGREEMENT MENTIONED ABOVE IS FOR IDENTIFICATION PURPOSES ONLY AND
IT IS NOT INTENDED THAT SAID LEASE AGREEMENT BE INCORPORATED HEREIN OR FORM PART OF THIS LETTER OF CREDIT. 
 PARTIAL DRAWINGS ARE ALLOWED. THIS
LETTER OF CREDIT MUST ACCOMPANY ANY DRAWINGS HEREUNDER FOR ENDORSEMENT OF THE DRAWING AMOUNT AND WILL BE RETURNED TO THE BENEFICIARY UNLESS IT IS FULLY UTILIZED. 
 DRAFT(S) AND DOCUMENTS MUST INDICATE THE NUMBER AND DATE OF THIS LETTER OF CREDIT. 
 THIS LETTER
OF CREDIT SHALL BE AUTOMATICALLY EXTENDED FOR AN ADDITIONAL PERIOD OF ONE YEAR, WITHOUT AMENDMENT, FROM THE PRESENT AND/OR EACH FUTURE EXPIRATION DATE UNLESS AT LEAST SIXTY (60) DAYS PRIOR TO THE THEN CURRENT EXPIRATION DATE WE NOTIFY YOU BY
OVERNIGHT COURIER SERVICE AT THE ABOVE ADDRESS THAT THIS LETTER OF CREDIT WILL NOT BE EXTENDED BEYOND THE CURRENT EXPIRATION DATE.IN NO EVENT SHALL THIS LETTER OF CREDIT BE AUTOMATICALLY EXTENDED BEYOND MARCH 31,2018 WHICH SHALL BE THE FINAL
EXPIRATION DATE OF THIS LETTER OF CREDIT. 
 THIS LETTER OF CREDIT IS TRANSFERABLE BY THE ISSUING BANK AT THE REQUEST OF BENEFICIARY ONE OR MORE
TIMES BUT IN EACH INSTANCE TO A SINGLE BENEFICIARY AND ONLY IN ITS ENTIRETY UP TO THE THEN AVAILABLE AMOUNT IN FAVOR OF ANY NOMINATED TRANSFEREE ASSUMING SUCH TRANSFER TO SUCH TRANSFEREE WOULD BE IN COMPLIANCE WITH THEN APPLICABLE LAW AND
REGULATIONS, INCLUDING BUT NOT LIMITED TO THE REGULATIONS OF THE U.S. DEPARTMENT OF TREASURY AND U.S. DEPARTMENT OF COMMERCE.AT THE TIME OF TRANSFER,THE ORIGINAL LETTER OF CREDIT AND ORIGINAL AMENDMENT(S),IF ANY, MUST BE SURRENDERED TO US TOGETHER
WITH OUR LETTER OF TRANSFER DOCUMENTATION (IN THE FORM OF EXHIBIT “B” ATTACHED HERETO).OUR TRANSFER FEE OF% OF 1% OF THE TRANSFER AMOUNT (MINIMUM $250.00) WILL BE PAID BY THE APPLICANT. ANY TRANSFER OF THIS LETTER OF CREDIT MAY NOT CHANGE
THE PLACE OF EXPIRATION OF THE LETTER OF CREDIT FROM OUR ABOVE-SPECIFIED OFFICE. EACH TRANSFER SHALL BE EVIDENCED BY OUR ENDORSEMENT ON THE REVERSE OF THE ORIGINAL LETTER OF CREDIT AND WE SHALL FORWARD THE ORIGINAL LETTER OF CREDIT TO THE
TRANSFEREE. 
 ALL DEMANDS FOR PAYMENT SHALL BE MADE BY PRESENTATION OF THE ORIGINAL APPROPRIATE DOCUMENTS ON A BUSINESS DAY AT OUR OFFICE (THE
“BANK’S OFFICE”) AT: SILICON VALLEY BANK, 3003 TASMAN DRIVE, SANTA CLARA, CA 95054, ATTENTION: STANDBY LETTER OF CREDIT NEGOTIATION SECTION. 
 WE HEREBY AGREE WITH THE DRAWERS, ENDORSERS AND BONA FIDE HOLDERS THAT THE DRAFTS DRAWN UNDER AND IN ACCORDANCE WITH THE TERMS AND CONDITIONS OF THIS LETTER OF CREDIT SHALL BE DULY HONORED UPON
PRESENTATION TO THE DRAWEE,IF NEGOTIATED ON OR BEFORE THE EXPIRATION DATE OF THIS CREDIT. 
 IF ANY INSTRUCTIONS ACCOMPANYING A DRAWING UNDER
THIS LETTER OF CREDIT REQUEST THAT PAYMENT IS TO BE MADE BY TRANSFER TO YOURACCOUNTWITHANOTHER BANK, WE WILL ONLY EFFECT SUCH PAYMENT BY FED WIRE TO A U.S. REGULATED BANK, AND WE AND/OR SUCH OTHER BANK MAY RELY ON AN ACCOUNT NUMBER SPECIFIED IN SUCH
INSTRUCTIONS EVEN IF THE NUMBER IDENTIFIES A PERSON OR ENTITY DIFFERENT FROM THE INTENDED PAYEE. 

 Tetraphase Pharmaceuticals, Inc. Confidential 

480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. Page 4 

 

 EXCEPT AS OTHERWISE PROVIDED HEREIN, THIS LETTER OF CREDIT IS SUBJECT TO THE UNIFORM CUSTOMS AND
PRACTICES FOR DOCUMENTARY CREDITS, (1993 REVISION), INTERNATIONAL CHAMBER OF COMMERCE, PUBLICATION NO. 500. 
  

					
	SILICON VALLEY BANK	 		 	
			
	  
	 		 	
	  
	 		 	
	AUTHORIZED SIGNATURE	 		 	 AUTHORIZED SIGNATURE

			
		 		 	PAGE20F2

 Tetraphase Pharmaceuticals, Inc. Confidential 

480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 5 

 

 EXHIBIT “A” to LETTER OF CREDIT 

 

			
	
DATE:                    

	 	
REF.NO.                    

      AT SIGHT OF THIS DRAFT 
 PAY TO THE ORDER OF US$                         

US DOLLARS  
  

			
	  
 	 	  

 DRAWN UNDER SILICON VALLEY BANK, SANTA CLARA, CALIFORNIA, STANDBY LETTER OF
CREDIT NUMBER NO.
                    DATED                  
   
  

					
	TO: SILICON VALLEY BANK	 		 	
	  
	 		 	
	3003 TASMAN DRIVE	 		 	
	SANTA CLARA, CA 95054	 		 	(BENEFICIARY’S NAME)
			
		 		 	Authorized Signature

 GUIDELINES TO PREPARE THE DRAFT 
 1.DATE:ISSUANCE DATE OF DRAFT. 
 2.REF. NO.: BENEFICIARY’S REFERENCE NUMBER, IF ANY.

 3. PAYTOTHE ORDER OF: NAME OF BENEFICIARY AS INDICATED IN THE LIC (MAKE SURE BENEFICIARY ENDORSES IT ON THE REVERSE SIDE). 

4. US$: AMOUNT OF DRAWING IN FIGURES. 
 5. US
DOLLARS: AMOUNT OF DRAWING IN WORDS. 
 6. LETTER OF CREDIT NUMBER:SILICON VALLEY BANK’S STANDBY UC NUMBER THAT PERTAINS TO THE
DRAWING. 
 7.DATED:ISSUANCE DATE OF THE STANDBY UC. 
 8.BENEFICIARY’S NAME: NAME OF BENEFICIARY AS INDICATED IN THE UC. 
 9.AUTHORIZED
SIGNATURE:SIGNED BY AN AUTHORIZED SIGNEROF BENEFICIARY. 
 IF YOU NEED FURTHER ASSISTANCE IN COMPLETING THIS DRAFT, PLEASE CALL OUR L/C PAYMENT
SECTION AND ASK FOR: 
 ALICE DA LUZ:408-654-7120 
 EFRAIN TUVILLA: 408-654-6349 
 28464922.2 0725011753? 98459290 

BOS111 12079564.8 

  
 © All rights
reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 Tetraphase Pharmaceuticals, Inc. Confidential 

480 ArsenalStreet/Tetraphase Pharmaceuticals, Inc. Page 6 

 

 EXHIBIT “B” to Letter of Credit 

 

			
	DATE:	 	
		
	TO: SILICON VALLEY BANK 3003 TASMAN DRIVE	 	RE: SANTA CLARA,.CA 95054
	ATTN:INTERNATIONAL DIVISION. STANDBY LETTERS OF CREDIT
		
	GENTLEMEN:	 	
	
	IRREVOCABLE STANDBY LETTER OF CREDIT NO.                     ISSUED
BY SILICON VALLEY BANK, SANTA CLARA UCAMOUNT:

 FOR VALUE RECEIVED,THE UNDERSIGNED BENEFICIARY HEREBY IRREVOCABLY TRANSFERS TO: 

(NAME OF TRANSFEREE) 
 (ADDRESS) 

ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY TO DRAW UNDER THE ABOVE LEDER OF CREDIT UP TO ITS AVAILABLE AMOUNT AS SHOWN ABOVE AS OF THE DATE OF THIS
TRANSFER. 
 BY THIS TRANSFER, ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY IN SUCH LEDER OF CREDIT ARE TRANSFERRED TO THE TRANSFEREE. TRANSFEREE
SHALL HAVE THE SOLE RIGHTS AS BENEFICIARY THEREOF,INCLUDING SOLE RIGHTS RELATING TO ANY AMENDMENTS, WHETHER INCREASES OR EXTENSIONS OR OTHER AMENDMENTS, AND WHETHER NOW EXISTING OR HEREAFTER MADE. ALL AMENDMENTS ARE TO BE ADVISED DIRECT TO THE
TRANSFEREE WITHOUT NECESSITY OF ANY CONSENT OF OR NOTICE TO THE UNDERSIGNED BENEFICIARY. 
 THE ORIGINAL OF SUCH LETTER OF CREDIT IS RETURNED
HEREWITH, AND WE ASK YOU TO ENDORSE THE TRANSFER ON THE REVERSE THEREOF, AND FORWARD IT DIRECTLY TO THE TRANSFEREE WITH YOUR CUSTOMARY NOTICE OF TRANSFER. 
  

	
	  

	  

	  

 SINCERELY, (BENEFICIARY’S NAME) (SIGNATURE OF BENEFICIARY) (NAME AND TITLE) 

28464922.2 072501 1753P 98459290 
 BOS111
12079564.8 

  
 © All rights
reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 Tetraphase Pharmaceuticals, Inc. Confidential 

480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 7 

 

 SIGNATURE AUTHENTICATED 
 The name(s}, title(s), and signature(s) conform to that/those on file with us for the company and the signature(s) is/are authorized to execute this instrument. 

We further confirm that the company has·been identified applying the appropriate que diligence and enhanced due diligence as required by BSA and
all its subsequent amendments. 
  

	
	  

	  

	  

	  

 (Name of Bank) 

(Address of Bank) 
 (City, State, ZIP Code)

	
	  

	  

 (Authorized Name and Title) 
 (Author-ized Signature) 
 (Telephone number) 

28464922.2 0725011753P 98459290 
 BOS111
12079564.8 

  
 © All rights
reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 Tetraphase Pharmaceuticals, Inc. Confidential 

480 Arsenal Street/Tetraphase Pharmaceuticals, Inc. - Page 8 

 

 EXHIBIT G TO LEASE 

ENVIRONMENTAL REPORTS 
 1. Phase I Environmental Site Assessment Report, prepared by GZA GeoEnvironmental, Inc. (“GZA”), dated June 2001. 
 2. Watertown Materials Management Center Facility Exit Report Volume Iand Volume II,prepared by GZA, dated February 2002. 
  

	3.	Tenant Exit Audit Review, prepared by ENVIRON International Corporation (“ENVIRON”), dated October 21, 2002. 

 

	4.	Mold Investigation and Remediation Report,prepared by ENVIRON, dated December 29, 2003. 

 

	5.	Decommissioning Plan Letter by Protein Forest, Inc. (“Protein Forest”},dated October 3, 2006. 

 

	6.	Surrender Plan from Protein Forest to Tim White of ARE, dated November 3,2006. 

 

	7.	Letter from the Commonwealth of Massachusetts to RusselGarlick of Protein Forest, dated September 27, 2005. 

 

	8.	ChemicalList for Premise Surrender by Protein Forest, dated November 4, 2006. 

 28464922.2 072501 1753P 98459290 
 BOS111 12079564.8 

  
 © All rights
reserved – Alexandria Real Estate Equities 2001 
 CONFIDENTIAL – DO NOT COPY OR DISTRIBUTE 

 FIRST AMENDMENT TO LEASE 

THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of September 9, 2011 by and between ARE-480
ARSENAL STREET, LLC, a Delaware limited liability company (“Landlord”), and TETRAPHASE PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). 

RECITALS 

A. Landlord and Tenant are parties to that certain Lease Agreement dated as of November 16, 2006 (the
“Lease”). Pursuant to the Lease, Tenant leases approximately 15,149 rentable square feet as more particularly described in Exhibit A to the Lease (the “Original premises”) in a building located at 480 Arsenal
Street, Watertown, Massachusetts. Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease. 
 B. Landlord and Tenant desire, subject to the terms and conditions set forth herein, to, among other things, amend the Lease to expand the Premises by adding approximately 750 rentable square feet
to the Original Premises for a total of 15,899 as more particularly described on Exhibit A to this First Amendment (the “Expansion Premises”). 
 NOW, THEREFORE, in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows: 

1. Delivery; Acceptance of Expansion Premises; Expansion Rent Commencement Date. 

(a) Landlord shall use reasonable efforts to deliver the Expansion Premises to Tenant on or before November 1, 2011
(“Delivery” or “Deliver”) with Landlord’s Work (defined below) substantially complete. Tenant acknowledges that there is currently a tenant occupying the Expansion Premises, and the parties agree that if
Landlord fails to timely Deliver the Expansion Premises, including, without limitation, as a result of such existing tenant’s failure to early vacate and surrender the Expansion Premises, Landlord shall not be liable to Tenant for any loss or
damage resulting therefrom, and this Lease with respect to the Expansion Premises shall not be void or voidable. For the purposes of this Section 1, “Landlord’s Work” shall mean the following work items to be done
within the Expansion Premises in conformance to Building standards and otherwise reasonable acceptable to Landlord and Tenant: the removal or a portion of the wall and the installation of a building-standard interior door between the Original
Premises and the Expansion Premises as depicted on Exhibit A to this First Amendment. Other than Landlord’s Work, Landlord shall have no obligation to perform any work at the Building in connection with Tenant’s occupancy or obtain
any permits, approvals or entitlements related to Tenant’s specific use of the Premises or Tenant’s business operations therein. 
 (b) The “Expansion Premises Commencement Date” shall be the date that Landlord Delivers the Expansion Premises to Tenant broom clean, free of all occupants with Landlord’s Work
substantially complete. Upon request of Landlord, Tenant shall execute and 

  
 1 

 
deliver a written acknowledgement of the Expansion Premises Commencement Date when the same is established in the form attached hereto as Exhibit B; provided, however, that Tenant’s
failure to execute and deliver such acknowledgement shall not affect Landlord’s rights hereunder. 
 (c) Except for
Landlord’s Work: (i) Tenant shall accept the Expansion Premises in their condition as of the Expansion Premises Commencement Date, subject to all applicable Legal Requirements; (ii) Landlord shall have no obligation for any defects in
the Expansion Premises; and (iii) Tenant’s taking possession of the Expansion Premises were in good condition at the time possession was taken. 
 (d) Tenant agrees and acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty with respect to the condition of all or any portion of the Expansion Premises,
and/or the suitability of the Expansion Premises for the conduct of Tenant’s business, and Tenant waives any implied warranty that the Expansion Premises are suitable for the Permitted Use. 

2. Base Rent. Commencing on the Expansion Premises Commencement Date, the following amendments shall be deemed made to
definitions contained on page 1 of the Lease: 
 3. Other Changes to Defined Terms. As of the Expansion Premises
Commencement Date, Base Rent shall be increased to $47,569.22. Thereafter, Base Rent shall adjust in accordance with Section 5 of the Lease. 
  

	 	(i)	The defined term “Premises” shall include the Original Premises and the Expansion Premises and shall comprise 15,889 rentable square feet. Exhibit
A to this First Amendment shall be deemed added to Exhibit A to the Lease; 

  

	 	(ii)	The defined term “Tenant’s Share of Operating Expenses” shall be increased to 11.296%. 

4. Early Termination. For avoidance of doubt, Section 3 of the Lease is hereby deleted in its entirely and is
of no further force or effect. 
 5. OFAC. Tenant, and all beneficial owners of Tenant, are currently (a) in
compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (“OFAC”) of the U.S. Department of Treasury and any statute, executive order, or
regulation relating thereto (collectively, the “OFAC Rules”), (b) not listed on, and shall not during the term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List maintained by OFAC and/or on
any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under
the OFAC Rules. 
 6. Broker. Landlord and Tenant each represents and warrants that it has not dealt with any
broker, agent or other person (collectively, “Broker”) in connection with the 

  
 2 

 
transaction reflected in this First Amendment and that no Broker brought about this transaction other than CBRE-NE. Landlord and Tenant each hereby agree to indemnify and hold the other harmless
from and against any claims by any Broker, other than CBRE-NE, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this leasing transaction. 

7. Miscellaneous. 
 (a) This First Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions.
This First Amendment may be amended only by an agreement in writing, signed by the parties hereto. 
 (b) This First Amendment
is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, representatives, officers, directors, divisions, subsidiaries, affiliates, assigns, heirs, successors in interest and shareholders. 

(c) This First Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which when
taken together shall constitute one and the same instrument. The signature page of any counterpart may be detached therefrom without impairing the legal effect of the signature(s) thereon provided such signature page is attached to any other
counterpart identical thereto except having additional signature pages executed by other parties to this First Amendment attached thereto. 
 (d) Except as amended and/or modified by this First Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by
this First Amendment. In the event of any conflict between the provisions of this First Amendment and the provisions of the Lease, the provisions of this First Amendment shall prevail. Whether or not specifically amended by this First Amendment, all
of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this First Amendment. 
 [Signatures are on the next page.] 

  
 3 

 IN WITNESS WHEREOF, the parties hereto have executed this First Amendment as of the
day and year first above written 
  

											
	LANDLORD:	 		 	 ARE-480 ARSENAL STREET, LLC,
 A Delaware limited liability company

				
		 		 	By:	 	 ALEXANDRIA REAL ESTATE EQUITIES, L.P.,
 a Delaware limited partnership,
 managing member

					
		 		 		 	By:	 	 ARE-QRS Corp.,

a Maryland corporation
 general
partner

						
		 		 		 		 	By:	 	 /s/ Eric S. Johnson

		 		 		 		 		 	 Eric S. Johnson
 Vice
President
 Real Estate Legal Affairs

			
	TENANT:	 		 	 TETRAPHASE PHARMACEUTICALS, INC.,
 A Delaware corporation

				
		 		 	By:	 	 /s/ Guy Macdonald

		 		 	Its	 	 President & CEO

  
 4 

 EXHIBIT A 
 EXPANSION PREMISES 
  
 

 

  
 5 

 EXHIBIT B 
 ACKNOWLEDGMENT OF EXPANSION PREMISES COMMENCEMENT DATE 
 This
ACKNOWLEDGEMENT OF EXPANSION PREMISES COMMENCEMENT DATE is made as of this      day of             , 20    , between ARE-480 ARSENAL
STREET, LLC, a Delaware limited liability company (“Landlord”), and TETRAPHASE PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”), and is attached to and made a part of the Lease dated as of
November 15, 2006, as amended by the First Amendment dated as of             , 2011, (as amended, the “Lease”), by and between Landlord and Tenant. Any initially
capitalized terms used but not defined herein shall have the meanings given them in the Lease. 
 Landlord and Tenant hereby
acknowledge and agree, for all purposes of the Lease, that the “Expansion Premises Commencement Date” is                     ,
                     and the termination date of the Base Term of the Lease shall be midnight on November 30, 2012. In case of a conflict
between this Acknowledgment of Expansion Premises Commencement Date and the Lease, this Acknowledgement of Expansion Premises Commencement Date shall control for all purposes. 
 IN WITNESS WHEREOF, Landlord and Tenant have executed this ACKNOWLEDGMENT OF EXPANSION PREMISES COMMENCEMENT DATE TO BE EFFECTIVE ON THE DATE FIRST WRITTEN ABOVE. 

 

									
	LANDLORD:	 		 	 ARE-480 ARSENAL STREET, LLC,
 A Delaware limited liability company

				
		 		 	By:	 	 ALEXANDRIA REAL ESTATE EQUITIES, L.P.,
 a Delaware limited partnership,
 managing member

					
		 		 		 	By:	 	 ARE-QRS Corp.,
 a Maryland
corporation
 general partner

				
		 		 	By:	 	  

			
	TENANT:	 		 	 TETRAPHASE PHARMACEUTICALS, INC.,
 A Delaware corporation

				
		 		 	By:	 	  

		 		 	Its	 	  

  
 6 

 SECOND AMENDMENT TO LEASE 

THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made as of March 15, 2012 by and between ARE-480
ARSENAL STREET, LLC, a Delaware limited liability company (“Landlord”), and TETRAPHASE PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). 

RECITALS 

A. Landlord and Tenant are parties to that certain Lease Agreement dated as of November 16, 2006 as amended by that certain
First Amendment to Lease dated as of September 9, 2011 (as amended, the “Lease”). Pursuant to the Lease, Tenant leases approximately 15,899 rentable square feet as more particularly described in the Lease in a building located
at 480 Arsenal Street, Watertown, Massachusetts. Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease. 
 B. The Base Term of the Lease expires on November 30, 2012. 
 C.
Landlord and Tenant desire, subject to the terms and conditions set forth herein, to, among other things, amend the Lease to (i) extend the Base Term of the Lease for a period of 6 months commencing on December 1, 2012 and ending on
May 31, 2013 (“Interim Extension Term”), (ii) provide for payment of Base Rent during the Interim Extension Term and (iii) amend Section 40 of the Lease. 

NOW, THEREFORE, in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises
and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows: 

1. Base Term. The Base Term of the Lease is hereby extended for a period of 6 months and shall expire on May 31,
2013. 
 2. Rent. Notwithstanding anything to the contrary in the Lease, Base Rent during the Interim Extension
Term shall be $50,452.83 per month and Tenant shall continue to pay Tenant’s Share of Operating Expenses and all other charges as set forth in the Lease. 
 3. Section 40/Right To Extend Term. The phrase “at least 12 months prior, and no earlier than 9 months prior, to expiration of the Base Term of the Lease or the expiration of any
prior Extension Term” in the first paragraph of Section 40(a) of the Lease is hereby deleted in its entirety and replaced with “no earlier than June 1, 2012 and no later than August 31, 2012”. 

4. Broker. Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person
(collectively, “Broker”) in connection with the transaction reflected in this Second Amendment and that no Broker brought about this transaction other than CBRE-NE. Landlord and Tenant each hereby agree to indemnify and hold the
other harmless from and against any claims by any Broker, other than CBRE-NE, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this leasing transaction. 

  
 Tetraphase
Pharmaceuticals, Inc. Confidential 

 5. Miscellaneous. 

(a) This Second Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior
and contemporaneous oral and written agreements and discussions. This Second Amendment may be amended only by an agreement in writing, signed by the parties hereto. 
 (b) This Second Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, representatives, officers, directors, divisions, subsidiaries,
affiliates, assigns, heirs, successors in interest and shareholders. 
 (c) This Second Amendment may be executed in any number
of counterparts, each of which shall be deemed an original, but all of which when taken together shall constitute one and the same instrument. The signature page of any counterpart may be detached therefrom without impairing the legal effect of the
signature(s) thereon provided such signature page is attached to any other counterpart identical thereto except having additional signature pages executed by other parties to this Second Amendment attached thereto. 

(d) Except as amended and/or modified by this Second Amendment, the Lease is hereby ratified and confirmed and all other terms of the
Lease shall remain in full force and effect, unaltered and unchanged by this Second Amendment. In the event of any conflict between the provisions of this Second Amendment and the provisions of the Lease, the provisions of this Second Amendment
shall prevail. Whether or not specifically amended by this Second Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Second Amendment. 

[Signatures are on the next page.] 

  
 Tetraphase
Pharmaceuticals, Inc. Confidential 
 2 

 IN WITNESS WHEREOF, the parties hereto have executed this Second Amendment as of the
day and year first above written. 
  

											
	LANDLORD:	 		 	 ARE-480 ARSENAL STREET, LLC,
 a Delaware limited liability company

				
		 		 	By:	 	 ALEXANDRIA REAL ESTATE EQUITIES, L.P.,
 a Delaware limited partnership,
 managing member

					
		 		 		 	By:	 	 ARE-QRS CORP.,

a Maryland corporation,
 general
partner

						
		 		 		 		 	By:	 	 /s/ Eric S. Johnson

		 		 		 		 		 	 Eric S. Johnson
 Vice President
 Real Estate Legal Affairs

			
	TENANT:	 		 	 TETRAPHASE PHARMACEUTICALS, INC., 
 a Delaware corporation 

				
		 		 	By:	 	 /s/ David Lubner

		 		 	Its:	 	 SVP, CFO

  
 Tetraphase
Pharmaceuticals, Inc. Confidential 
 3 

 THIRD AMENDMENT TO LEASE 

THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of September 18, 2012 by and between ARE-480
ARSENAL STREET, LLC, a Delaware limited liability company (“Landlord”), and TETRAPHASE PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). 

RECITALS 

A. Landlord and Tenant are parties to that certain Lease Agreement dated as of November 16, 2006 as amended by that certain
First Amendment to Lease dated as of September 9, 2011 and that certain Second Amendment to Lease dated as of March 15, 2012 (as amended, the “Lease”), Pursuant to the Lease, Tenant leases approximately 15,899 rentable
square feet as more particularly described in the Lease in a building located at 480 Arsenal Street, Watertown, Massachusetts. Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease. 

B. The Base Term of the Lease expires on May 31, 2013. 

C. Landlord and Tenant desire, subject to the terms and conditions set forth herein, to, among other things, amend the Lease to
(i) extend the Base Term of the Lease for a period of one year commencing on June 1, 2013 and ending on May 31, 2014 (“Extension Term”), (ii) provide for payment of Base Rent during the Extension Term,
(iii) delete Section 40 of the Lease and (iv) increase the Security Deposit. 
 NOW, THEREFORE, in
consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, Landlord and Tenant hereby agree as follows: 
 1. Base Term. The Base Term of the Lease is hereby
extended for a period of one year and shall expire on May 31, 2014. 
 2. Rent. Notwithstanding anything to
the contrary in the Lease, Base Rent during the Extension Term shall be $52,996.66 per month and Tenant shall continue to pay Tenant’s Share of Operating Expenses and all other charges as set forth in the Lease. 

3. Section 40/Right To Extend Term. Section 40 of the Lease is hereby deleted in its entirety and Tenant shall
have no further right to extend the Term. 
 4. Security Deposit. Notwithstanding anything to the contrary in the
Lease, effective as of May 31, 2013, the Security Deposit amount shall be increased from $120,813.27 to $158,989.98 (“Increased Security Deposit Amount”). On or before May 31, 2013, Tenant shall deliver to Landlord
(i) a substitute Letter of Credit or (ii) an amendment to the existing Letter of Credit, in compliance with Section 7 of the Lease and reflecting the Increased Security Deposit Amount. 

  
 Tetraphase
Pharmaceuticals, Inc. Confidential 

 5. Broker. Landlord and Tenant each represents and warrants that it has not
dealt with any broker, agent or other person (collectively, “Broker”) in connection with the transaction reflected in this Third Amendment and that no Broker brought about this transaction other than CBRE-NE. Landlord and Tenant
each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than CBRE-NE, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with
regard to this leasing transaction. 
 6. Miscellaneous. 

(a) This Third Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior
and contemporaneous oral and written agreements and discussions. This Third Amendment may be amended only by an agreement in writing, signed by the parties hereto. 
 (b) This Third Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, representatives, officers, directors, divisions, subsidiaries,
affiliates, assigns, heirs, successors in interest and shareholders. 
 (c) This Third Amendment may be executed in any number
of counterparts, each of which shall be deemed an original, but all of which when taken together shall constitute one and the same instrument. The signature page of any counterpart may be detached therefrom without impairing the legal effect of the
signature(s) thereon provided such signature page is attached to any other counterpart identical thereto except having additional signature pages executed by other parties to this Third Amendment attached thereto. 

(d) Except as amended and/or modified by this Third Amendment, the Lease is hereby ratified and confirmed and all other terms of the
Lease shall remain in full force and effect, unaltered and unchanged by this Third Amendment. In the event of any conflict between the provisions of this Third Amendment and the provisions of the Lease, the provisions of this Third Amendment shall
prevail. Whether or not specifically amended by this Third Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Third Amendment. 

[Signatures are on the next page.] 

  
 Tetraphase
Pharmaceuticals, Inc. Confidential 
 2 

 IN WITNESS WHEREOF, the parties hereto have executed this Third Amendment as of the
day and year first above written. 
  

											
	LANDLORD:	 		 	 ARE-480 ARSENAL STREET, LLC,
 a Delaware limited liability company

				
		 		 	By:	 	 ALEXANDRIA REAL ESTATE EQUITIES, L.P.,
 a Delaware limited partnership,
 managing member

					
		 		 		 	By:	 	 ARE-QRS CORP.,

a Maryland corporation,
 general
partner

						
		 		 		 		 	By:	 	 /s/ Eric S. Johnson

		 		 		 		 		 	 Eric S. Johnson
 Vice President
 Real Estate Legal Affairs

			
	TENANT:	 		 	 TETRAPHASE PHARMACEUTICALS, INC., 
 a Delaware corporation

				
		 		 	By:	 	 /s/ David Lubner

		 		 	Its:	 	 SVP, CFO

  
 Tetraphase
Pharmaceuticals, Inc. Confidential 
 3EX-10.20

 Exhibit 10.20 

 

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Double asterisks denote omissions. 

 
  
  

LICENSE AGREEMENT 
 Between 
 TETRAPHASE PHARMACEUTICALS, INC. 

And 

PRESIDENT AND FELLOWS OF 
 HARVARD COLLEGE 
  
  

 
  

 Table of Contents 

 

							
	 Section
	 	 	  	Page	 
			
	   1.
	 	Definitions	  	 	1	  
			
	   2.
	 	Title; Disclosure	  	 	6	  
			
	   3.
	 	Patent Filing, Prosecution and Maintenance	  	 	7	  
			
	   4.
	 	License Grant	  	 	9	  
			
	   5.
	 	Development and Commercialization	  	 	13	  
			
	   6.
	 	Consideration for Grant of License	  	 	14	  
			
	   7.
	 	Reports; Payments; Records	  	 	19	  
			
	   8.
	 	Enforcement of Patent Rights	  	 	20	  
			
	   9.
	 	Warranties; Limitation of Liability	  	 	22	  
			
	 10.
	 	Indemnification	  	 	23	  
			
	 11.
	 	Term and Termination	  	 	25	  
			
	 12.
	 	Miscellaneous	  	 	27	  

  

					
	 Exhibit 1.5
	  	Development Milestones	  	
			
	 Exhibit 1.6
	  	Development Plan	  	
			
	 Exhibit 6.2.1
	  	Form of Investment Representation Letter	  	
			
	 Exhibit 6.2.2.1
	  	Capitalization Table	  	

  
 ii 

 LICENSE AGREEMENT 

This License Agreement is entered into as of this 3rd day of August, 2006 (the “Effective Date”), by and between Tetraphase
Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business c/o Mediphase Venture Partners, 3 Newton Executive Park, Suite 104, Newton, MA 02462 (“Licensee”) and President and Fellows of Harvard College, Holyoke
Center, Suite 727, 1350 Massachusetts Ave., Cambridge, MA (“Harvard”). Dr. Andrew G. Myers shall also be party to this Agreement, but solely for purposes of Article 2. 

WHEREAS, Harvard is the owner of the Harvard Patent Rights (as defined below) and has the right to grant licenses under the Harvard
Patent Rights; and 
 WHEREAS, Harvard desires to have products based on such patent rights developed and commercialized to
benefit the public and is willing to grant a license under such patent rights; and 
 WHEREAS, Licensee has represented to
Harvard, in order to induce Harvard to enter into this Agreement, that Licensee shall commit itself to commercially reasonable efforts to develop, obtain regulatory approval for and commercialize products based on such patent rights; and 

WHEREAS, Licensee wishes to obtain a license under such patent rights and Harvard wishes to grant Licensee a license under such patent
rights, all in accordance with the terms and conditions of this Agreement; and 
 WHEREAS, Licensee wishes to retain the
services of Dr. Andrew G. Myers as a consultant with respect to the subject matter of this Agreement. 
 NOW,
THEREFORE, the panics hereto, intending to be legally bound, hereby agree as follows: 
 1. Definitions. 

Whenever used in this Agreement with an initial capital letter, the terms defined in this Article I, whether used in the singular or the
plural, shall have the meanings specified below. 
 1.1. “Affiliate” shall mean, with respect to either party,
any person, organization or entity controlling, controlled by or under common control with, such party. For purposes of this definition only, “control” of another person, organization or entity shall mean the possession, directly or
indirectly, of the power to direct or cause the direction of the activities, management or policies of such person, organization or entity, whether through the ownership of voting securities, by contract or otherwise. Without limiting the foregoing,
control shall be presumed to exist when a person, organization or entity (i) owns or directly controls fifty percent (50%) or more of the outstanding voting stock or other ownership interest of the other organization or entity, or
(ii) possesses, directly or indirectly, the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the organization or other entity. The parties acknowledge that in the case of certain entities
organized under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such cases such lower percentage shall be
substituted in the preceding sentence. 

  
 1 

 1.2. “Calendar Quarter” shall mean each of the periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 and December 31, for so long as this Agreement is in effect. 
 1.3. “Combination Product” shall mean a pharmaceutical preparation that includes one or more Non-Covered Components in addition to one or more Covered Components. All references to
Licensed Product in this Agreement shall be deemed to include Combination Product. 
 1.4. “Covered Component”
shall mean any compound (or part thereof) the production, making, use, sale or importation of which falls within the scope of a Valid Claim. 
 1.5. “Development Milestones” shall mean the development and commercialization milestones set forth in Exhibit 1.5 hereto. 

1.6. “Development Plan” shall mean the plan for the development and commercialization of Licensed Products attached
hereto as Exhibit 1.6, as such plan may be adjusted from time to time pursuant to Section 5.2. 
 1.7. “Dr.
Myers” shall mean Dr. Andrew G. Myers. 
 1.8. “FDA” shall mean the United States Food and
Drug Administration. 
 1.9. “Harvard Inventions” shall mean any inventions or discoveries made solely by
Dr. Myers (so long as he is an employee of Harvard) in the performance of services for Licensee relating to tetracycline chemistry, including methods of synthesis and novel analogs of tetracycline. 

1.10. “Harvard Patent Rights” shall mean, in each case to the extent owned and controlled by Harvard: (a) [**]
(including the PCT application and/or the US regular utility application filed at or prior to the one year conversion date claiming priority to such provisional application); (b) any patent or patent application that claims priority to and is a
divisional, continuation, reissue, renewal, reexamination, substitution or extension of any patent or patent application identified in (a); (c) any patents issuing on any of the patent applications identified in (a) or (b) and any
reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a continuation-in-part application or patent that is entitled to the priority date of, and is directed specifically to subject matter specifically
described in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart of any of the patents or patent applications identified in (a), (b) or (c) or of the claims identified in
(d); and (f) any claim of any United States or foreign patent or patent application to the extent specifically directed to subject matter of Harvard Inventions. 
 1.11. “IND” shall mean an FDA Investigational New Drug application, Clinical Study Application, Clinical Trial Exemption, or similar application or submission for approval to conduct
human clinical investigations filed with or submitted to a Regulator Authority in any country in conformance with the requirements of such Regulatory Authority. 

  
 2 

 1.12. “IND-Enabling GLP Toxicology Studies” shall mean genotoxicity, acute
toxicology, safely pharmacology, and/or sub-chronic toxicology studies, in species that satisfy applicable regulatory requirements, using applicable Good Laboratory Practices, that meet the standard necessary for submission as part of the filing of
an IND with a Regulatory Authority. 
 1.13. “Infringed Patent” shall mean an issued and unexpired patent
(a) that has not been abandoned, held invalid, revoked, held or rendered unenforceable or lost through interference and (b) the claims of which would be infringed by Licensee’s practice of the Harvard Patent Rights and/or Joint Patent
Rights in the making, using, offering for sale, selling or importation of Licensed Products. 
 1.14.
“Initiation” shall mean, with respect to a Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial, the administration of the first dose to the first patient in such Clinical Trial. 

1.15. “Joint Inventions” shall mean all inventions and discoveries made jointly by (a) one or more employees (or
others on behalf) of Licensee and (b) Dr. Myers (so long as he is an employee of Harvard) in the performance of services for Licensee relating to tetracycline chemistry, including methods of synthesis and novel analogs of tetracycline.

 1.16. “Joint Patent Rights” shall mean (a) any and all patents and patent applications claiming any
Joint Inventions; (b) any United States or foreign patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of at least one of the patents or patent
applications identified in (a); (c) any patents issuing on any of the patent applications identified in (a) or (b) and any reissues, renewals, reexaminations, substitutions or extensions thereof; and (d) any claim of a
continuation-in-part application or patent that is entitled to the priority date of, and is directed specifically to subject matter specifically described in, at least one of the patents or patent applications identified in (a), (b) or (c).

 1.17. “Licensed Patent Rights” shall mean the Harvard Patent Rights and Harvard’s interest in the Joint
Patent Rights. 
 1.18. “Licensed Product” shall mean any product, the manufacture, use, offer for sale, sale
or importation of which falls within the scope of a Valid Claim. 
 1.19. “Major European Country” shall mean
any of the following: (a) France, Germany, Italy or the United Kingdom; or (b) the European Union as a whole. 

1.20. “Marketing Authorization” shall mean all approvals from the relevant Regulatory Authority necessary to market and
sell a Licensed Product in a country. 
 1.21. “NDA” shall mean a New Drug Application, Biologies License
Application, Worldwide Marketing Application, Marketing Authorization Application, filing pursuant to Section 510(k) of the United States Federal Food, Drug, and Cosmetic Act, or similar application or submission for Marketing Authorization of
a Licensed Product filed with a Regulatory Authority to obtain marketing approval for a biological pharmaceutical or diagnostic product in that country or in that group of countries. 

  
 3 

 1.22. “Net Sales” shall mean the gross amount billed or invoiced by or on
behalf of Licensee, its Affiliates and Sublicensees (in each case, the “Invoicing Entity”) on sales, leases or other transfers of Licensed Products, less the following to the extent applicable on such sales, leases or other transfers of
Licensed Products and not previously deducted from the gross invoice price: (a) customary trade, quantity, and cash discounts to the extent actually allowed and taken; (b) amounts actually repaid or credited by reason of rejection or
return of any previously sold, leased or otherwise transferred Licensed Products and uncollectible portions of billed or invoiced amounts with respect to any previously sold, leased or otherwise transferred Licensed Products; (c) rebates,
chargebacks, retroactive price reductions, allowances and fees actually paid or credited to customers, wholesalers, distributors, third party payors, governmental agencies, administrators and contractees with respect to Licensed Products sold,
leased or otherwise transferred; (d) transportation, freight and insurance charges that are paid by or on behalf of the Invoicing Entity; and (e) to the extent separately stated on purchase orders, invoices, or other documents of sale, any
sales, value added or similar taxes, custom duties or other similar governmental charges levied directly on the production, sale, transportation, delivery, or use of a Licensed Product that are paid by or on behalf of the Invoking Entity, but not
including any tax levied with respect to income; provided that: 
 (i) in any transfers of Licensed Products among an Invoicing
Entity, Affiliates of such Invoicing Entity and Sublicensees, not for the purpose of resale by any such Affiliate or Sublicensee, Net Sales shall be equal to the fair market value of the Licensed Products so transferred, assuming an arm’s
length transaction made in the ordinary course of business; and 
 (ii) in the event that an Invoicing Party receives
non-monetary consideration for any Licensed Products or in the case of transactions not at arm’s length with a non-Affiliate of such Invoicing Entity that is not a Sublicensee, Net Sales shall be calculated based on the fair market value of
such consideration or transaction, assuming an arm’s length transaction made in the ordinary course of business. 
 Sales
of Licensed Products by an Invoicing Party to an Affiliate of such Invoicing Party or to a Sublicensee for resale by such Affiliate or Sublicensee shall not be deemed Net Sales and Net Sales shall be determined based on the gross amount invoiced or
billed by such Affiliate or Sublicensee on resale to an independent third party purchaser. 
 In the event that a Licensed
Product is sold in any country in the form of a Combination Product, Net Sales of such Combination Product will be adjusted by multiplying actual Net Sales of such Combination Product (i.e., Net Sales as determined above without regard to this
paragraph) in such country by the fraction A/(A+B), where A is the average invoice price in such country of a Licensed Product containing the same strength of Covered Component(s) that is included in such Combination Product sold without the
Non-Covered Components, if sold separately in such country, and B is the average invoice price of the Non-Covered Component(s) that is included in such Combination Product in such country, if sold separately in such country.

  
 4 

 
If, in a specific country, either the Covered Component(s) or the Non-Covered Component(s) is not sold separately, the relative value of the Covered Component(s) and the Non-Covered Component(s)
in the Combination Product shall be negotiated in and agreed upon in good faith by the parties in order to determine the appropriate ratio for calculating Net Sales with respect to such Combination Product in such country. 

1.23. “Non-Covered Component” shall mean a clinically active component of a product that is not a Covered Component.

 1.24. “Non-Royalty Sublicense Income” shall mean any payments or other consideration that Licensee or any of
its Affiliates receives in connection with a Sublicense, other than royalties based on sales, leases or other transfers of Licensed Products by a Sublicensee. In the event that Licensee or an Affiliate of Licensee receives non-monetary consideration
in connection with a Sublicense or in the case of transactions not at arm’s length, Non-Royalty Sublicense Income shall be calculated based on the fair market value of such consideration or transaction, assuming an arm’s length transaction
made in the ordinary course of business. Non-Royalty Sublicense Income shall not include payments specifically committed to cover future costs to be actually incurred by Licensee or any of its Affiliates (including customary overhead) in the
performance of research and development activities to be performed by Licensee or any of its Affiliates in connection with a Licensed Product or a product expected to become a Licensed Product. 

1.25. “Phase I Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of
21 CFR 312.21(a). 
 1.26. “Phase II Clinical Trial” shall mean a human clinical trial in any country that
would satisfy the requirements of 21 CFR 312.21(b). 
 1.27. “Phase III Clinical Trial” shall mean a human
clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(c). 
 1.28. “Regulatory
Authority” shall mean any applicable government regulatory authority involved in granting approvals for the manufacturing, marketing, reimbursement and/or pricing of a Licensed Product, including, in the United States, the FDA. 

1.29. “Relative Contribution Rate” shall mean the relative contribution of Dr. Myers in conceiving, making and/or
reducing to practice a Joint Invention. Promptly after disclosure of a Joint Invention under Section 2.4 or 2.5, the parties will negotiate in good faith to agree upon the Relative Contribution Rate, which shall not exceed [**] percent ([**]%).
If the parties are unable to agree upon the Relative Contribution Rate within [**] days of such disclosure, the matter will be referred to an independent patent counsel appointed by and mutually acceptable to the parties, who will determine the
Relative Contribution Rate (not to exceed [**] percent ([**]%)). 
 1.30. “Sublicense” shall mean: (a) any
right granted, license given, or agreement entered into by Licensee to or with any other person or entity (or by a Sublicensee to or with a further Sublicensee permitted by Section 4.2.2.4), under or with respect to or permitting any use of any
of the Licensed Patent Rights or otherwise permitting the development, manufacture, 

  
 5 

 
marketing, distribution, use and/or sale of Licensed Products; (b) any option or other right granted by Licensee to any other person or entity (or by a Sublicensee to a further Sublicensee
permitted by Section 4.2.2.4) to negotiate for or receive any of the rights described under clause (a); or (c) any standstill or similar obligation undertaken by Licensee toward any other person or entity (or by a Sublicensee toward a
further Sublicensee permitted by Section 4.2.2.4) not to grant any of the rights described in clause (a) or (b) to any third party; in each case regardless of whether such grant of rights, license given or agreement entered into is
referred to or is described as a sublicense. For clarity, “Sublicense” does not include any implied license that may be deemed to be granted as part of a sale of a License Product. 

1.31. “Sublicensee” shall mean any person or entity granted a Sublicense. 

1.32. “Third Party Proposed Product” shall mean an actual or potential Licensed Product (a) that is for a
therapeutic category (e.g., infectious diseases, inflammatory conditions and oncological conditions) for which no Licensed Product is being developed or commercialized by Licensee, any Affiliate of Licensee or any Sublicensee and (b) that does
not contain or consist of any Covered Component that is included in a Licensed Product that is being clinically developed or commercialized by Licensee, any Affiliate of Licensee or any Sublicensee. For the avoidance of doubt, sub-categories within
the same general therapeutic category shall be considered the same therapeutic category (e.g., infectious diseases shall include subcategories such as bacterial diseases and fungal diseases). 

1.33. “Valid Claim” shall mean: (a) a claim of an issued and unexpired patent within the Harvard Patent Rights or,
except as excluded pursuant to Section 3.4.2, Joint Patent Rights that has not been (i) held permanently revoked, unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable
or unappealed within the time allowed for appeal, (ii) rendered unenforceable through disclaimer or otherwise, (iii) abandoned, or (iv) lost through an interference proceeding; (b) a pending claim of a pending patent application
within the Harvard Patent Rights (in a particular country) that (i) has been asserted and continues to be prosecuted in good faith, (ii) has not been abandoned or finally rejected without the possibility of appeal or refiling and
(iii) has not remained un-issued for a period of [**] or more years from the date of issuance of the first substantive patent office action considering the patentability of such claim by the applicable patent office in such country, provided
that if after the earliest possible date for requesting examination in such country Harvard fails to request examination by such patent office within [**] days after Licensee requests Harvard to do so, such [**]-year period shall run from the
date of Licensee’s request that Harvard request examination; or (c) except as excluded pursuant to Section 3.4.2, a pending claim of a patent application within the Joint Patent Rights. 

2. Title; Disclosure. 

2.1. The entire right, title and interest in Harvard Inventions shall be owned solely by Harvard. 

2.2. The entire right, title and interest in Joint Inventions shall be owned jointly by Harvard and Licensee. 

  
 6 

 2.3. All determinations of inventorship under this Agreement shall be made in
accordance with United States patent law. In case of dispute between Harvard and Licensee over inventorship, a mutually acceptable outside patent counsel shall make the determination of the inventor(s) by applying the standards contained in United
States patent law. 
 2.4. Harvard shall disclose to Licensee in a confidential writing the development, making,
conception or reduction to practice of any Harvard Inventions or Joint Inventions of which it becomes aware, promptly after its receipt of an invention disclosure form from Dr. Myers. 

2.5. Licensee shall disclose to Harvard’s Office of Technology Development in a confidential writing the development, making,
conception or reduction to practice of any Harvard Inventions or Joint Inventions promptly after it becomes aware thereof. 

2.6. Dr. Myers shall disclose to Licensee and Harvard’s Office of Technology Development in a confidential writing the
development, making, conception or reduction to practice of any Harvard Inventions or Joint Inventions promptly after he becomes aware thereof. 
 2.7. Any consulting or other agreement pursuant to which Dr. Myers performs services for or on behalf of Licensee (so long as he is an employee of Harvard) (a “Consulting Agreement”)
shall be consistent with and subordinate to the provisions of this Article 2. Any such Consulting Agreement shall require Dr. Myers to assign his rights in Harvard Inventions and Joint Inventions in a manner consistent with the
provisions of this Article 2 and shall allow Dr. Myers to make the disclosures contemplated by Section 2.6. 
 2.8.
In the case of any discrepancy between Article 2 of this Agreement and any Consulting Agreement, the terms of this Agreement shall prevail; provided that (a) Licensee shall have no liability for or obligation to enforce
Dr. Myers’ obligations hereunder and (b) Licensee’s sole and exclusive liability to Harvard and Harvard’s sole and exclusive remedy against Licensee for such discrepancy shall be for Licensee to acknowledge that the terms of
this Agreement prevail over the noncompliant provisions of such Consulting Agreement and to take reasonable steps to amend the Consulting Agreement to render it consistent with this Agreement. 

3. Patent Filing, Prosecution and Maintenance. 
 3.1. Harvard Patent Rights. Harvard shall be responsible for the preparation, filing, prosecution, protection and maintenance of all Harvard Patent Rights, using patent counsel reasonably
acceptable to Licensee. With respect to Harvard Patent Rights, Harvard shall: (a) use independent patent counsel reasonably acceptable to Licensee and instruct such patent counsel to furnish the Licensee with copies of all correspondence
relating to the Harvard Patent Rights from the United States Patent and Trademark Office (USPTO) and any other patent office, as well as copies of all proposed responses to such correspondence in time for Licensee to review and comment on such
response; (b) give Licensee an opportunity to review the text of each patent application before filing; (c) consult with Licensee with respect thereto; (d) supply Licensee with a copy of the application as filed, together with notice
of its filing date and serial number; (e) keep Licensee advised of the status of actual and prospective patent filings; and (f) provide advance copies of any papers related to the filing, prosecution, protection and maintenance of such
patent filings. Harvard shall give Licensee the opportunity to provide comments on and make requests of Harvard concerning the preparation, filing, prosecution, protection and maintenance of the Harvard Patent Rights, and shall consider such
comments and requests in good faith. 

  
 7 

 3.2. Joint Patent Rights. Licensee shall have the first right to prepare, file,
prosecute, protect and maintain Joint Patent Rights, at its cost; provided, however, that Licensee may elect to waive such right on a case-by-case basis and if so, Licensee shall notify Harvard promptly in writing and Harvard shall have the right,
but not the obligation, to prepare, file, prosecute, protect and maintain such Joint Patent Rights. With respect to Joint Patent Rights, the filing party shall: (a) use independent patent counsel reasonably acceptable to the non-filing party
and instruct such patent counsel to furnish the non-filing party with copies of all correspondence relating to the Joint Patent Rights from the USPTO and any other patent office, as well as copies of all proposed responses to such correspondence in
time for the other party to review and comment on such response; (b) give the non-filing party an opportunity to review the text of each patent application before filing; (c) consult with the non-filing party with respect thereto;
(d) supply the non-filing party with a copy of the application as filed, together with notice of its filing date and serial number; (e) keep the non-filing party advised of the status of actual and prospective patent filings; and
(f) provide advance copies of any papers related to the filing, prosecution, protection and maintenance of such patent filings. The filing party shall give the non-filing party the opportunity to provide comments on and make requests of the
filing party concerning the preparation, filing, prosecution, protection and maintenance of the Joint Patent Rights, and shall consider such comments and requests in good faith. 

3.3. Expenses. Subject to Section 3.4 below, Licensee shall reimburse Harvard for all documented, out-of-pocket expenses
incurred by Harvard pursuant to this Article 3 within [**] days after Harvard invoices Licensee. In addition, Licensee shall reimburse Harvard for all documented, out-of-pocket expenses incurred by Harvard prior to the execution of this Agreement
with respect to the preparation, filing, prosecution, protection and maintenance of Harvard Patent Rights (estimated to be approximately [**] U.S. Cents ($[**])) within [**] days after the date on which the financing described in Section 11.2.2
below closes. 
 3.4. Abandonment. Should Licensee decide that it does not wish to pay for the preparation, filing,
prosecution, protection or maintenance of any Harvard Patent Rights and/or Joint Patent Rights in a particular country (“Abandoned Patent Rights”), Licensee shall provide Harvard with prompt written notice of such election. Upon receipt of
such notice by Harvard, Licensee shall be released from its obligation to reimburse Harvard for the expenses incurred thereafter as to such Abandoned Patent Rights; provided, however, that expenses authorized prior to the receipt by Harvard of such
notice shall be deemed incurred prior to the notice. 
 3.4.1. Effect of Abandonment of Harvard Patent Rights. In the
event of Licensee’s abandonment of any Harvard Patent Rights (“Abandoned Harvard Patent Rights”), any license granted by Harvard to Licensee hereunder with respect to such Abandoned Harvard Patent Rights will terminate, and Licensee
will have no rights whatsoever to exploit such Abandoned Harvard Patent Rights. Harvard shall then be free, without further notice or obligation to Licensee, to grant rights in and to such Abandoned Harvard Patent Rights to third parties. Such
Abandoned Harvard Patent Rights shall cease to constitute Harvard Patent Rights. 

  
 8 

 3.4.2. Effect of Abandonment of Joint Patent Rights. In the event of Licensee’s
abandonment of any Joint Patent Rights (“Abandoned Joint Patent Rights”), Harvard, in its sole discretion, may choose to terminate any license granted by Harvard to Licensee hereunder with respect to such Abandoned Joint Patent Rights. If
Harvard exercises its right to terminate and continues to pay for the preparation, filing, prosecution, protection and maintenance of such Abandoned Joint Patent Rights, it thereafter shall have the right to practice and exploit the inventions
claimed in such Abandoned Joint Patent Rights without any duty to account to Licensee or any obligation to obtain any consent or approval of Licensee for such use and exploitation. Harvard also shall then be free, without further notice or
obligation to Licensee, and Licensee hereby grants Harvard an exclusive license, to grant rights in and to such Abandoned Joint Patent Rights to third parties; provided, however, that Licensee shall have (and Harvard hereby grants Licensee) the
right, without further notice or obligation to Harvard, to practice and exploit the inventions claimed in such Abandoned Joint Patent Rights in connection with Licensee’s development and commercialization of a Licensed Product and to grant
rights in and to such Abandoned Joint Patent Rights to third parties in connection with any license of a Licensed Product developed by or on behalf of Licensee. The claims of any such Abandoned Joint Patent Rights shall cease to constitute Valid
Claims. 
 3.5. No Warranty. Nothing contained herein shall be deemed to be a warranty by either party that it can or
will be able to obtain patents on patent applications included in the Harvard Patent Rights or Joint Patent Rights, or that any of the Harvard Patent Rights or Joint Patent Rights will afford adequate or commercially worthwhile protection.

 3.6. Small Entity Designation. If Licensee, any Sublicensee and/or any holder of an option to obtain a Sublicense does
not qualify, or at any point during the term of this Agreement ceases to qualify, as a “small entity’” as provided by the USPTO, Licensee shall so notify Harvard immediately, in order to enable Harvard to comply with USPTG regulations
regarding payment of fees with respect to Harvard Patent Rights and Joint Patent Rights. 
 4. License Grant. 

4.1. Licenses. 
 4.1.1. Harvard Patent Rights. Subject to the terms and conditions set forth in this Agreement, Harvard hereby grants to Licensee an exclusive (except as set forth in clauses (a) and
(b) below), worldwide, royalty-bearing license under the Harvard Patent Rights solely to develop, make, have made, use, market, offer for sale, sell and import Licensed Products; provided, however, that: 

(a) Harvard shall retain the right to make and use Licensed Products, and to grant licenses to other not-for-profit research
organizations to make and use Licensed Products, for internal research, teaching and other educational purposes and not for the purpose of commercial manufacture, distribution or provision of services for a fee; and 

(b) the U.S. federal government shall retain rights in the Licensed Patent Rights pursuant to 35 USC §§200-212, 37 CFR
§401 et seq. and applicable governmental implementing regulations, and any right granted in this Agreement greater than that permitted under 35 USC §§200-212 or 37 CFR §401 et seq. shall be subject to modification as may be
required to conform to the provisions of those statutes and regulations. 

  
 9 

 4.1.2. Joint Patent Rights. Subject to the terms and conditions set forth in this
Agreement, Harvard hereby grants to Licensee an exclusive, worldwide, royalty-bearing license under Harvard’s interest in the Joint Patent Rights solely to develop, make, have made, use, market, offer for sale, sell and import Licensed
Products. 
 4.2. Sublicense. 
 4.2.1. Sublicense Grant. Licensee shall be entitled to grant Sublicenses to third parties under the licenses granted pursuant to Section 4.1 if the contemplated Sublicense complies with the
terms of this Section 4.2. Any such Sublicense shall be on terms and conditions in compliance with and not inconsistent with the terms of this Agreement. Such Sublicenses shall only be made for consideration and in bona-fide arm’s length
transactions. 
 4.2.2. Sublicense Agreements. Sublicenses shall be granted only pursuant to written agreements, which
shall be subject and subordinate to the terms and conditions of this Agreement. Such Sublicense agreements shall contain, among other things, provisions to the following effect: 

4.2.2.1. All provisions necessary to ensure Licensee’s ability to perform its obligations under this Agreement, including
without limitation its obligations under Sections 6.3, 6.4, 6.5, 7.1.1, 7.3, 9.1 and 12.1; 
 4.2.2.2. A section
substantially the same as Article 10, which also shall state that the Indemnitees (as defined in Article 10) are intended third party beneficiaries of such Sublicense agreement for the purpose of enforcing such indemnification and insurance
provisions; 
 4.2.2.3. In the event of termination of the licenses set forth in Section 4.1 above (in whole or in
part (e.g., termination in a particular country)), any existing Sublicense shall terminate to the extent such licenses terminate; provided, however, that, for each Sublicensee, upon termination of a Sublicense agreement, if the Sublicensee is not
then in breach of the Sublicense such that Licensee would have the right to terminate such Sublicense agreement, such Sublicensee shall have the right to seek a license from Harvard. Harvard agrees to negotiate such licenses in good faith under
reasonable terms and conditions, which shall not impose any representations, warranties, obligations or liabilities on Harvard that are not included in this Agreement; 
 4.2.2.4. The Sublicensee shall not be entitled to sublicense its rights under such Sublicense agreement without Harvard’s prior written consent; provided that, if the Sublicensee is a
major pharmaceutical company, the Sublicensee may grant further Sublicenses with respect to Licensed Products that the Sublicensee is developing and/or commercializing in at least one of (a) the United States, (b) any Major European
Country or (c) Japan, in each case subject to Sections 4.2.2.1, 4.2.2.2, 4.2.2.3 and 4.2.2.5, without Harvard’s consent; and 

  
 10 

 4.2.2.5. The Sublicensee shall not be entitled to assign the Sublicense agreement
without the prior written consent of Harvard, except that Sublicensee may assign the Sublicense agreement to an Affiliate or to a successor in connection with the merger, consolidation, or sale of all or substantially all of its assets or that
portion of its business to which the Sublicense agreement relates; provided, however, that any permitted assignee agrees in writing in a manner reasonably satisfactory to Harvard to be bound by the terms of such Sublicense agreement. 

4.2.3. Delivery of Sublicense Agreement. Licensee or Sublicensee shall furnish Harvard with a fully executed copy of any
Sublicense agreement or further Sublicense agreement under Section 4.2.2.4, promptly after its execution. Harvard shall keep any such copies of Sublicense agreements in its confidential files and shall use them solely for the purpose of
monitoring Licensee’s and Sublicensees’ compliance with their obligations hereunder and enforcing Harvard’s rights under this Agreement. 
 4.2.4. Breach by Sublicensee. Any act or omission by a Sublicensee that would have constituted a breach of this Agreement had it been an act or omission by Licensee, shall constitute a breach of
this Agreement. 
 4.3. Improvements. In the future event that Harvard owns and controls patents and/or patent
applications for which Dr. Myers is an inventor that (a) are not Harvard Patent Rights or Joint Patent Rights and (b) include claims that are dominated by any Valid Claims of the Harvard Patent Rights described in Section 1.10(a)
– (e), Licensee may notify Harvard in writing that it wishes to obtain a license under such patents and/or patent applications solely with respect to those claims that are dominated by such Valid Claims of the Harvard Patent Rights described in
Section 1.10(a) – (e). Harvard will grant Licensee a license under such claims by amending this Agreement to include such claims in the definition of Licensed Patent Rights if (i) Harvard is not, at the time of its receipt of
Licensee’s notice, subject to any legal or pre-existing contractual obligations or restraints that would prevent it from granting the requested license and (ii) either (A) the inventors of the invention claimed in such claims (and, in
the case of non-Harvard inventors, the institutions with which such inventors are affiliated) do not reasonably object to the grant of the requested license based on an argument that the terms of the license contemplated by this Section 4.3,
when considered from the perspective of the parties as of the date of such license, do not provide fair value to Harvard for the license of such patent rights (and, consequently, such inventors’ financial interest in such patent rights will be
adversely affected) or (B) if any such inventors or institutions do object, the neutral third party appointed by the parties pursuant to the immediately following sentence does not affirmatively determine that the terms of the license
contemplated by this Section 4.3, when considered from the perspective of the parties as of the date of such license, do not provide fair value to Harvard for the license of such patent rights. If Harvard relies upon clause (ii) above to
refuse to grant Licensee a license under such claims, Licensee will have the right to seek a determination from a neutral third party (mutually acceptable to the parties) as to whether the terms of the license contemplated by this Section 4.3,
when considered from the perspective of the parties as of the date of such license, provide fair value to Harvard for the license of such patent rights. Licensee shall not be required to pay any additional upfront consideration for such license,
except for a license issuance fee to be agreed upon by the parties, which will not exceed [**] U.S. Dollars ($[**]). The other financial terms of this Agreement (e.g., milestone payments, royalty

  
 11 

 
payments and payments on account of Non-Royalty Sublicense Income) will apply to the requested license (i.e., other than the to-be-agreed upfront consideration, the effect of such requested
license shall be to include such additional patents and/or patent applications in Harvard Patent Rights licensed to Licensee under this Agreement, without modifying the economic terms of this Agreement). 

4.4. Future Inventions. In the future event that Harvard owns and controls patents and/or patent applications for which
Dr. Myers is an inventor that (a) are not dominated by any Valid Claims of the Harvard Patent Rights described in Section 1.10(a) – (e) and (b) include claims with respect to tetracycline chemistry, including methods of
synthesis and novel analogs of tetracycline, Licensee may notify Harvard in writing that it wishes to obtain a license under such patents and/or patent applications solely with respect to claims covering tetracycline chemistry, including methods of
synthesis and novel analogs of tetracycline. Harvard will enter into good faith negotiations with Licensee for a license under such claims if (a) Harvard is not, at the lime of its receipt of Licensee’s notice, subject to any legal, public
policy or pre-existing contractual obligations or restraints that would prevent it from granting the requested license and has not already commenced negotiations for any agreement that would impose such obligations or restraints and (b) Harvard
believes that Licensee is an appropriate party to which to grant the requested license (taking into account Licensee’s resources and the potential applications for such patent rights). 

4.5. Third Party Proposed Products. 
 4.5.1. If, at any time following the [**] anniversary of the Effective Date of this Agreement, a third party makes a bona fide proposal to Harvard for developing a Third Party Proposed Product and
Harvard is interested in having such Third Party Proposed Product developed and commercialized, Harvard shall notify Licensee of and shall provide Licensee with information regarding the third party’s proposal. Within [**] days of the receipt
of such notification from Harvard, Licensee shall notify Harvard whether it is interested in developing such Third Party Proposed Product 
 4.5.2. If Licensee notifies Harvard within such [**] day period that it is interested in developing such Third Party Proposed Product, the parties will agree upon a development plan with respect to
such Third Party Proposed Product, which development plan shall be similar to the Development Plan with respect to other Licensed Products developed by Licensee, subject to necessary adjustments, and will include reasonable milestones. In such case,
Licensee shall be obligated (a) to use commercially reasonable efforts to develop and commercialize the Third Party Proposed Product in accordance with such new development plan and (b) to meet the milestones with respect to the Third
Party Proposed Product. 
 4.5.3. In the event Licensee thereafter fails to comply in any material respect with such
mutually agreed development and commercialization obligations, and fails to cure such noncompliance after notice from Harvard within the time periods specified in Section 11.2.3.2, Harvard shall be entitled to terminate the license granted in
this Agreement under Harvard Patent Rights with respect to such Third Party Proposed Product and shall be free to grant a third party a license under any relevant Harvard Patent Rights solely to develop, make, have made, use, market, offer for sale,
sell, and import such Third Party Proposed Product. 

  
 12 

 4.5.4. If Licensee states in its notification to Harvard that it is not interested in
developing such Third Party Proposed Product but that it wishes to grant a Sublicense under any relevant Harvard Patent Rights to such third party with respect to such Third Party Proposed Product, Licensee shall have [**] days (or such longer time
as shall be agreed to by the parties in writing) to negotiate and enter into such a Sublicense agreement with such third party; provided, however, that if Licensee demonstrates that it and such third party have entered into a term sheet with respect
to such a Sublicense agreement during such [**] days, Licensee shall be entitled to extend that period for the execution of a binding Sublicense agreement by an additional [**] days. 

4.5.5. If Licensee fails to enter into such a Sublicense agreement within such [**] day period or [**] day period, as applicable,
Licensee shall promptly (but in any event within [**] days of the end of such period) provide Harvard in writing an explanation for such failure along with the proposed terms offered by Licensee to Sublicensee. If Harvard determines in its good
faith judgment that the terms offered by Licensee to such third party were not commercially reasonable, Harvard shall notify Licensee of such determination and provide Licensee with an additional [**] days to enter into a Sublicense with such third
party. If Licensee fails to enter into an agreement with such third party within such additional [**] day period, then Harvard shall be free to grant such third party a license under the relevant Harvard Patent Rights solely to develop, make, have
made, use, market, offer for sale, sell and import such Third Party Proposed Product; provided, however, that (a) Harvard shall not grant such third party license on terms more favorable to the third party than the terms of the license granted
to Licensee in this Agreement with respect to such Third Party Proposed Product unless Harvard first amends this Agreement to provide Licensee with such more favorable terms (and after such amendment provides Licensee with a notice pursuant to
Section 4.5.1 that commences a [**] day notice period thereunder during which Licensee may elect to develop such Third Party Proposed Product, in which case Sections 4.5.2 and 4.5.3 will apply) and (b) Harvard must grant such third party
license within [**] days after the end of the [**] day period referenced above. The license granted to Licensee in this Agreement under Harvard Patent Rights with respect to such Third Party Proposed Product shall terminate automatically on the
effective date of such third party license. 
 4.6. No Other Grant of Rights. Except as expressly provided in this
Agreement, nothing in this Agreement shall be construed to confer any ownership interest, license or other rights upon Licensee by implication, estoppel or otherwise as to any technology, intellectual property rights, products or biological
materials of Harvard or any other entity, regardless of whether such technology, intellectual property rights, products or biological materials are dominant, subordinate or otherwise related to any Licensed Patent Rights. 

5. Development and Commercialization. 
 5.1. Diligence. Licensee shall use commercially reasonable efforts, and shall cause its Sublicensees to use commercially reasonable efforts: (i) to develop Licensed Products in accordance with
the Development Plan; (ii) to introduce Licensed Products into the commercial market; and (iii) to market Licensed Products following such introduction into the market. In addition, Licensee, by itself or through its Affiliates or
Sublicensees, also shall achieve each of the Development Milestones within the time periods specified in Exhibit 1.5. Licensee’s sole and exclusive liability and Harvard’s sole and exclusive remedy for any breach of this Section 5.1
shall be the termination right set forth in Section 11.2.3.1, to the extent applicable. 

  
 13 

 5.2. Adjustment of Development Plan. Licensee shall be entitled, from time to time,
to make such adjustments to the then applicable Development Plan as Licensee believes, in its good faith judgment, are needed in order to improve Licensee’s ability to meet the Development Milestones. Licensee shall provide Harvard with copies
of any such adjusted Development Plans. 
 5.3. Reporting. Within [**] days after the end of each calendar year, Licensee
shall furnish Harvard with a written report summarizing its, its Affiliates, and its Sublicensees’ efforts during the prior year to develop and commercialize Licensed Products, including without limitation: (i) research and development
activities, including in reasonable detail medicinal chemistry efforts and animal efficacy and toxicity studies relating to potential Licensed Products; (ii) commercialization efforts; and (iii) marketing efforts. Each report shall contain
a sufficient level of detail for Harvard to assess whether Licensee is in compliance with its obligations under Section 5.1. 
 5.4. Failure. Both parties agree that timely achievement of Development Milestones is subject to considerable uncertainty, given the novelty of the technology embodied in the Licensed Patent
Rights, territorial or legal restrictions on the use of pharmaceutical products, the regulatory climate and approval process, and pricing or other government restrictions on certain pharmaceutical products. Accordingly, in the event Licensee fails
to achieve any Development Milestone, the parties agree to discuss and, if appropriate, revise said milestone by adding a period of up to [**] months to achieve such milestone, upon Licensee’s written notice to Harvard, accompanied by an
explanation for the reasons for such failure and a detailed written plan for promptly achieving such milestones. If Licensee does not provide Harvard with a reasonable basis for its failure to meet a Development Milestone (and lack of finances shall
not constitute reasonable basis for such failure) or does not provide Harvard with a detailed written plan for promptly achieving such milestones, Harvard shall notify Licensee in writing of Licensee’s failure and shall allow Licensee [**] days
to cure its failure. Licensee’s failure to cure such delay within such [**]-day period shall constitute a material breach of this Agreement and Harvard shall have the right to terminate this Agreement forthwith. 

6. Consideration for Grant of License 
 6.1. License Issuance Fee. As partial consideration for the license granted hereunder, Licensee shall pay Harvard a non-refundable license fee of [**] U.S. Dollars ($[**]) within [**] days after
the date on which Licensee completes a Qualifying Financing (as defined in Section 11.2.2 below). 

  
 14 

 6.2. Equity. 

6.2.1. Initial Grant. As partial consideration for the license granted hereunder, and subject to the execution and delivery of an
investment representation letter by Harvard in substantially the form attached hereto as Exhibit 6.2.1, within [**] days after the date on which Licensee completes a Qualifying Financing (as defined in Section 11.2.2 below), Licensee shall
issue to Harvard such number of shares of common stock (the “Shares”) of Licensee that constitutes the greater of: 

(a) [**] shares of common stock, adjusted for any stock splits and similar events; or 

(b) [**] percent ([**]%) of the outstanding common stock of Licensee, on a Fully Diluted Basis, as of the date of
completion of the Qualifying Financing, after giving effect to such issuance to Harvard and to the sale in the Qualifying Financing of shares of capital stock having an aggregate purchase price, which together with the aggregate purchase price
received by the Company from any investment in its capital stock made prior to the Qualifying Financing, does not exceed the Funding Threshold (i.e., assuming only such shares issued in the Qualifying Financing that are necessary to achieve the
Funding Threshold are then outstanding). For purposes of illustration, if the Qualifying Financing were to involve the sale of shares of capital stock having an aggregate purchase price of $[**] and no cash investment in Licensee’s capital
stock had been made prior to the Qualifying Financing, then the calculation above in this clause (b) shall only apply to and shall only include the shares of capital stock sold in the Qualifying Financing having an aggregate purchase price of
$[**] and shall not include the additional shares of capital stock sold in the Qualifying Financing (i.e., Harvard’s shareholdings will be diluted with respect to the additional shares of capital stock sold in the Qualifying Financing).

 6.2.2. Representations and Warranties. Licensee hereby represents and warrants to Harvard that: 

6.2.2.1. The capitalization table attached hereto as Exhibit 6.2.2.1 (the “Cap Table”) sets forth all of the
outstanding capital stock of Licensee on a Fully Diluted Basis as of the Effective Date after assuming and giving effect to the Shares to be issued to Harvard under Section 6.2.1; 

6.2.2.2. Other than as set forth in the Cap Table, as of the Effective Date, there are no outstanding shares of capital stock,
convertible securities, outstanding warrants, options or other rights to subscribe for purchase or acquire from Licensee any capital stock of Licensee and there are no contracts or binding commitments providing for the issuance of, or the granting
of rights to acquire, any capital stock of Licensee or under which Licensee is obligated to issue any of its securities; and 

6.2.2.3. The Shares, when issued pursuant to the terms hereof, shall, upon such issuance, be duly authorized, validly issued,
fully paid and nonassessable. 

  
 15 

 6.2.3. Anti-Dilution. If, at any time, after the initial issuance of Shares pursuant
to Section 6.2.1 and prior to the achievement of the Funding Threshold (as defined below), Licensee issues Additional Securities (as defined below) that would cause the common stock issued to Harvard under this Article 6 to represent less than
[**] percent ([**]%) of Licensee’s outstanding stock on a Fully-Diluted Basis (a “Diluting Issuance”), then, within [**] days after the date of such Diluting Issuance, subject to the execution and delivery of an investment
representation letter by Harvard in substantially the form attached hereto as Exhibit 6.2.1, Licensee shall issue additional shares of common stock to Harvard such that after giving effect to such issuance to Harvard, the common stock issued to
Harvard under this Article 6 shall represent [**] percent ([**]%) of Licensee’s outstanding stock on a Fully Diluted Basis. Such issuances to Harvard shall continue until such time and with respect to those securities as are issued by Licensee
prior to Licensee achieving the Funding Threshold. Upon achievement of the Funding Threshold, no additional shares shall be due to Harvard pursuant to this Section 6.2.3. 
 6.2.4. Definitions. The following terms shall have the following meanings: 

(a) “Additional Securities” shall mean shares of capital stock, convertible securities, warrants, options or other rights
to subscribe for, purchase or acquire from Licensee any capital stock of Licensee 
 (b) “Fully Diluted Basis”
shall mean, as of a specified date, the number of shares of common stock of Licensee then outstanding (assuming conversion of all other classes of stock into common stock) plus the number of shares of common stock of Licensee issuable upon exercise
or conversion of then outstanding convertible securities (other than other classes of stock), options, rights or warrants of Licensee (which shall be determined without regard to whether such securities are then vested, exercisable or convertible).

 (c) “Funding Threshold” shall mean a total investment from and after the incorporation of Licensee of [**]
U.S. Dollars ($[**]) in cash in exchange for Licensee’s capital stock. 
 6.3. Milestone Payments. 

6.3.1. As partial consideration for the license granted hereunder, Licensee shall pay Harvard the following milestone payments
with respect to each Licensed Product, regardless of whether such milestones are achieved by Licensee, an Affiliate of Licensee or a Sublicensee: 
 6.3.1.1. [**] U.S. Dollars ($[**]) upon [**] with respect to such Licensed Product; 
 6.3.1.2. [**] U.S. Dollars ($[**]) upon [**] with respect to such Licensed Product; 
 6.3.1.3. [**] U.S. Dollars ($[**]) upon [**] with respect to such Licensed Product; 
 6.3.1.4. [**] U.S. Dollars ($[**]) upon [**] with respect to such Licensed Product; 
 6.3.1.5. Two Million U.S. Dollars ($2,000,000) upon Initiation of a Phase III Clinical Trial with respect to such Licensed Product; 

  
 16 

 6.3.1.6. [**] U.S. Dollars ($[**]) upon [**] with respect to such Licensed Product;

 6.3.1.7. [**] U.S. Dollars ($[**]) upon [**] with respect to such Licensed Product; 

6.3.1.8. [**] U.S. Dollars ($[**]) upon [**] with respect to such Licensed Product; 

6.3.1.9. [**] U.S. Dollars ($[**]) upon [**] with respect to such Licensed Product; 

6.3.1.10. [**] U.S. Dollars ($[**]) upon [**] with respect to such Licensed Product; and 

6.3.1.11. [**] U.S. Dollars ($[**]) upon [**]. 
 Licensee shall notify Harvard in writing within [**] days following the achievement of each milestone described in this Section 6.3.1, and shall make the appropriate milestone payment within [**]
days after the achievement of such milestone. Each milestone payment set forth in this Section 6.3.1 shall be payable no more than once per Licensed Product. 
 For purposes of this Section 6.3.1, [**] shall include [**] by operation of rule or regulation due to the [**]. 
 For purposes of this Section 6.3.1, if all active pharmaceutical ingredient(s) in a Licensed Product that are Covered Component(s) are the same (irrespective of formulation differences that are not
deemed by the applicable Regulatory Authority to result in different active pharmaceutical ingredient(s)) as active pharmaceutical ingredient(s) in Licensed Products for which Licensee has already paid a given milestone payment under this
Section 6.3.1, then Licensee shall not be required to pay such milestone payment with respect to such Licensed Product. 

6.3.2. The milestones set forth in Section 6.3.1 are intended to be successive, except that the [**] milestones set forth in
Sections 6.3.1.6, 6.3.1.7, 6.3.1.8, 6.3.1.9, 6.3.1.10 and 6.3.1.11 are not intended to be successive (i.e., the achievement of such milestones in [**] may occur in any order). In the event that a Licensed Product is not required to [**] associated
with a particular milestone (“Skipped Milestone”), such Skipped Milestone shall be deemed to have been achieved upon the achievement by such Licensed Product of the next successive milestone (“Achieved Milestone”).
Payment for any Skipped Milestone that is owed in accordance with the provisions of this Section 6.3.2 shall be due within [**] days after the achievement of the Achieved Milestone. 

6.4. Net Sales. 
 6.4.1. Royalties. As partial consideration for the license granted hereunder, Licensee shall pay Harvard an amount equal to the following percentages of Net Sales of Licensed Products: 

  
 17 

 6.4.1.1. [**] percent ([**]%) of calendar year annual Net Sales up to [**] U.S.
Dollars ($[**]); 
 6.4.1.2. [**] percent ([**]%) of calendar year annual Net Sales in excess of [**] U.S. Dollars
($[**]) up to [**] U.S. Dollars ($[**]); 
 6.4.1.3. [**] percent ([**]%) of calendar year annual Net Sales in excess of
[**] U.S. Dollars ($[**]) up to [**] U.S. Dollars ($[**]); and 
 6.4.1.4. [**] percent ([**]%) of calendar year annual
Net Sales in excess of [**] U.S. Dollars ($[**]). 
 With respect to each Licensed Product, royalties will be payable on a
country-by-country basis, so long as the making, using or selling of the Licensed Product is covered by a Valid Claim in the country in which such Licensed Product is made, used or sold. 

6.4.2. Joint Patent Rights Only Licensed Products. Notwithstanding the foregoing, in the event that the making, using or selling
of a Licensed Product is covered only by a Valid Claim within the Joint Patent Rights (and not by any Valid Claim within the Harvard Patent Rights) in a certain country, the royalty payment rates specified above with respect to such Licensed Product
shall be multiplied by the Relative Contribution Rate in such country. 
 6.4.3. Third Party Royalty Set Off.
Notwithstanding the foregoing, in the event that Licensee is required to obtain a license from a third party to an Infringed Patent (as defined below) in order to make, use or sell Licensed Products, and Licensee obtains such a license after
arm’s length negotiations, Licensee may offset an amount of up to [**] percent ([**]%) of any amounts paid under such third party license with respect to sales of such Licensed Product against the royalty payments that are due to Harvard
pursuant to this Section 6.4 with respect to sales of such Licensed Product in such country; provided that in no event shall (a) the royalty payments to Harvard with respect to such Licensed Product be reduced for any Calendar Quarter by
more than [**] percent ([**]%) of the amount otherwise due for such Calendar Quarter with respect to such Licensed Product under this Section 6.4 and (b) the offset that Licensee is entitled to make against royalty payments due to Harvard
be greater than any offset that Licensee is entitled to make against royalty payments due to such third party licensee on account of royalty payments made to Harvard under this Agreement. If Licensee is unable to fully offset [**] percent ([**]%) of
such amounts paid under third party licenses against royalties due for a Calendar Quarter, Licensee shall be entitled to carry forward to subsequent Calendar Quarters any undeducted amounts for deduction in such subsequent Calendar Quarters, subject
to the limitations set forth in subsections (a) and (b) above. 
 6.5. Non-Royalty Sublicense Income. As
partial consideration for the license granted hereunder, Licensee shall pay Harvard an amount equal to the following percentages of Non-Royalty Sublicense Income: 
 6.5.1. if Licensee grants a Sublicense [**] with respect to the Licensed Product that is the subject of such Sublicense, Licensee shall pay Harvard an amount equal to [**] percent ([**]%) of all
Non-Royalty Sublicense Income received in connection with such Sublicense; 

  
 18 

 6.5.2. if Licensee grants a Sublicense [**] with respect to the Licensed Product that
is the subject of such Sublicense, Licensee shall pay Harvard an amount equal to [**] percent ([**]%) of all Non-Royalty Sublicense Income received in connection with such Sublicense; and 

6.5.3. if Licensee grants a Sublicense [**] with respect to the Licensed Product that is the subject of such Sublicense, Licensee
shall pay Harvard an amount equal to [**] percent ([**]%) of all Non-Royalty Sublicense Income received in connection with such Sublicense. 

7. Reports; Payments; Records. 
 7.1. Reports and Payments. 
 7.1.1. Reports. Within [**] days after
the conclusion of each Calendar Quarter commencing with the first Calendar Quarter in which Net Sales are generated or Non-Royalty Sublicense Income received, Licensee shall deliver to Harvard a report containing the following information (in each
instance, with a Licensed Product-by-Licensed Product breakdown): 
 (a) the number of units of Licensed Products sold by
Licensee, its Affiliates and Sublicensees for the applicable Calendar Quarter; 
 (b) the gross amount billed for Licensed
Products sold by Licensee, its Affiliates and Sublicensees during the applicable Calendar Quarter; 
 (c) a calculation of
Net Sales for the applicable Calendar Quarter, including an itemized listing of applicable deductions; and 
 (d) the
total amount payable to Harvard in U.S. Dollars on Net Sales for the applicable Calendar Quarter, together with the exchange rates used for conversion. 
 In addition, Licensee shall include in each such report a statement of all Non-Royalty Sublicense Income and the amounts payable to Harvard in respect thereto for the applicable Calendar Quarter. Each
such report shall be certified on behalf of Licensee as true, correct and complete in all material respects by Licensee’s Chief Financial Officer or an executive level officer with comparable authority. If no amounts are due to Harvard for any
Calendar Quarter, the report shall so state. 
 7.1.2. Payment for Net Sales. Within [**] days after the end of each
Calendar Quarter, Licensee shall pay Harvard all amounts due with respect to Net Sales and Non-Royalty Sublicense Income for the applicable Calendar Quarter. 
 7.2. Payment Currency. All payments due under this Agreement shall be payable in U.S. Dollars. Conversion of foreign currency to U.S. Dollars shall be made at the conversion rate existing in the
United States (as reported in The Wall Street Journal) on the last working day of the applicable Calendar Quarter. Such payments shall be without deduction of exchange, collection, or other charges. 

  
 19 

 7.3. Records. Licensee shall maintain, and shall cause its Affiliates and
Sublicensees to maintain, complete and accurate records of Licensed Products that are made, used or sold under this Agreement, any amounts payable to Harvard in relation to such Licensed Products and all Non-Royalty Sublicense Income received by
Licensee and its Affiliates, which records shall contain sufficient information to permit Harvard to confirm the accuracy of any reports or notifications delivered to Harvard under Section 7.1. Licensee, its Affiliates and/or its Sublicensees,
as applicable, shall retain such records relating to a given Calendar Quarter for at least [**] years after the conclusion of that Calendar Quarter, during which time Harvard shall have the right, at its expense, to cause an independent, certified
public accountant to inspect such records during normal business hours for the sole purpose of verifying any reports and payments delivered under this Agreement. Such accountant shall enter into a confidentiality agreement reasonably satisfactory to
Licensee and shall not disclose to Harvard any information other than information relating to the accuracy of reports and payments delivered under this Agreement. The parties shall reconcile any underpayment or overpayment within [**] days after the
accountant delivers the results of the audit. In the event that any audit performed under this Section 7.3 reveals an underpayment in excess of five percent (5%) in any calendar year, the audited entity shall bear the full cost of such
audit. Harvard may exercise its rights under this Section 7.3 [**] per audited entity and only with reasonable prior notice to the audited entity. 
 7.4. Late Payments. Any payments by Licensee that are not paid on or before the date such payments are due under this Agreement shall bear interest at the lower of (a) [**] percent ([**]%) per
month and (b) the maximum rate allowed by law. Interest shall accrue beginning on the first day following the due date for payment and shall be compounded quarterly. Payment of such interest by Licensee shall not limit in any way,
Harvard’s right to exercise any other remedies Harvard may have as a consequence of the lateness of any payment. 
 7.5.
Payment Method. Each payment due to Harvard under this Agreement shall be paid by check or wire transfer of funds to Harvard’s account in accordance with written instructions provided by Harvard. If made by wire transfer, such
payments shall be marked so as to refer to this Agreement. 
 7.6. Withholding and Similar Taxes. Licensee shall use
reasonable and legal efforts to reduce tax withholding on payments made to Harvard hereunder. Notwithstanding such efforts, if Licensee concludes that tax withholdings under the laws of any country are required with respect to payments to Harvard,
Licensee shall withhold the required amount and pay it to the appropriate governmental authority. In such a case, Licensee will promptly provide Harvard with original receipts or other evidence reasonably desirable and sufficient to allow Harvard to
document such tax withholdings adequately for purposes of claiming foreign tax credits and similar benefits. 
 8. Enforcement of Patent
Rights. 
 8.1. Notice. In the event either party becomes aware of any possible or actual infringement of any Licensed
Patent Rights relating to Licensed Products (collectively, an “Infringement), that party shall promptly notify the other party and provide it with details regarding such Infringement 

  
 20 

 8.2. Suit by Licensee. Licensee shall have the first right, but not the obligation,
to take action in the prosecution, prevention, or termination of any Infringement. Before Licensee commences an action with respect to any Infringement, Licensee shall consider in good faith the views of Harvard and potential effects on the public
interest in making its decision whether to sue. Should Licensee elect to bring suit against an infringer, Licensee shall keep Harvard reasonably informed of the progress of the action and shall give Harvard a reasonable opportunity in advance to
consult with Licensee and offer its views about major decisions affecting the litigation. Licensee shall give careful consideration to those views, but shall have the right to control the action; provided, however, that if Licensee fails to defend
in good faith the validity and/or enforceability of the Licensed Patent Rights in the action, or if Licensee’s license to a Valid Claim in suit terminates, Harvard may elect to take control of the action pursuant to Section 8.3. Should
Licensee elect to bring suit against an infringer and Harvard is joined as party plaintiff in any such suit, Harvard shall have the right to approve the counsel selected by Licensee to represent Licensee and Harvard, such approval not to be
unreasonably withheld, delayed or conditioned (the parties agree that counsel’s conflict of interest shall be reasonable grounds for withholding approval). The expenses of such suit or suits that Licensee elects to bring, including any expenses
of Licensors incurred in conjunction with the prosecution of such suits or the settlement thereof, shall be paid for entirely by Licensee and Licensee shall hold Licensors free, clear and harmless from and against any and all costs of such
litigation, including attorney’s fees. Licensee shall not compromise or settle such litigation without the prior written consent of Harvard, which consent shall not be unreasonably withheld, delayed or conditioned (the parties agree that
Harvard may withhold approval of any settlement that may reasonably be interpreted to impose any obligations on Harvard or limit the scope, validity or enforceability of any Licensed Patent Rights). In the event Licensee exercises its right to sue
pursuant to this Section 8.2, it shall first reimburse itself out of any sums recovered in such suit or in settlement thereof for all costs and expenses of every kind and character, including reasonable attorney’s fees, reasonably incurred
in the prosecution of any such suit. If, after such reimbursement, any funds shall remain from said recovery, then Harvard shall receive an amount equal to [**] percent ([**]%) of such funds and the remaining [**] percent ([**]%) of such funds shall
be retained by Licensee. 
 8.3. Suit by Harvard. If Licensee does not take action in the prosecution, prevention, or
termination of any Infringement pursuant to Section 8.2 above, and has not commenced negotiations with the infringer for the discontinuance of said Infringement, within [**] days after receipt of notice to Licensee by Harvard of the existence
of an Infringement, Harvard may elect to do so. Should Harvard elect to bring suit against an infringer and Licensee is joined as party plaintiff in any such suit, Licensee shall have the right to approve the counsel selected by Harvard to represent
Harvard, such approval not to be unreasonably withheld, delayed or conditioned (the parties agree that counsel’s conflict of interest shall be reasonable grounds for withholding approval). The expenses of such suit or suits that Harvard elects
to bring, including any expenses of Licensee incurred in conjunction with the prosecution of such suits or the settlement thereof, shall be paid for entirely by Harvard and Harvard shall hold Licensee free, clear and harmless from and against any
and all costs of such litigation, including attorney’s fees. Harvard shall not compromise or settle such litigation without the prior written consent of Licensee, which consent shall not be unreasonably withheld, delayed or conditioned (the
parties agree that Licensee may withhold approval of any settlement that may reasonably be interpreted to impose any obligations on Licensee or limit the scope, validity or enforceability of any

  
 21 

 
Licensed Patent Rights). In the event Harvard exercises its right to sue pursuant to this Section 8.3, it shall first reimburse itself out of any sums recovered in such suit or in settlement
thereof for all costs and expenses of every kind and character, including reasonable attorney’s fees, reasonably incurred in the prosecution of any such suit. If, after such reimbursement, any funds shall remain from said recovery, then
Licensee shall receive an amount equal to [**] percent ([**]%) of such funds and the remaining [**] percent ([**]%) of such funds shall be retained by Harvard. 
 8.4. Own Counsel. Each party shall always have the right to be represented by counsel of its own selection and at its own expense in any suit instituted under this Article 8 by the other party for
Infringement. 
 8.5. Cooperation. Each party agrees to cooperate fully in any action under this Article 8 which is
controlled by the other party, provided that the controlling party reimburses the cooperating party promptly for any costs and expenses incurred by the cooperating party in connection with providing such assistance. 

8.6. Standing. If a party lacks standing and the other party has standing to bring any such suit, action or proceeding, then such
other party shall do so at the request of and at the expense of the requesting party. If either party determines that it is necessary or desirable for another party to join any such suit, action or proceeding, the other party shall execute all
papers and perform such other acts as may be reasonably required in the circumstances. 
 8.7. Declaratory Judgment. If a
declaratory judgment action is brought naming Licensee and/or any of its Affiliates or Sublicensees as a defendant and alleging invalidity or unenforceability of any claims within the Harvard Patent Rights, Licensee shall promptly notify Harvard in
writing and Harvard may elect, upon written notice to Licensee within [**] days after Harvard receives notice of the commencement of such action, to take over the sole defense of the invalidity or unenforceability aspect of the action at its own
expense. The Party defending any such action shall give the other Party the opportunity to provide comments on and make requests of the defending Party concerning the conduct of such defense, and shall consider such comments and requests in good
faith. 
 9. Warranties; Limitation of Liability. 
 9.1. Compliance with Law. Licensee represents and warrants that it will comply, and will ensure that its Affiliates and Sublicensees comply, with all local, state, and international laws and
regulations relating to the development, manufacture, use, sale and importation of Licensed Products. Without limiting the foregoing, Licensee represents and warrants that it will comply, and will ensure that its Affiliates and Sublicensees will
comply, with all United States export control laws and regulations with respect to Licensed Products. 
 9.2. No Warranty.

 9.2.1. Harvard makes no warranties whatsoever as to the commercial or scientific value of the Harvard Patent
Rights or Joint Patent Rights or the inventions disclosed therein. Harvard makes no representation that the practice of the Harvard Patent Rights or Joint Patent Rights or the development, manufacture, use, sale or importation of any Licensed
Product, or any element thereof, will not infringe the patent or proprietary rights of any third party. 

  
 22 

 9.2.2. Except as otherwise expressly provided in this Agreement, no party makes any
warranty with respect to any technology, patents, goods, services, rights or other subject matter of this Agreement and hereby disclaims warranties of merchantability, fitness for a particular purpose and noninfringement with respect to any and all
of the foregoing. 
 9.3. Limitation of Liability. 

9.3.1. Except with respect to Licensee’s indemnification obligations under Article 10, neither party will be liable to the
other with respect to any subject matter of this Agreement under any contract, negligence, strict liability or other legal or equitable theory for (i) any indirect incidental, consequential or punitive damages or lost profits or (ii) cost
of procurement of substitute goods, technology or services. 
 9.3.2. Harvard’s aggregate liability for all damages
of any kind arising out of or relating to this Agreement or its subject matter shall not exceed the amounts paid to Harvard under this Agreement. 
 10. Indemnification. 
 10.1. Indemnity. 

10.1.1. Licensee shall indemnify, defend and hold harmless Harvard and its current or former directors, governing board members,
trustees, officers, faculty, medical and professional staff, employees, students, and agents and their respective successors, heirs and assigns (collectively, the “Indemnitees”) from and against any third party claim, liability, cost,
expense, damage, deficiency, loss or obligation or any kind or nature (including, without limitation, reasonable attorney’s fees and other costs and expenses of litigation) (collectively, “Claims”), based upon, arising out of, or
otherwise relating to any acts or omissions of the Licensee, its Affiliates, or any of its Sublicensees in connection with Licensed Products or this Agreement or any cause of action relating to product liability concerning any product, process, or
service made, used or sold pursuant to any right or license granted under this Agreement. Neither Licensee nor Harvard shall settle any Claim without the prior written consent of the other, which consent shall not be unreasonably withheld, delayed
or conditioned, except that Licensee may settle any Claim to which Licensee’s indemnification obligations hereunder apply without the consent of Harvard if such settlement releases all Indemnitees from liability in respect of such Claim, does
not impose any obligations on any Indemnitee and does not limit the scope, validity or enforceability of any Licensed Patent Right. 
 10.1.2. Licensee shall, at its own expense, provide attorneys reasonably acceptable to Harvard to defend against any actions brought or filed against any Indemnitee hereunder with respect to the
subject of indemnity contained herein, whether or not such actions are rightfully brought. 

  
 23 

 10.2. Insurance. 

10.2.1. Beginning at the time any Licensed Product is being commercially distributed or sold (other than for the purpose of
obtaining regulatory approvals) by Licensee, or by an Affiliate, Sublicensee or agent of Licensee, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than $[**] per incident
and $[**] annual aggregate and naming the Indemnitees as additional insureds. During clinical trials of any such Licensed Product, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in such
equal or lesser amount as Harvard shall require, naming the Indemnitees as additional insureds. Such commercial general liability insurance shall provide: (a) product liability coverage and (b) broad form contractual liability coverage for
Company’s indemnification under this Agreement. 
 10.2.2. If Licensee elects to self-insure all or part of the
limits described above in Section 10.2.1 (including deductibles or retentions which are in excess of $[**] annual aggregate) such self-insurance program must be acceptable to Harvard and the Risk Management Foundation of the Harvard Medical
Institutions, Inc. in their sole discretion. The minimum amounts of insurance coverage required shall not be construed to create a limit of Licensee’s liability with respect to its indemnification under this Agreement. 

10.2.3. Licensee shall provide Harvard with written evidence of such insurance upon request of Harvard. Licensee shall provide
Harvard with written notice at least [**] days prior to the cancellation, non-renewal or material change in such insurance; if Licensee does not obtain replacement insurance providing comparable coverage within such [**]) day period, Harvard shall
have the right to terminate this Agreement effective at the end of such [**] day period without notice or any additional waiting periods. 
 10.2.4. Licensee shall maintain such commercial general liability insurance beyond the expiration or termination of this Agreement during: (a) the period that any Licensed Product is being
commercially distributed or sold by Licensee, or an Affiliate, Sublicensee or agent of Licensee; and (b) a reasonable period after the period referred to in (a) above which in no event shall be less than [**] years. 

  
 24 

 11. Term and Termination. 
 11.1. Term. The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as provided in this Article 11, shall continue in full force and effect on a Licensed
Product-by-Licensed Product and country-by-country basis until expiration of the last to expire of the Harvard Patents Rights and Joint Patent Rights. 
 11.2. Termination. 
 11.2.1. Termination Without Cause. Licensee may
terminate this Agreement upon sixty (60) days prior written notice to Harvard. 
 11.2.2. Termination for Failure to
Obtain Financing. In the event that Licensee fails to complete an investment in the capital stock of Licensee that results in the receipt by Licensee of at least [**] U.S. Dollars ($[**]) (a “Qualifying Financing”) within [**] days
after the Effective Date, Harvard may terminate this Agreement immediately upon written notice to Licensee. Notwithstanding the foregoing, if Harvard fails to exercise this right to terminate and Licensee subsequently completes a Qualifying
Financing (after the [**] day period) and issues Shares to Harvard as set forth in Section 6.2.1, the termination right set forth in this Section 11.2.2 shall expire and have no further force or effect. The termination right set forth in
this Section 11.2.2 is Harvard’s sole and exclusive remedy and Licensee’s sole and exclusive liability for any failure by Licensee to complete a Qualifying Financing. 

11.2.3. Termination for Default. 
 11.2.3.1. In the event that either party commits a material breach of its obligations under this Agreement and fails to cure that breach within [**] days after receiving written notice thereof, the
other party may terminate this Agreement immediately upon written notice to the party in breach. 
 11.2.3.2. If
Licensee defaults in its obligations under Section 10.2 to procure and maintain insurance or, if Licensee has in any event failed to comply with the notice requirements contained therein and does not cure such failure within [**] business day
of written notice thereof from Harvard, then Harvard may terminate this Agreement immediately without notice or additional waiting period. 
 11.2.4. Bankruptcy. Harvard may terminate this Agreement upon notice to Licensee if Licensee becomes insolvent, is adjudged bankrupt, applies for judicial or extra-judicial settlement with its
creditors, makes an assignment for the benefit of its creditors, voluntarily files for bankruptcy or has a receiver or trustee (or the like) in bankruptcy appointed by reason of its insolvency, or in the event an involuntary bankruptcy action is
filed against Licensee and not dismissed within ninety (90) days, or if the other party becomes the subject of liquidation or dissolution proceedings or otherwise discontinues business; provided that the termination right set forth in
this Section 11.2.4 shall not be exercisable if Licensee continues to perform its obligations under this Agreement in all material respects. 

  
 25 

 11.3. Effect of Termination. 

11.3.1. Termination of Rights. Upon termination of this Agreement by either party pursuant to any of the provisions of
Section 11.2: (a) the rights and licenses granted to Licensee under Article 4 shall terminate and all rights in and to and under the Harvard Patent Rights and Harvard’s interest in the Joint Inventions shall revert to Harvard; and
(b) any existing agreements that contain a Sublicense shall terminate to the extent of such Sublicense; provided, however, that, for each Sublicensee, upon termination of the Sublicense agreement with such Sublicensee, if the Sublicensee is not
then in breach of its Sublicense agreement with Licensee such that Licensee would have the right to terminate such Sublicense, such Sublicensee shall have the right to seek a license from Harvard. Harvard agrees to negotiate such licenses in good
faith under reasonable terms and conditions, which shall not impose any representations, warranties, obligations or liabilities on Harvard that are not included in this Agreement. Notwithstanding the foregoing, Licensee shall have a non-exclusive
license under Harvard’s interest in any Joint Patent Rights to develop, make, have made, use, market, offer for sale, sell and import Licensed Products, provided that Licensee pays the applicable royalties and payments to Harvard in accordance
with Sections 6.4 and 6.5, provides reports and audit rights to Harvard pursuant to Article 7 and maintains insurance in accordance with the requirements of Section 10.2. 
 11.3.2. Accruing Obligations. Termination of this Agreement shall not relieve the parties of obligations occurring prior to such termination, including obligations to pay amounts accruing hereunder
up to the date of termination. 
 11.3.3. Transfer of Regulatory Filings. In addition, in the event Licensee terminates
this Agreement pursuant to Section 11.2.1 or Harvard terminates this Agreement pursuant to Section 5.4, 11.2.2, 11.2.3 or 11.2.4, at Harvard’s request Licensee shall promptly deliver and assign to Harvard all documents and other
materials filed by or on behalf of Licensee and its Affiliates with regulatory agencies in furtherance of applications for regulatory approval in the relevant country with respect to Licensed Products (“Assigned Materials”). 

11.3.3.1. In the event that Harvard grants a third party a license to make, use, offer for sale, sell or import a Licensed
Product and, in connection therewith, also grants the third party a license under or with respect to, or access to, any of the Assigned Materials relating to such Licensed Product, Harvard shall pay Licensee royalties in the amount of [**] percent
([**]%) of all Net Harvard Receipts (as defined below) received by Harvard in connection with such Licensed Product under such license. All such royalties shall be paid by Harvard within [**] days of receipt. With such distribution, Harvard shall
provide a financial accounting showing Harvard Receipts (as defined below) received and all deductions therefrom. Licensee shall keep such reports in confidence; provided that Licensee shall be permitted to include the information in such
reports in its financial statements and public disclosures as reasonably required to satisfy accounting rules and securities laws and regulations. 
 11.3.3.2. “Net Harvard Receipts” shall mean Harvard Receipts less Harvard Expenses. 

  
 26 

 11.3.3.3. “Harvard Receipts” shall mean all amounts in cash and other
consideration actually received by Harvard from the grant of a license to make, use, offer for sale, sell or import a Licensed Product, which license is accompanied by a license or grant of right to use the Assigned Materials with respect to such
Licensed Product. Notwithstanding the above, “Harvard Receipts” shall not include payments specifically committed to (a) reimburse patent expenses incurred by Harvard in connection with such Licensed Product and (b) cover future
costs to be actually incurred by Harvard (including customary overhead) in accordance with detailed budgets and research workplans included in sponsored research agreements relating to such Licensed Product. The parties do not envision that Harvard
would ever elect to commercialize the Licensed Product directly or through any Harvard Affiliate; however, in the event that Harvard commercializes the Licensed Product directly or through an Affiliate, the parties will negotiate appropriate royalty
rates to be paid by Harvard comparable to the royalty rates to be paid by Licensee under Section 6.4.1. 
 11.3.3.4.
“Harvard Expenses” shall mean all out-of-pocket expenses and professional fees that are not reimbursed or otherwise paid by a licensee or other third party, including legal fees, patent agent fees and fees paid to other experts,
incurred by Harvard in connection with: (a) the filing, prosecution, maintenance or enforcement of any patent application or patent covering the relevant Licensed Product; or (b) the preparation, negotiation, execution and/or enforcement
of any agreement pursuant to which the Harvard Receipts are received. 
 11.4. Survival. The parties’ respective
rights, obligations and duties under Articles 7 and 10 and under this Article 11, as well as any rights, obligations and duties which by their nature extend beyond the expiration or termination of this Agreement, shall survive any expiration or
termination of this Agreement. In addition, Licensee’s obligations under Section 6.5 with respect to Sublicenses granted prior to termination of the Agreement shall survive termination; provided that the basis for the Non-Royalty
Sublicense Income under such Sublicenses received after the termination of this Agreement to which such surviving Section 6.5 obligations relate is, in whole or in part, licenses and/or sublicenses under Harvard Patent Rights or Joint Patent
Rights and not exclusively other rights and licenses granted by Licensee in connection with such Sublicense. Harvard’s obligations under Section 12.15 shall survive expiration or termination of this Agreement. 

12. Miscellaneous. 

12.1. Preference for United States Industry. During the period of exclusivity of this license in the United States, Licensee shall
cause any Licensed Product produced for sale in the United States to be manufactured substantially in the United States. 

12.2. Use of Name. Licensee shall not, and shall ensure that its Affiliates and Sublicensees shall not, use the name or insignia
of Harvard or the name of any of Harvard officers, faculty, other researchers or students, or any adaptation of such names, in any advertising promotional or sales literature, including without limitation any press release or any document employed
to obtain funds, without the prior written approval of Harvard; provided that Dr. Myers’ consent to the use of his name and his affiliation with Harvard shall be sufficient approval for the use of his name and affiliation. The
restriction set forth in this Section 12.2 shall not apply to any information required by law to be disclosed to any governmental entity, including without limitation any information required to be disclosed pursuant to rules and regulations
promulgated by the United States Securities and Exchange Commissions or the rules and regulations of any stock exchange or NASDAQ. 

  
 27 

 12.3. Entire Agreement. This Agreement is the sole agreement with respect to the
subject matter hereof and except as expressly set forth herein, supersedes all other agreements and understandings between the parties with respect to the same. 
 12.4. Notices. Unless otherwise specifically provided, all notices required or permitted by this Agreement shall be in writing and may be delivered personally, or may be sent by facsimile or
certified mail, return receipt requested, to the following addresses, unless the parties are subsequently notified of any change of address in accordance with this Section 12.4: 

 

			
	 If to

License:
	    	 Tetraphase Pharmaceuticals, Inc.
 c/o Mediphase Venture Partners
 3 Newton Executive Park, Suite 104

Newton, Massachusetts 02462

		
		    	Attn.: Chief Executive Officer
		
	 If to

Harvard:
	    	 Office of Technology Development
 Harvard University
 Holyoke Center 727
 1350 Massachusetts Avenue
 Cambridge, Massachusetts 02138

		
		    	Attn.: Chief Technology Development Officer

 Any notice shall be deemed to have been received as follows: (i) by personal delivery, upon receipt;
(ii) by facsimile, one business day after transmission or dispatch; (iii) by airmail, seven (7) business days after delivery to the postal authorities by the party serving notice. If notice is sent by facsimile, a confirming copy of
the same shall be sent by mail to the same address. 
 12.5. Governing Law and Jurisdiction. This Agreement will be
governed by, and construed in accordance with, the substantive laws of the Commonwealth of Massachusetts, without giving effect to any choice or conflict of law provision, except that questions affecting the construction and effect of any patent
shall be determined by the law of the country in which the patent shall have been granted. Sole jurisdiction is hereby granted by the parties to the state courts of the Commonwealth of Massachusetts or the federal courts of the District of
Massachusetts, without restricting any right of appeal. 
 12.6. Binding Effect. This Agreement shall be binding upon and
inure to the benefit of the parties and their respective legal representatives, successors and permitted assigns. 

  
 28 

 12.7. Headings. Article, section and subsection headings are inserted for convenience
of reference only and do not form a part of this Agreement. 
 12.8. Counterparts. This Agreement may be executed
simultaneously in two or more counterparts, each of which shall be deemed an original. 
 12.9. Amendment; Waiver. This
Agreement may be amended, modified, superseded or canceled, and any of the terms may be waived, only by a written instrument executed by each party or, in the case of waiver, by the party waiving compliance. The delay or failure of any party at any
time or times to require performance of any provisions hereof shall in no manner affect the rights at a later time to enforce the same. No waiver by either party of any condition or of the breach of any term contained in this Agreement, whether by
conduct, or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. 

12.10. No Agency or Partnership. Nothing contained in this Agreement shall give any party the right to bind another, or be deemed
to constitute either parties as agents for each other or as partners with each other or any third party. 
 12.11. Assignment
and Successors. This Agreement may not be assigned by either party without the consent of the other, which consent shall not be unreasonably withheld, delayed or conditioned, except that each party may, without such consent, assign this
Agreement and the rights, obligations and interests of such party to any of its Affiliates, to any purchaser of all or substantially all of its business, stock, assets or research to which the subject matter of this Agreement relates, or to any
successor corporation resulting from any merger or consolidation of such party with or into such corporation; provided, in each case, that the assignee agrees in writing to be bound by the terms of this Agreement. Any assignment purported or
attempted to be made in violation of the terms of this Section 12.11 shall be null and void and of no legal effect. 

12.12. Force Majeure. Neither party will be responsible for delays resulting from causes beyond the reasonable control of such
party, including without limitation fire, explosion, flood, war, strike, or riot, provided that the nonperforming party uses commercially reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this
Agreement with reasonable dispatch whenever such causes are removed. 
 12.13. Interpretation. The parties hereto
acknowledge and agree that: (i) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are
resolved against the drafting party shall not be employed in the interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be construed fairly as to both parties hereto and not in favor of or against either
party, regardless of which party was generally responsible for the preparation of this Agreement. 
 12.14. Severability.
If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of the parties that the remainder of this Agreement shall not be affected.

  
 29 

 12.15. Confidentiality. Harvard shall keep confidential, not disclose to any third
party and not use for any purpose other than monitoring Licensee’s performance under this Agreement any information (including reports) provided to Harvard by Licensee or by Dr. Myers under Sections 2.5, 2.6, 5.3, 7.1 and 7.3 of this
Agreement; provided, however, that Harvard (i) may include in its annual reports totals derived from information received from Licensee (without attribution to Licensee) that show revenues generated by the patents and patent applications
licensed under this Agreement and (ii) may use and disclose information provided under Sections 2.5 and 2.6 to file patent applications with respect to Harvard Inventions and, as permitted under this Agreement, Joint Inventions; and provided
further that the non-disclosure and non-use obligations shall not apply to any information that (a) is or becomes part of the public domain other than by Harvard’s breach of this Section 12.15, (b) is included within Abandoned
Harvard Patent Rights or Abandoned Joint Patent Rights, or (c) is required to be disclosed by Harvard pursuant to interrogatories, requests for information or documents, subpoena, civil investigative demand issued by a court or governmental
agency or as otherwise required by law (provided that, in such case, Harvard shall notify Licensee immediately upon receipt thereof and give Licensee sufficient advance notice to permit it to seek a protective order or other similar order with
respect to such information). To the extent that it is reasonably necessary, Harvard may disclose information it is otherwise obligated under this Section 12.15 not to disclose to (y) its employees on a need-to-know basis and on condition
that such employees abide by the obligations set forth in this Section 12.15 and (z) in confidence, to lawyers, accountants and financial advisors. 
 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives as of the date first written above. 

 

									
	President and Fellows of Harvard College	 		 	Tetraphase Pharmaceuticals, Inc.
					
	By:	 	 /s/  Isaac Kohlberg
	 		 	By:	 	 /s/  Lawrence G. Miller

					
	Name:	 	  
	 		 	Name:	 	 Lawrence G. Miller

					
	 Title:
	 	  
	 		 	Title:	 	 President

 I, the undersigned, hereby confirm that I have read the Agreement, that its contents are acceptable to me and that I
agree to be bound by the terms of Article 2. 
  

									
	/s/  Andrew G. Myers	 		 		 	
	Andrew G. Myers	 		 		 	

  
 30 

 Exhibit 1.5 
 Development Milestones 
 1. Licensee shall commence [**] with respect to a
Licensed Product within [**] months of the Effective Date. 
 2. Licensee shall commence [**] with respect to a Licensed Product
within [**] months of the Effective Date. 
 3. Licensee shall [**] for a Licensed Product within [**] months of the Effective
Date. 

  
 31 

 Exhibit 1.6 
 Development Plan 

  
 32 

 Tetraphase Pharmaceuticals 

CONFIDENTIAL 
 Tetraphase Pharmaceuticals: Initial Plan 
 Summary 

This company is to be formed to ensure rapid development of commercial products based on the groundbreaking studies of tetracycline synthesis conducted by
Prof. Andrew Myers and colleagues in the Department of Chemistry and Chemical Biology at Harvard University. The initial goal of the company is to create multiple antibiotic candidates based on these synthetic technologies, and to advance these
candidates into clinical trials. Subsequently, the company will pursue further antibacterial compounds, through synthetic pathways or in-licensing. The overall goal is to become an integrated pharmaceutical company and a leader in the development of
antibacterials. The company name, Tetraphase Pharmaceuticals, refers to the initial focus on tetracyclines, as well as the multiple phases of development that will encompass other types of antibacterials (see below). 

Background 
 Tetracyclines as a class of
anti-infective compounds were first employed in the 1940s (chlortetracycline); tetracycline itself was introduced in 1953, and second generation tetracyclines appeared in the 1960s and early 1970s. Indeed, over the three decades from the late
1940’s onward, nearly 30% of all approved antibiotics were tetracyclines. Their use has spanned the spectrum of bacterial infections, including gram-positive and gram-negative bacteria, Chlamydia, mycoplasma and spirochetes. Of note, the
anti-inflammatory properties of tetracyclines were also recognized, and it is likely that the effectiveness of this class in conditions such as acne derives at least in part from anti-inflammatory efficacy. 

Although tetracyclines, especially doxycycline, remain in widespread use, resistance to tetracyclines emerged as a major problem in
the 1970s and has led to reduced efficacy and utility of this class. However, as resistance has subsequently developed to other classes of antibiotics, interest in tetracyclines has been rekindled, in part due to their oral absorption and
potentially wide spectrum of action. A new class of tetracyclines, the glycylcyclines, was synthesized in the 1990s, and in mid-2005, a member of this class, tigecycline (Tygacil, Wyeth), received approval in the U.S. 

Despite significant interest in this class over the last 15 years, development of new tetracyclines has been hampered by difficulties in synthesis.
Little structural diversity has been generated, with almost all efforts directed at a small number of core intermediates. This lack of chemical diversity has led to limitations in anti-infective diversity, with little success in overcoming drug
resistance. The glycylcyclines, such as tigecycline, appear to provide an improvement in overcoming resistance, although toxicity remains an issue. 
 The Myers technology offers a way out of this “box”, with the potential to create multiple novel structures based on different intermediates, and even to expand the number of rings overall.
Based on the performance of compounds in this class, it is reasonable to hypothesize that compounds can be designed with improved efficacy, i.e., decreased resistance, coupled with limited toxicity. 

  

					
	CONFIDENTIAL	 	1	 	March 2006

 Tetraphase Pharmaceuticals 

CONFIDENTIAL 
  

Market 
 The worldwide market for
anti-infectives is in excess of $25 billion, but the market is in transition. Although the total worldwide anti-infective market was in excess of $25 billion in 2004, growth in this sector has been limited. Indeed, through much of the last
1980’s and 1990’s, this market was perceived as stagnant: effective antibiotics were available for most bacterial pathogens. This perception encouraged a lack of effort in this area. Indeed, several major pharmaceutical companies have
reduced or eliminated their antibiotic development programs. Only a handful of new antibacterials have been approved in the last 10 years, most for complex, often hospital-based infections. In a survey conducted in 2004, only 6 of 506 drugs under
development at the pharmaceutical companies and larger biotechnology companies were new antibacterial agents (Spellberg et al., 2004). Concurrently, rapidly-developing resistance is limiting the utility of current antibacterials; resistant
staphylococcus species are becoming endemic (especially methicillin resistant staphylococcus aureus, or MRSA), and resistance in other gram-positive and gram-negative pathogens is increasing. 
 The confluence of these trends creates a significant opportunity for anti-infective development, and in particular for a company with an intense focus on antibacterials. There are clear opportunities to
develop branded antibiotics which can generate annual sales of $300-500 million. 
 The target compound for the expanded tetracycline class
would therefore have the following characteristics: 
  

	 	•	 	 Efficacy against staph, aureus and gram negative organisms 

 

	 	•	 	 Limited gastrointestinal adverse effects 

  

	 	•	 	 Oral and parenteral availability 

 These features would make the compound applicable to the following common indications: 
  

	 	•	 	 Urinary tract infections, including catheter and non-catheter based 

 

	 	•	 	 Skin and soft tissue infections 

  

	 	•	 	 Intra-abdominal infections, e.g., appendicitis, diverticulitis, post-operative 

 

	 	•	 	 Pneumonia, both hospital and community-acquired 

 Note that Tygacil, the recently approved tetracycline, has been approved for both skin and soft tissue infections and intro-abdominal infections. 
 An enhanced tetracycline which could address the indications listed above would be expected to have a market opportunity of at least $500 million, and perhaps as much as $1 billion. 

Current Status of Tetracyclines 
 When
first introduced into clinical practice in the 1940’s, the tetracyclines had broad activity against gram-positive and gram-negative bacteria and chlmaydia, mycoplasma, etc. The class was used widely in both humans and animals, and by 1953
initial resistance was observed. Since 

  

					
	CONFIDENTIAL	 	2	 	March 2006

 Tetraphase Pharmaceuticals 

CONFIDENTIAL 
  

that time, resistance to tetracyclines has increased markedly, limited the use of the class in many common infections. Current indications include urinary tract infections, Lyme disease,
shigellosis and rickeettsial, chlamydial and mycoplasmal infections. Doxycycline is the most widely used tetracycline currently, due to limited adverse effects and twice daily dosing. 
 The first new tetracycline in over 30 years, tigecycline (Tygacil, Wyeth) was approved in June 2005. Tigecycline, the first glycylcycline tetracycline, is a minocycline analog characterized by a
substitution at the 9 position (or position 1 of the D ring; see below), It has substantial advantages over earlier tetracyclines. It is active against methicillin-resistant staphylococcous aureus (MRSA), as well as some gram-negatives, including
enterococci, enterobacteria, and possibly acinetobacter. Tigecycline evades the major bacterial tetracycline efflux pumps, and also binds to modified bacterial ribosomes, another potential cause of resistance. The drug is approved for complex skin
and soft tissue infections, as well as complicated intra-abdominal infections. Major adverse events, as is common in the tetracycline class, occur in the gastrointestinal system. In Phase III studies, 29.5% of patients reported nausea, 19.7%
vomiting and 12.7% of patients experienced diarrhea. Tigecycline is administered intravenously every 12 hours. 
 As such, tigecycline has an
attractive clinical spectrum, and pre-approval studies indicate efficacy comparable to currently first-line antibiotics. However, the drug must be administered intravenously and leads to a disturbing incidence of gastrointestinal adverse events.
Launch of tigecycline has rekindled interest in the tetracycline class, but there is clearly room for improvement over tigecycline characteristics. 
 A second glycylcycline is under development by Paratek (PTK-0796). Although limited information is available, this compound is in Phase I clinical trials and is said to possess a similar antibacterial
spectrum as tigecycline, but with reduced potency against gram-negative bacteria. The compound was recently partnered with Merck. 

Tetracycline optimization 
 The core
structure of all clinically useful tetracyclines is similar, consisting of 4 rings, and conserved areas to the “east” and “south” of the molecule (see below), the areas known to participate in binding to the bacterial ribosomal
target. Limited substitutions from tetracycline itself have led to analogs with some improvements in spectrum and clinical characteristics. Prior to the introduction of tigecycline, clinically available tetracyclines had substitutions on the 5, 6
and 7 positions compared to tetracycline (e.g., doxycycline, chlortetracycline, oxytetracycline, minocycline). 

  

					
	CONFIDENTIAL	 	3	 	March 2006

 Tetraphase Pharmaceuticals 

CONFIDENTIAL 
  

 
 

 
 The recently introduced tigecycline and the investigational Paratek compound (PTK-0796) are analogs of minocycline,
with substitutions at the 9 position as illustrated below: 
  
 

 

  

					
	CONFIDENTIAL	 	4	 	March 2006

 Tetraphase Pharmaceuticals 

CONFIDENTIAL 
  

The Myers approach allows a tremendous range of variations, most obviously at positions 6, 7, 8, 9 and 10 (on the C and D rings), but also at other
positions likely to be involved in ribosomal binding. Addition of a fifth ring with concomitant substitutions also becomes possible. The shaded area in the figure below is constant in clinically-useful tetracyclines, and is accessible in the Myers
synthesis. The Myers synthesis also offers broad opportunities in the unshaded area. 
  
 

 
 [**] 
 These
criteria [**]. 
 [**] 
  

											
		  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]

 Company Objectives 
 As described the above, the overall objective is to create an integrated pharmaceutical company focused on antibacterials. Initial phases of development will focus on tetracyclines, subsequently
broadening to include other classes and types of antibacterials. 

  

					
	CONFIDENTIAL	 	5	 	March 2006

 Tetraphase Pharmaceuticals 

CONFIDENTIAL 
  

Stage I 
 Initially, the company will be
[**] 
 Thus, the near-term objectives of the company will be: 
 [**] 
 This process is estimated to require approximately [**] 

Stage II 
 [**]. The company will [**].

 Stage III 
 [**], the company will
[**]. 
 Stage IV 
 [**], the company
will [**]. 
 Intellectual Property 
 The company will [**]. 
 Company structure and pre-clinical development 

As noted above, the core competencies of the company will be [**] development. 
 Pre-clinical [**]. After review of proposals and cost estimates, the consensus of company advisors is that [**]. 
 [**]. 
 Goals: 
 [**] 

  

					
	CONFIDENTIAL	 	6	 	March 2006

 Tetraphase Pharmaceuticals 

CONFIDENTIAL 
  

 

	
	Tasks
	 [**]

	
	 [**]

	
	 [**]

	

 [**] 
 The
goals are to [**]. 
 Goals: [**]. 
  

	
	Tasks
	 [**]

	
	 [**]

	
	 [**]

	
	 [**]

	
	 [**]

	
	 [**]

	
	 [**]

	
	 [**]

	
	 [**]

	

 [**] 
 [**]

 Goals: [**] 
  

	
	Tasks
	 [**]

	
	 [**]

	
	 [**]

	
	 [**]

	
	 [**]

	
	 [**]

	
	 [**]

	

 [**] 

  

					
	CONFIDENTIAL	 	7	 	March 2006

 Tetraphase Pharmaceuticals 

CONFIDENTIAL 
  

 

	
	Tasks
	 [**]

	
	 [**]

	 [**]

	
	 [**]

	
	 [**]

	
	 [**]

	
	 [**]

	

 Clinical development 
 [**]. The company will develop [**]. 
 Commercial Potential 

Estimation of the commercial potential of [**]. 

Pricing 
 Using [**] it is estimated that
the [**]. 
 Forecast 
 At this
time there are [**]. The forecast is built on the following assumptions: 
 • [**] 
 • [**] 
 • [**] 
 • [**] 
 Sales Forecast 

($ in millions) 
  

											
	  	  	Year 1	 	Year 2	 	Year 3	 	Year 4	 	Year 5
	 U.S. Sales
	  	[**]	 	[**]	 	[**]	 	[**]	 	[**]

 Potential 

As previously stated, this proposal is built on the Tetraphase product [**] the forecast above. 
 Company personnel and recruitment 
 As noted above, approximately [**] personnel will be
required for [**], organized as follows: 
 [**] 
 [**] 

  

					
	CONFIDENTIAL	 	8	 	March 2006

 Tetraphase Pharmaceuticals 

CONFIDENTIAL 
  

With regard to recruitment, [**]. 
 Facility

 [**]. 
 Advisors

 Advisors with [**]. 
 Prof.
Andrew Myers, Chairman: Prof. Myers’ expertise in synthetic chemistry forms the basis for the company, and his ongoing involvement is crucial in the creation and execution of the appropriate synthetic pathways and compounds. Prof. Myers will
work closely with the company on a regular basis, attending research meetings and providing guidance. 
 Dr. Eric Gordon, Drug Development
Advisor: Dr. Gordon is Chairman of the Mediphase Scientific Advisory Board and is widely known for his expertise and success in the development of anti-infectives. While holding senior positions in chemistry at Bristol Myers Squibb, Dr. Gordon
supervised the development of approved drugs. He subsequently was a founder of two anti-infective-focused biotechnology companies, Versicor and Vicuron. 
 Dr. Joaquim Trias, Bacteriology Advisor: Dr. Trias served as Vice President, Microbiology Drug Research at Vicuron for 8 years. Previously, he was a senior scientist at Microcide Pharmaceuticals, and
prior to that was in the Dept. of Microbiology at the University of Barcelona. 
 [**] 

 

			
	Timeline	 	 
	 [**]
	 	[**]
	 [**]
	 	[**]
	 [**]
	 	[**]
	 [**]
	 	[**]
	 [**]
	 	[**]
	 [**]
	 	[**]
	 [**]
	 	[**]
	 [**]
	 	[**]
	 [**]
	 	[**]
	 [**]
	 	[**]

 Financing 

[**] initial financing for the company, which will likely include [**]. The initial financing will [**]. 

Budget 
 See attached. 

  

					
	CONFIDENTIAL	 	9	 	March 2006

																																													
	 Budget Yrs. 1-2
	  	Q1	 	  	Q2	 	  	Q3	 	  	Q4	 	  	Year 1	 	  	Q5	 	  	Q6	 	  	Q7	 	  	Q8	 	  	Year 2	 	  	Total	 
	 Personnel
	  				  				  				  				  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
	 [**]
	  				  				  				  				  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
	 [**]
	  				  				  				  				  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
	 Supplies/External
	  				  				  				  				  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
	 [**]
	  				  				  				  				  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
	 [**]
	  				  				  				  				  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
	 [**]
	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  	 	[**]	  	  			
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total
	  				  				  				  				  	 	[**]	  	  				  				  				  				  	 	[**]	  	  	 	[**]	  
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Capital equipment
	  				  				  				  				  				  				  				  				  				  				  			
	 [**]
	  				  				  				  				  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  				  				  				  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  				  				  				  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  				  				  				  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  				  				  				  				  				  				  				  				  				  			
	 [**]
	  	 	[**]	  	  				  				  				  				  				  				  				  				  				  			
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total
	  	 	[**]	  	  				  				  				  				  				  				  				  				  				  			
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 

 Exhibit 6.2.1 
 Form of Investment Representation Letter 

 Exhibit 6.2.1 
 Investment Representation Letter 
 Tetraphase Pharmaceuticals, Inc. 

c/o Mediphase Venture Partners 
 3 Newton
Executive Park 
 Newton, MA 02462 
 Re: Issuance of Shares of Common Stock of Tetraphase Pharmaceuticals, Inc. 
 Dear Sirs:

 In order to induce Tetraphase Pharmaceuticals, Inc. (the “Company”) to issue to President and Fellows of
Harvard College (“Harvard”) [ ] shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”), pursuant to Section 6.2.1 of that certain License
Agreement, dated July [ ], 2006, between the Company and Harvard (the “License Agreement”), Harvard hereby represents, warrants and covenants to the Company as follows: 

1. Harvard is acquiring the Shares for its own account for investment only, and not with a view to, or for sale in connection with any
distribution of the Shares in violation of the Securities Act of 1933, as amended, (the “Securities Act”), or any rule or regulation under the Securities Act. 
 2. Harvard has had such opportunity as it has deemed adequate to obtain from representatives of the Company such information as is necessary to permit Harvard to evaluate the merits and risks of its
acquisition of the Shares. 
 3. Harvard has sufficient experience in business, financial and investment matters to be able to
evaluate the risks involved in the acquisition of the Shares and to make an informed investment decision with respect to such acquisition. 
 4. Harvard can afford a complete loss of the value of the Shares and is able to bear the economic risk of holding such Shares for an indefinite period. 

5. Harvard understands that (i) the Shares have not been registered under the Securities Act and are “restricted
securities” within the meaning of Rule 144 under the Securities Act; (ii) the Shares cannot be sold, transferred or otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption from registration is
then available; (iii) in any event, the exemption from registration under Rule 144 or otherwise may not be available for at least one year and even then will not be available unless a public market then exists for the Common Stock, adequate
information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and (iv) there is now no registration statement on file with the Securities and Exchange Commission with respect
to any stock of the Company and the Company has no obligation or current intention to register the Shares under the Securities Act. 

 6. A legend substantially in the following form will be placed on the certificates
represented the Shares: 
 “The shares represented by this certificate have not been registered under the Securities Act of
1933, as amended, and may not be sold, transferred or otherwise disposed of in the absence of an effective registration statement under such Act or an opinion of counsel satisfactory to the corporation to the effect that such registration is not
required.” 
 7. The foregoing representations and warrants are true as of the date of this Investment Representation Letter
and shall be true as of the date the Company issues the Shares to Harvard. If such representations and warranties shall not be true in any respect prior to such date, Harvard will give prompt written notice of such fact to the Company. 

8. Harvard agrees, in connection with the initial underwritten public offering of the Company securities pursuant to a registration
statement under the Securities Act, (i) not to sell, make short sale of, loan, grant any options for the purchase of, or otherwise dispose of any shares of Common Stock held by Harvard (other than those shares included in the offering) without
the prior written consent of the Company or the underwriters managing such initial underwritten public offering of the Company’s securities for a period of 180 days from the effective date of such registration statement, and (ii) to
execute any agreement reflecting clause (i) as may be requested by the Company or the managing underwriters at the time of such offering. 
 [Remainder of page intentionally left blank.] 

 This Investment Representation Letter shall be binding upon and inure to the benefit of the
Company and Harvard and its assigns. 
 This Investment Representation Letter shall be construed and enforced in accordance with
and governed by the laws of the Commonwealth of Massachusetts without giving effect to the principles of conflicts of laws thereof. 
 This Investment Representation Letter may be exercised in counterparts and by facsimile signature. 
  

			
	President and Fellows of Harvard College
		
	By:	 	  
		 	Name:
		 	Title:
		
	Date:	 	  

 Investment Representation Letter Signature Page 

 A6820amend1 
 Amendment to License Agreement 
 This Amendment to
License Agreement (this “Amendment”) is entered into as of this 31st day of January, 2007 (the “Effective Date”), by and between Tetraphase Pharmaceuticals, Inc., a Delaware corporation, with its
principal place of business 480 Arsenal St., Suite 110, Watertown, MA 02472 (“Licensee”) and President and Fellows of Harvard College, Holyoke Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 01238
(“Harvard”). 
 WHEREAS, the parties entered into a License Agreement as of August 3, 2006 (the
“License Agreement”), pursuant to which Harvard granted to Licensee an exclusive license under Harvard Patent Rights and Harvard’s interest in Joint Patent Rights (as such terms are defined in the License Agreement); 

WHEREAS, Dr. Andrew G. Myers, a Harvard researcher, is (or by definition will be) an inventor of the inventions claimed in the
Harvard Patent Rights and Joint Patent Rights; 
 WHEREAS, Dr. Myers is an inventor of technology claimed in a new patent
application [**] owned by Harvard that is neither a Harvard Patent Right nor a Joint Patent Right, but which claims subject matter related thereto; and 
 WHEREAS, Licensee wishes to obtain a license under such new patent application and Harvard wishes to grant Licensee a license thereunder; 

NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows: 

 

	1.	Capitalized terms used in this Amendment that are not defined herein shall have the meanings set forth in the License Agreement. 

 

	2.	Section 1.10 of the License Agreement is replaced in its entirety with the following: 

“Harvard Patent Rights” shall mean, in each case to the extent owned and controlled by Harvard: (a) [**] (including
the PCT applications and/or the US regular utility applications filed at or prior to the one year conversion date claiming priority to such provisional applications); (b) any patent or patent application that claims priority to and is a
divisional, continuation, reissue, renewal, reexamination, substitution or extension of any patent or patent application identified in (a); (c) any patents issuing on any of the patent applications identified in (a) or (b) and any
reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a continuation-in-part application or patent that is entitled to the priority date of, and is directed specifically to subject matter specifically
described in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart of any of the patents or patent applications identified in (a), (b) or (c) or of the claims identified in
(d); and (f) any claim of any United States or foreign patent or patent application to the extent specifically directed to subject matter of Harvard Inventions. 
  

	3.	Section 6.1 of the License Agreement is replaced in its entirety with the following: 

 License Issuance Fee. As partial consideration for the license granted hereunder,
Licensee shall pay Harvard the following non-refund able license fees: 
 (a) [**] U.S. Dollars ($[**]), payable
within [**] days after the date on which Licensee completes a Qualifying Financing (as defined in Section 11.2.2 below); and 
 (b) [**] U.S. Dollars ($[**]) with respect to [**] by January 31, 2007. 
  

	4.	Section 3.3 of the License Agreement 

 Expenses. Subject to Section 3.4 below, Licensee shall reimburse Harvard for all documented, out-of-pocket expenses incurred by Harvard pursuant to this Article 3 within [**] days after
Harvard invoices Licensee. In addition, Licensee shall reimburse Harvard for all documented, out-of-pocket expenses incurred by Harvard prior to the execution of this Agreement with respect to the preparation, filing, prosecution, protection and
maintenance of Harvard Patent Rights (estimated to be approximately [**] U.S. Cents ($[**])) within [**] days after the date on which the financing described in Section 11.2.2 below closes. In the event that this Agreement is amended in
accordance with Section 4.3 to add a new patent or patent application to the definition of Harvard Patent Rights, Licensee shall reimburse Harvard for all documented, out-of-pocket expenses incurred by Harvard prior such amendment with respect
to the preparation, filing, prosecution, protection and maintenance of such new patent or patent application within [**] days after Harvard invoices Licensee. 
  

	5.	All other terms and conditions of the License Agreement shall remain unchanged and in full force and effect. 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized
representatives as of the date first written above. 
  

									
	President and Fellows of Harvard College	 		 	Tetraphase Pharmaceuticals, Inc.
					
	By:	 	/s/ Isaac T. Kohlberg	 		 	By:	 	/s/ David C. Lubner
					
	Name:	 	Isaac T. Kohlberg	 		 	Name:	 	David C. Lubner
					
	Title:	 	Sr. Associate Provost	 		 	Title:	 	SVP, COO
		 	Chief Technology Dev. Officer	 		 		 	

 Amendment to License Agreement 

This second Amendment to License Agreement (this “Second Amendment”) is entered into as of this 6th day of April, 2010 (the
“Effective Date”), by and between Tetraphase Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 480 Arsenal St., Suite 110, Watertown, MA 02472 (“Licensee”) and President and Fellows of Harvard
College, Holyoke Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 01238 (“Harvard”). 
 WHEREAS,
the parties entered into a License Agreement as of August 3, 2006 (as previously amended, the “License Agreement”), pursuant to which Harvard granted to Licensee an exclusive license under Harvard Patent Rights and Harvard’s
interest in Joint Patent Rights (as such terms are defined in the License Agreement); 
 WHEREAS, on January 31, 2007, the
parties amended the License Agreement to include a new patent application [**] under Harvard Patent Rights; 
 WHEREAS,
Dr. Myers is an inventor of technology claimed in an additional new patent application [**] owned by Harvard that is neither a Harvard Patent Right nor a Joint Patent Right, but which claims subject matter related thereto; and 

WHEREAS, Licensee wishes to obtain a license under such new patent application and Harvard wishes to grant Licensee a license thereunder;

 NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows: 

 

	 	1.	Capitalized terms used in this Second Amendment that are not defined herein shall have the meanings set forth in the License Agreement. 

 

	 	2.	Section 1.10 of the License Agreement is replaced in its entirety with the following: 

“Harvard Patent Rights” shall mean, in each case to the extent owned and controlled by Harvard: (a) [**] being
referred to as the “Additional Patent Application”) (including the PCT applications and/or the US regular utility applications filed at or prior to the one year conversion date claiming priority to such provisional applications);
(b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of any patent or patent application identified in (a); (c) any patents issuing on
any of the patent applications identified in (a) or (b) and any reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a continuation-in-part application or patent that is entitled to the priority
date of, and is directed specifically to subject matter specifically described in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart of any of the patents or patent applications
identified in (a), (b) or (c) or of the claims identified in (d); and (f) any claim of any United States or foreign patent or patent application to the extent specifically directed to subject matter of Harvard Inventions. The
Additional Patent Application and all patents and patent applications listed in clauses (b) through (e) that correspond to the Additional Patent 

 
Application shall be referred to herein as the “Additional Patent Rights.” For clarity, Additional Patent Rights are a subset of Harvard Patent Rights. 

 

	 	3.	Section 5.4 of the License Agreement is amended by adding to the end of such Section the following: 

“Notwithstanding the foregoing, in the event that the Development Milestone that is not achieved and not cured under this
Section 5.4 and with respect to which Licensee is in material breach is an Additional Patent Right Development Milestone (as set forth on Exhibit 1.5), then Harvard’s right to terminate this Agreement under Section 5.4 shall be
limited to the Additional Patent Rights such that the license and other rights granted under this Agreement to the Additional Patent Rights shall terminate, with this Agreement otherwise remaining in full force and effect in all respects.

  

	 	4.	Section 6.1 of the License Agreement is replaced in its entirety with the following: 

License Issuance Fee. As partial consideration for the license granted hereunder, Licensee shall pay Harvard the following
non-refundable license fees: 
 (a) [**] U.S. Dollars ($[**]), payable within [**] days after the date on which
Licensee completes a Qualifying Financing (as defined in Section 11.2.2 below); 
 (b) [**] U.S. Dollars
($[**]) with respect to [**] by January 31, 2007. 
 (c) [**] U.S. Dollars ($[**]) with respect to the
Additional Patent Rights by April 23, 2010. 
  

	 	5.	Section 6.3.1.4 of the License Agreement is replaced in its entirety with the following: 

[**] U.S Dollars ($[**]) upon [**] with respect to such Licensed Product; provided however, that if such Licensed Product is covered by
the Additional Patent Rights then the amount due for this milestone payment shall be [**] U.S Dollars ($[**]). 
  

	 	6.	Exhibit 1.5 of the License Agreement is replaced in its entirety with the Exhibit 1.5 attached to this Second Amendment, so as to include additional Development
Milestones with respect to the Additional Patent Rights. 

  

	 	7.	Harvard acknowledges that Licensee has paid the license fees required by Section 6.1(a) and (b). 

 

	 	8.	All other terms and conditions of the License Agreement shall remain unchanged and in full force and effect. 

IN WITNESS WHEREOF, the parties have caused this Second Amendment to be executed by their duly authorized representatives as of the date first
written above. 

			
	President and Fellows of Harvard College	  	Tetraphase Pharmaceuticals, Inc.
		
	By: /s/ Isaac T. Kohlberg	  	By: /s/ Guy Macdonald
		  	
	Name: Isaac T. Kohlberg, Senior Associate Provost	  	Name: Guy Macdonald
		  	
	 Title: Chief Technology Development Officer 
 Office of Technology Development
 Harvard University
	  	Title: President & CEO

 Exhibit 1.5 
 Development Milestones 
  

	 	1.	Licensee shall commence [**] with respect to a Licensed Product within [**] months of the Effective Date. 

 

	 	2.	Licensee shall commence [**] with respect to a Licensed Product within [**] months of the Effective Date. 

 

	 	3.	Licensee shall [**] for a Licensed Product within [**] months of the Effective Date. 

The following Development Milestones (the “Additional Patent Rights Development Milestones”) will apply with respect to
Licensed Products covered by the Additional Patent Rights: 
  

	 	1.	[**] with respect to such a Licensed Product by [**]. 

  

	 	2.	[**] with respect to such a Licensed Product by [**]. 

  

	 	3.	[**] with respect to such a Licensed Product by [**]. 

  

	 	4.	[**] with respect to such a Licensed Product by [**]. 

 Third Amendment to License Agreement 

This Third Amendment to License Agreement (this “Third Amendment”) is entered into as of this 18 day of February, 2011
(the “Effective Date”), by and between Tetraphase Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 480 Arsenal St., Suite 110, Watertown, MA 02472 (“Licensee”) and President and Fellows of
Harvard College, Holyoke Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 01238 (“Harvard”). 

WHEREAS, the parties entered into a License Agreement as of August 3, 2006 (as previously amended, the “License
Agreement”), pursuant to which Harvard granted to Licensee an exclusive license under Harvard Patent Rights and Harvard’s interest in Joint Patent Rights (as such terms are defined in the License Agreement); 

WHEREAS, on January 31, 2007, the parties amended the License Agreement (the “First Amendment”) to include a new patent
application [**] under Harvard Patent Rights; 
 WHEREAS, on April 6, 2010, the parties amended the License Agreement (the
“Second Amendment”) to include the Additional Patent Application (as defined in the Second Amendment) under Harvard Patent Rights; and 
 WHEREAS, the parties agreed in a letter dated June, 2, 2010 to include [**] for all purposes of the License Agreement as Additional Patent Rights (as defined in the Second Amendment); and 

WHEREAS Dr. Myers is an inventor of technology claimed in a new patent application [**] owned by Harvard which claims subject matter
related to the License Agreement; 
 WHEREAS, Licensee wishes to obtain a license under such new patent application and Harvard
wishes to grant Licensee a license thereunder; 
 NOW, THEREFORE, the parties hereto, intending to be legally bound,
hereby agree as follows: 
  

	 	1.	Capitalized terms used in this Third Amendment that are not defined herein shall have the meanings set forth in the License Agreement. 

 

	 	2.	Section 1.10 of the License Agreement is replaced in its entirety with the following: 

“Harvard Patent Rights” shall mean, in each case to the extent owned and controlled by Harvard: (a) [**] being
referred to as the “Additional Patent Applications”) (including the PCT applications and/or the US regular utility applications filed at or prior to the one year conversion date claiming priority to such provisional applications);
(b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of any patent or patent application identified in (a); (c) any patents issuing on
any of the patent applications identified in (a) or (b) and any reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a continuation-in-part application or patent that is

 
entitled to the priority date of, and is directed specifically to subject matter specifically described in, at least one of the patents or patent applications identified in (a), (b) or (c);
(e) any foreign counterpart of any of the patents or patent applications identified in (a), (b) or (c) or of the claims identified in (d); and (f) any claim of any United States or foreign patent or patent application to the
extent specifically directed to subject matter of Harvard Inventions. The Additional Patent Applications and all patents and patent applications listed in clauses (b) through (e) that correspond to the Additional Patent Applications shall
be referred to herein as the “Additional Patent Rights.” For clarity, Additional Patent Rights are a subset of Harvard Patent Rights. 
  

	 	2.	All other terms and conditions of the License Agreement shall remain unchanged and in full force and effect. 

IN WITNESS WHEREOF, the parties have caused this Third Amendment to be executed by their duly authorized representatives as of the date first
written above. 
  

			
	President and Fellows of Harvard College	  	Tetraphase Pharmaceuticals, Inc.
		
	By: /s/ Isaac T. Kohlberg	  	By: /s/ Guy Macdonald
		  	
	Name: Isaac T. Kohlberg, Senior Associate Provost	  	Name: Guy Macdonald
		  	
	 Title: Chief Technology Development Officer 
 Office of Technology Development
 Harvard University
	  	Title: President & CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]